var title_f26_18_26912="Medullary sponge kidney using multidetector row CT";
var content_f26_18_26912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Medullary sponge kidney using multidetector row CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 363px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFrAdgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKkhjMsqIvBYgZrcs9HjHEzb29BxigDn609M0qS8G4nYnrWymmwIceX0OckVb+WOMJF8o74oAwL/ThuVLZV3Drziqp0u6z9wf99CujSNSxY81ZhCZARdx9+1AHPw2S2pDN8z479qtQqWILflWx9kU/MVBz2p0Voo4PHoKAM1FLNjGKPs7N8p4ra+yxLwwyw6GmvCOdox3oAwb2waWPYANw6H2rc0uEQ2yrjnvTvlGMDBx3qS3wEOaAJwnX0FAI3ZA+tCDvzzQeM8YoAbxkn1PFKeTjJxTTgkUrcnNAFa6680yJ0AKdzUl0QACeuelQ2ab5WfOcHGKAJUt2XLZ69qExk7qtDBXPYVC4GeDQAmVzgjtSZH8PSkOOcdBQq/Lk8GgCUAtGfaocckd6kV8ZANNdcEEUABBxj0oU5PtTRkng9etKB1IoAOhpwXcMnOc01MsxB6GnNleB0oAaoy2CKCNrHHWpFbcA3cU0puG73oA5nX9JKFrq3GVPLr6e9c9Xokg3pgjK+h71zGsaSyyGW1TK91A6fSgDCopSMHBpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKkhiknkCRKWY9hQBHWrpumi4jdpg6nI29s1q2mkwxx8pvJxu3YOK0UgC4HIA6AUAUrHT4rXdty2eTuqZBhwRV8AbNp+lRPCoIwOnSgBzgPBuzVZUbzOB2q1jcue1PgQgE+tAFRrckpgfWrcEQQcfSpVGKUe4/KgBVHGD+FKB3HWlx70HBfgUAMGSD6HvTHPUDqBUi8kjsKZKDgkYxQAwtlQNuTUkPQgjkGovMwfQipoDuX60ASlvmz2pSScd6ULuAyKAQDwOgoAYTg0mMqfWnkZ2k01hkHA70AVbsEY71Balo3Y5qe6zkfnUUMUjHOODQBI1y2NigZPepFU7M4OaekO3GRnFSMSFKnqaAIV4XGMGlbGMfxU8Lg54ppx1oAbt/A0Nk4xjFS4DLmo2QjvxQAxgQcUIN3ejkLk0gJC/0oADwpxTh8yjPOKQHtjinNgYwOaAEKlQKJCQp5p5OccUMuRzQBEoJXnpTvLBXO4D8KeAdhAA6UiRk/eoA4XV7KSzumDKQjElWPeqFehapaJd2zxyKCcfK2MlfpXATIY5WQ8lTigBlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWjp2nNcktJlIxx75oApwwyTMBGjNk44FdPo9obNWViGL4PTpxVm2s0iTbEgQHrjvVwIExgY9aAFiG0E4xT++TQMAcmlB5HNACjaFpnG7p0p5+8T2pNuB7mgBo6GpoVCpls4NR47VInAxmgBSwAzQBgF/WhsHA7Uq4IIoAAeDSqQT+FNxnNLnBA70AHQA4ye9V55ACB0q0q85zx71UuwPMwGA49KAIgcuOPxNXbZflOO1U0RpmAUjNXbVPKBSQZP1oAlBKrnNIcZzk4pCRknnFKpyeDz6UABG0EEZNIB8uaezF+vWhW7YzQBW8vfcL1wKuooxyce1MQbpDkjFTKBkYHAoAaVHrTGQDqM1ZKjPHSmOuWOKAKjQkrlSRVd45ExxkVpkfLjpSFRtPrQBlmTAGOKlU71GTUssAIOBUJiCgjkmgBSvy+1JgemPeo9zDr0HSneYf4qAECfNSsu0c9aeHB5B5pVYZ680ARbuPenLJntTwoI7Um0HkYzQBKhUL6mgAYpgTuCeaYzEDGaAJcgnnpXG+LIVj1BWUY3rk11oUkcVm+I4Fn0tm2bnTlTjmgDiKKXoaSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACpIYZJm2xqWI9KaqljgA10um6esZXZ97H3j3FADdJ01Ym3OA7HvjjFbMcIBPGRT4l2gBV4p/U9KAAKAv16Uo6c9adjNIVxQAmOx6U8HIIo4/D+dNGMH1oAdjC5PSk+UEZ5oJ6A5xSbQRk8CgBR344NOQZNQs2081MARjHSgBzE7sCgYBwTR1BJpF6cigBxbnAoJ5GaaDgnjml4BGeSaAF39utUL05mFXcA5IBqtMm9z2wPzoArx56DitG0+ZRuzxVRIW2sOM44NW7bhcY+b0oAsMoxk+vSmHhhxTiM5JpO4PpQApBHPTNGcLzSbyzc9O1I4+SgCWDlcj1qQ5U1Dbk7MDpmrCnJGe1AEmc45pHXANCEZHpUxUuFAHNAFfkAUEE9au2+nXU7bYoXbHoKsvoN8sJd4HGO2KAMggY96bgCp3heNsOCCOtQsR0FAFeSEPknqKrSREdASK0jggYHJqNk49qAM1c5x096Xcexqw8QBJxzVd1IOMcmgByuRwKFYEjjFMAwKVznv0oAsKc/xcConBJyOaYjce1SKw29M0AIzfJxwar/MznOcdqn4/Om7MEmgDh9Vs5LS6YSDhiWUjoRVKtrxVKX1BUxwi8H61i0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRT442kcIgLMeABQBu6HCnlKVUGRupNdBAmxcdqoaLp7Wdv+9z5r8lfStTHH0FAApPbil9zTVPOfzp4+bHpQAi8k07nPNIc49P60hyKAFJA6U3GWp7FTjApvegBccYz0ppPanAkA55qvNKQNijk96AEKl5MnoKuqcRYI5qsw8soRySRVljk5/SgAA6Zozlce9IPWjJ29OCaAHEYHvSYBBPcUhbn60gJVCM9aAFHpmq9037zg4GMVOvBGBio7pVJUjp3oAjgyULHPHrVmEsOeuaqSsfLCL3q5D/AKkZoAl3ZwD0pDhm46Cmr3zTugJHWgAU5PtTXbZGRmgGmXOQmR6UAP0+TdG2OzVcT7pI61m6SDtk9etaaFtpAoAUYIFb3hqyF7cpvOFzgmsKMbmAPevTPDOn/wDEsT90Q2OCBQB7F4G8G6f/AGclwArAjpjNafiHw9YxohWJBuBGMda4zwh4nudDAjuFLW+cEHtXVeK9etb3T7OWwmVmZs4HUUAeN+K/DcLWd/LCuJISTgCvKXAA4619B6lIg0q9mcBmZSH96+f7n/XSY7scUARqSQPQU5uVHGKckTMPlBOPSkKMo5GD2oAhI+b9Kgnj3ZxwR+tWyMZz1pjDjFAGWcrx3oHp3q3cQ7hx1qkQR160AKevFKGxjikGM0p60AORhu55FEkixn5jxTR1Oaq6ihe1kAYqQN2aAOY1+QS6nIw6cAVm05mLMWY5JptABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRViytZLycRQgbjzk9BQBFFG0siogJZjgV2Ok6bHYRkkh5mP3sdPpUmlaetjBtGGc8sT6+1XT1GO1AABlsmjoSe9Pjjd244HrVhLdc5bk0AVVUEjI4qXAB9varZgXooHTmk8lcnjNAFPazAcdOlIwIxuq8ibT7UkiAn1FAFHGMUjc844qzJAM9+tQuCMjGMc0ARs21CxI4qmrfPubuadPLuO0dKjwDjnjOKALpwzJ3GasFeh/OoIQARg5I9Kn24+Y9KAG4OCaU/dB9O1KO47UJg8UAMJzyBTuo5pwAApjHnk0ADjCj1phX5Rk8U6RsDOKjmkJVeBigBpVWbjr2q2ikKM9Kz45Sz1fUnywT2oAcckn0obPYYpHycHgZpXJ49KAEK4+91qC8cBAPXipxktkVQuTul57GgC1pXLOAOBWkoPGBWVpJ/eSVrxADJJoA0tAs0vdVghJHzNXrc0KaHCpEoOB93NeSaLP8AZtRjlXnb0rT1vWprhX3OwPbmgDr77xIr28iLGXD9h2qT4eTT35uN7fu42yATz9K8s+3XDDaZG211XgnWhpazFifn70Ae56Z4ZbxFGhLLFaLxJ6t7V4j8QvCE2jeK7u2gTFuWzGcdq9H+G3xDjs/Ea6beSYsrr7jHoj//AF6v/HGeCG/tU+XzZQCp9RQB5fZaVb2emo0uGkPOKzb/AExJ42kQBcdK6ebRruOKKeSOQQsMhmHBqS30S7vYX+zpkYyfagDyuZDHIQeoNI3r6jNa2u6dPb3jh42ABxnFZY64NAEDDj3qvdQ5XcBzVxgCeCaY4yOaAMhetL3qW5Ty3JXoaiHTOOtACnrTGAOQQCD609T8tIwyeKAOK1SBYLp1RSFzVOuh1aIqs28c4zmueoAKKKKACiiigAooooAKKKKACiiigAooqxZ20l1MEjUn1PoKAJdN0+W+kIT5UHVyOBXYWlrFaxBI0C8ckDrRY26Wtuscf3V7461ZQbjjGfagAxkjBqzFb5B3nHcCnwwhMEjmrGOc4yaAGouABjpT9mOcdaVVJxUoVicCgCFRgnJpT94BelPmUI+D1NRgYoADkE9KRhkk1MUyoOKjbrjpQBEwJUc8VHcRh48d8dasMvFR4646UAc+6MshU9RTc7Rt9TWpfRBhvHUVQiiLuOOAetAFq2TZEMnrUxIzjNBwCKHABBoAXI7dab9e9KQNoIoGNpJFADieuOvamYOdopVf2pT948/N2NAER75IxVa5YdFPNPnY7tgHTrigRofkY7W6j3oAWxgPkrKxHpjvV7dhcAVBBCI/kBznrzVpkA+6eBQAxQSM0j5yKe3XOOOmBSFvWgBjABQd3NZ0zGSTitFj8mcdKqBdpOR1oAdpZAmYZ61sIfSseBBDOmSfmrXRhjjrQBPDmOQbTzUl0xMZLdTUaHBGR70Tvuj56igCtEvzgk8E9KuRylEx2qmo+YetTgkjkYNAEwuHDq6fK6EMCPUV6d46urnxL4L0DV4wXubUeW+OuK8sBHzZHavf/AthDZ/DJLy/wLYndyKAMW817Ub3QNOt9Qj8pNnycYzVnTb250y0jjICpKfmbNbfia80jxN4Qt5tKeMTWYwVGARiuahvIJdKTf8AM+MCgC34tk0iXQnWJFe5Yfe7ivDZwUlYHsa9I1GNgrt/Ae1cJqwjF2QnTvQBnnk+1HGeaUjB9qOpIAyaAKt2mYz7c1ns2RgdBWu69fesyePy3K469KAIs8D3peRg00ccU7OSaAK2oW63MTK46jGRXFToY5nQgjBI5rvwAVPrXI6/C63jybTs4GfegDKooooAKKKKACiiigAooooAKsWAtje24v2mSzMqiZoVDOI8/MVBIBOM4BI5qvRQB7/4w+Cem6/of/CUfBy//tjS9uZdNZs3EJA5C55J/wBhsN6bsivMdH037Ch89ZEuTw6OCpQjqCPUVc+GOt6z4Q1JdZ0W+ktpWG0opykq56OvRh/kV9BR3fg/40QrFfCLw94024SZf9Xcn07bvofmHYkA0AeBkc4HPfAq9aQ+WAzD5jXpXhX4U6jbfEiw0DxPZuLSbzHaeIkxyoqE5Rvrt9CMjIrlvGPhy78K+IrzSL0ZeFv3b4wJIzyrj6j8jkdqAMngUp657VH1HXmhnJOOgFAD1U7scitG1hxHu6mqdrG07hV611miaLNcxucElRmgDj73/XHNIhLFeOelS30ZS8mU8FWxiu0+G3gu41+5a5kjItIxkse9AHNtCyRAuvbis+ZCh3Y4r1rxb4cjQEQJhVHWvMb63dLnyXBXFAGeDnOepqOTjIA4FWZIwgK56VA5GMjpQBUuI8xtk4FVUARRjpV+X505NUuxWgBCSRxSjH8R59KVRkikAyTgUAB6AnkU/wCUgYpuw4znikf5SBQAjPhhxxTJJMsFHanY5IPSgIATQBVVZN5bpVkIAOepqVAGX5vXioZ2OSF6g9aAJUG0qOtWEI3AHpWfa7zO2T92rxPp1oAfIwPCjA61CxJ4NO69TzSADDNnkUAIx+Xg9ajXbjk8inAgEEngdqQZZyVNAEZP7wNWnGSQMDjFZpA3Y61dgf5Bz0oAuKeMY/GnOq7eeSaiUjilL4/GgBqgK59RVhDuI457VXZ84IGKch+YdRQBPbQtPfxW6/elkCD8TX0J8aWHh34XaXo9uNhlKRnHsMmvLvg7obeIPHNkrIWgtX8+VuwC9P1r3n4p+G4PEdxp0d1KEig3Hb65wKAPlWw1C6sVcW0rIHGGA6Gr1hr9xbgpJ8ydq77xZ8LZ7C6xYnejDK47151q2j3mnTtHcxMrL1oA1P8AhJS8LI68Y71hTn7RI0g+pqFVz1FTxAqCBwCOaAKxwfWnBQORSc55FKO2KAGN0qneJuXcOoq82c4qJl3ZHrQBj7SPrS89BTsEOwLYwaTPPB6UAH8XNZesWizQuzE46jFaqnII701l3qVPT3oA8+orQ1mzFpdHaQUbkcdKz6ACiiigAooooAKKKKACrulWZvbpUGNo+Zue1QW1vLcyBIVLHv7V2GmafFZRnZy7ABiefyoAtwQxxRiOJAqDoK0dB0ubUdTgtoZIInkbCyTyrEi+5ZiAKrQIXfaPujrWnEPLwFoA+0fh3Y3th4YtoNT1xNcnTpcoQwUY+6G6tjn5jya5f47eCP8AhJvDw1Gxi3arpyl1AHMsXVk9yOo/Ed6+YLO6urKUS2dzNby/3onKH8xXWaR8UvGemkLFrU86DqtyqzZ/FgT+tAHDOME7TSDAK8Zq/qc76hqM915EUMk7mQxwqVQE9cDJwPatfQfClzqhHBX0460AL4L0xryWSQDKp1r1/wAJaV5VrcsQBhPSsrwvoDeGdKuY76I+ZIcqxHat3T9Xiitp0jILOhXA9aAPJ9e0y2bU3C43s+D+dfRXgO3toPDttYWSrnYPMYV4ZqWmSWmoSPcjDONwzXtHwuli0/wqbq7cbicjJ5xQA7xla2VhbHzMEqMkGvmnxZc+drM0qAKhPGBXsniy7udZvZWIYREkj6V5B4xthbXa4BAPc0Ac8zncSTnNRP8AWhyAeDS7Ttz2oAjcYHUHiqcnBOKuEAkfSqs4AHvQA1frxThkcjmmrjIz0pwJ7UAB+6AaRgduTwaUEl89hRIxc8CgCP5h0GTUDSMH296sqcY7+tQTKPObHcUAIjMCe/tTXkYjIAHNPQEAEio364WgCxaA7ixxz1qcnkHFV7cnJGKm4C5z+FADwMn0prHqB1pcDAFNOBnPWgCvKQJjn0pY5AQQ3B9arO26Uk8knipZRwCeKALR29RQrFee5qKBw3Bp45BIoAseec/d4ppkZmHNRhsipIgHccZoAtKCUGKkUkgKQc5wKRMn2I4r0P4K+EG8T+Ko5blc2FkRLLkfePZaAPafgV4Rbw54Z+13abb6+w7ZHKp2FQfGme4sp9LuIRIUfchKA8HtXqSgKoVRgDgAdqjnghnAE8SSBTkb1zg0AeZ+GLvVtYS1VrOVNg4eVcD61z3xL0xXSUzxL9pU/OQOK6X4p/EO28MRwQ6ddRPeK+XiXnj0PpXCL4xh8Xtds7LAzLkqepPtQBy/h7wjHeu0zI3lk8cVLqXhmCGYpGOcV29pc/ZrGO3swpYryRVKe3aCKSacHcRnJoA8Z1m2FpdtEB0qgOAMVteKGU3pIwWYk1jZGD1zQAhJz0phHc1KoyckZpgXJPBoAyryLM3B61A429OtX9STaoYdj1rOJ396AFDDdjoad16VC6/Nkdh+dNhnEg64NAFHxBbeZblkX5x1NcpXfTAvAwGDn1ri9Rtvs1xt7EZA9KAKtFFFABRRT40aRwsalmPQAUAMp8UbSyKiAlmOABVqLTLyUkLbuMeoxWvo2kXFvcrPOQm3+HqTQBe0XTjYwuZNplY9R6VpbemOtO+9jA5q/Y2wLqXHWgAto9kfPXvVhfXNXLpVCjYOAKpnp096AH8lRzSxfKWNQ7s/Snj86AOl8GRW1zrEcd1gA9K+n/C3haxtIILgRqeMjA618i6fO1rdRyr1Qg17v4U+KCx2tvbSSAqcA7uq0Ael+Nre1fTnEqqPl446V4hp8MQ1CRg8m9XPHYDNet6zenxPo+zShvlH8Q5qt4V8EXFnptyuoLA9xOSdzDlaAPMPHeox6g8BiXaY12kjvW14QvXuNOX7XKq2cYwBu61zPxOu4dEY6fZqHk3EPL715wmr3kcflrcOI85C54zQB7/qF9GsLNDGCp4zivK/iCUmjVgBuFdF4Cv5dbsZIXb514rlvH8MlrN5TggA96AOJXhs9hUwdfLORzTQwx0qNiNpz3NACEjOfaqNwf3pxV7gnPaqUwzLkdM0AA2kADrQDt9aiYhX+Xual3cEYoATODx6UHOQQMAUgJwN3BFKuWFADMcHjnrTHyW61KQMHnntTGHcYJoAG+4MmoyvOc1JzjBFNP0oAlhVQx7Zp7Djn9KjjI/GngllIzgUAB9jTWXjj8aeFxyaRmwvHGaAKMa5lJweDUtyhZUK8CpMAtgcUXTARADr9aAK6hk7jNSl2C5AOKij+ZgM9TVhwcAZHtQBGJNijPertgclm7CqMwAjCnqK3fCek3Os31tYWKGS4uJAigDp6mgDa8IeGtQ8VaollpkRZicu/ZB6k19beAfCdp4Q0NLK2+eVvmmlPVm/wpvgHwhY+D9Fis7RAZ2UGaYjl27/AIV0/SgA5ry743eO5fC+mxWGmuV1K7BO8dY06Z+teonpXi3xU8MHVPEc11MpZnVUiz2GP8c0AfO15NNdXLTXEjySucs7ckmn2kjwyB4nKMvccV6rq3w8jtdEa5RhuBwcdjWPZ+BRcadLOzFXAyo9aANb4beIbaS/aO/wCQBkmu38b31iujSNA6ZC4GK8EntLvSpS21hjowqWfWbm6tgk0pIA6UAUr9zJcMxPXpmoFxuAOK0tL0y61a4jjt4XZm6HFdTqHw01awtBcSRkgjJ46UAcG/LEjpTokABJ71blsWhkKPwQcGoZAFBVfzoAqToJI2QjINc/LH5UhQgjFb7kjJzVS/hEsZYAbh0oAyHyEJ9qpRKQXwMgCrbhhE/pioIBtgbjrQAiXG1tpJwe1ZviOFGjScZDA7cVeI3ScUrxRyoFmG5Mg4oA5Cir+tpHHqUqxKFQYwB9KKAGw6fLIyZwoPX2rpdL0kWKB2YPI/Ix2pEiVFAArRhB2AUAPHXBoJzxTsfLQi7mAHfigCa1hz8xH0q/F8uc9ajQBFCjtUq/dFAF2CQGNlcc1E8ZHCjrTVGOhrS0yITSAOPloAyDEfwpQMda6i/0TbGGiOc1kz6Xcw2ouGjPlk4zjpQBnDH41LAzIwPQ+tQnIyD1pdxOMmgD0n4afEC48M6gsM6mWzlYK2T90V9K6vqHk+Hri/tst+58xD16ivi7RIZLrVbW2j+Yyyqv619rixWTRFsJBlTAIj+WKAPnX4k2VvdeHzel1NzndXjbngV3XjR7yx1K90i6LDyJCoB7jtXEOuG54xQB1Xw61Q6fqrlm2oVrb+KFxFqEdrNActjmuC05vKuQfUVcvLmR12sScdKAMtcgHNI2QvPenso49e9RsMY74oAhkO3gmqw5kGTU1yOfc1EMAHNAEUrBXAqTcNoqm53yk88VbVBtznigCX5SMn0pEbqBRnim9e9ADWYenemT5AU96c64XNQzF2YZOMcUASRsdxLdBVaRju4J21PHG+dx5BqMxOxIVCcdc0ATWxyOeuasK2CRUFqOMHg96sZUHnvQAPyeDUMzERn2qbChvmOAOahkZXBBHGc0ANt8lSzkA44qC6OWABzSuwA68mgjAyTkdqAGxALz6VYVx5qE8iqxy3Y+wpyH957UAWbhNy7hxivef2U9EW5udS1qZM/Z8QxE/wB48k/lXhMpxGO+a+rf2Y7Vbf4bCRR801y7N+HFAHrf1o/WgnjJpM9+1AC81R1fTYtSt/Lf5XHKuByKunkccCl74FAHC6n4JmltnWO/kdD8xjK9asjQrbU9Gt0slWJ4so+Rg5HBFdj24ryPw18QbbS/E+s6Rrj+RsuGKFuKANaf4eQTWc0NwkZBB+avB9F0LTj46l03UZ1jtYnYZzjdjtXr/j/4t6db6bNbaK5luXBUOOgr5zmupJ7qS4dz5rMWLd80AfRXgX+xo9auUAjVYPlj+lbnijUmu7eSCAqyAYzXzboWvTWFwzvIxB6nPNdBL4zlETbJGOaAMfxdGbfVGXOM81zzSZq9ql42oStNLyx71mgdc0AIxzUTZ3cipM460EknPagDFvwI1dfWqMz+XCoFXtSIeY/lWdft8yKo6DFAET/Iu/J5oScNhcc4qO5V32qoOB3ogibzcEY49KAK+qWX2iJp4wfMHb1FFbEHUgDgUUARsDuJq9aHKEN1FUzls+lSQSGOTnp0NAF0mpIBukXHSowVJz2qe1Xc5boBQBdjGSTUgxgDNMQEA4PagEjnFADwxVsVu+GLmMXipNgKe9YHOBSxuY3ypwR3oA9st9NtDbGfzUZQM8npXIaprlq0E9gqArk4+tYWlHVr2FooXk8s9a0dP8NSG4zcE8c5NAHNzWTqVYK2D7VZ0vRbvUrpLazheSZuigV7BomiafeXdjCyDavL+9ej6Roel6d4ntZrSBVZoyoOO9AHA/Cj4VXVhrEWra6oQQHdHD6t717t60fU0dz6UAeRfHHwE2s239taVHm/gX94g/jUf1r5puUYTMsilXBwwIwRX3kemD0rzD4i/CfTvEQkvNMC2eonk4HyyH3oA+WImImX0Bqe4YtJxWr4h8M6l4bv3ttVtmjdT8rYyre4NYkhO7igAYdM1G3TqMUrPxzg4qs8nOAc5oAjdzuJ7CqssmAfU1I8mzcT1PSqbZJyepoAA20kkAg8c1dUgoo6VSfJ4Jq5GMgDPAFAATyQMHml/hNAADY9KCpL4WgAkIwF9Ka0ixqd/ORTuQxLdKq3RylAE0cwA+UH25qaFy5ILDmqURJGewokJC7hkehFAFrALMY/4TzU2DgEkVW07cynd35qwMZwOnagBZDxxzVO8f5FA4zVzeV3AAc1UugNnPJ70AVkU4HGD2qSTI6nJoZxvyp47U2RgX9qAFBwBzz2oiJMy896QqNpwOafbgiZe5oAusQE565r6s/ZluPO+HjJ/wA87lx+dfKcp7HvX0Z+ynqO7TtZ04t/q5FlA+oxQB7y3WjcFRmYgAcknsKUjJFedfG3xS3h/wALtbWz7by+zGhB5Ve5oA5T4j/FuWG6l07wyU+QlXuCM8/7NeXnxr4s84TLqU7EHJHaubSXAOOWzkmva/g9oWnazZs96isw7UAWfht8YjdXcWm+JlEcjnalx0Gfek+PngprzZ4k0mPewXFwEH3h2at7xj8L9Gl0yeezjEdwo3KemDVj4Pavd3+jTaLraeZJbAojsMiRPSgD5ZPJJzUmzA9Tivdfin8JbW3tbnVdDbyduWeE9Pwrx7S9B1G+fy4YTkcEmgDGbJPoKQk4Neg2fw8vX0+WaRT5idQBXE39q9pcPFIuCDQBVB7Ggn06UmOSKQgr14oAD06c1FcOsUZOeopzZOOeapX26QgA9KAMm4LNPknipvLBQZAzQ8EgPzKfUVIwCqNxxQBCY+cAcVLsVgOBmohOASQM8U1LgE5zigCXZtyB1oqFpyOMc+tFACDgU0HOQeuaDkDNEXzHJoAmjm2jYfwrZt12IBnPGaxIl/ej61uxjao9KAJFyOnenrwBwaFHzACpAmcigCLG7PrV7TIUe4QSjjNRRqFG40ecQwKnGaAPbfCl5pFjZAy7BxVTVNUs7yYpagKAc7q8mhvZwdrOcfWpodQmUnDUAfRnhFNPi0yObaGlZwC/vXUa9qdpbQ4tmRrpAMbeTmvmqw8b3lhokligBYtkP6V1vw41pCJNR1ifzGDYCk0AeiWvi/WY4ZnmMLsp4Rlwa6Dwt43tdYvfsFxGba/25CE8MPavNY/Edhc6usoK7TKcr2xUXia/so/G2gT6SQspuIwQvucEUAe/dOtFAPSkOfSgDN1/QtP16xe11O3SaNhjkcj6Gvmb4nfC6+8MSvd6erXWmE5DKMmP619V54OOtMnhjniaOZFkjYYZWGQaAPz/AJ3HmbQfqaqs4UkZr2X49fDP/hH531vR4ydNlb95GvPlMe/0rxJmwaAGyncTzwKfEvGT1NNOCRxQCc4oAdMwJqYE4GKgcjjI+tTK3THSgBwG0479akfqpHTFAADD3pG4bFACZ+ZR1HegRI5IY8daFAG6gjcMr1oAkESMny8AccVEkS5Kkkjr+NPQlOGbI9KUFR85PtQA1SEU4HNOUgZ9qaSMn1p0X3MelAAzA81n3RLN8p6GrbHMTYwDVJfvigAI59xS4ycClcfPyaan3wTQAp44J6VNaYFwCKgkwWP1qeyGJwfagC2cFiTXpv7NmsDT/iItq5IS9iaPGeMjkV5gzgZJPFavgfUDpfi7SruM4KXC5PsTQB969sd6+Xv2g9Ue88dG1B/d2kQUfU9a+noZA8Ky/wALKG/SvjH4kah/aPjnVp1bKmYqv0HFAGEmATu69q9J+EHif+ydWjtrg4jkYAGvMgTkk1YtpHRg6sVZTlSO1AH2j4kgF3oUxSXaNm4MDwa4fwVrC20ttZCEJNuwzkdRR4Wk1MeBrC51a4LxtgmPuVrb0S2sdX1Zp7aPbHBjjGMmgDqNasl1HTJ7V+N68Y9e1cTY+HrawsDchArL976122r3sWmaZPdSZ2xqT689qz/DlzDrGjx3BClZOq0Ac099ELeSGLA8wcjFeDfE6GOHVQYwACO1fS+seHrIW81wgEZVSx54r5V8cXv27XZxG+6NG2g0Ac1yOc0jvmnlfmI6ioyu0ZNADM+tULmTbcYPTFXiCapXURlkGO1ADzOnlbn7Cuce5Ml05z8meKvasSkYjQ4J61ilwgwRz3oA0fM3RbR+dPjCqgPWqsLZjOKkjJ4oAs4BHHXrRQp6UUAJkg4I5pY++RRjdknrSAnpmgCZD+9Vu2a3UO5R9K55c4wD05rftCHhUg9RQBOhxipHbBG3vTMYbBNIAT06ZoAUynGBSb8N05pWTk+op2zdyooACxIGOgpUkKjIpY4yz4NW0spJV2xITjqaAKqHJO7vVmO6eKPYrlUPbNbOi+GJ9QfZghqpeINDm0qXZPwaAKMV7JG+Vdh6V6R8GtEvPE3i62vpd32TT2EruehI6CuK8IeGbnxHq1vZwZWN2AaT0FfX3hXw/ZeGtHh0/TYgkajLN3du5NAGxnmig0UAFHPT9aTv70uaAKeq6fbarptxY3sayW86FHUjsa+GPiL4bfwp4tvtKYErG+6Jj3Q9K+8s181/tY6QI7/R9XQY8xGgc47jkUAfPsfDjIpNx8wgcZpyo2d3IWlRAXOOcUARzcMBzzVxBuxgVEcYBIFSwtgdKAHE4PAoXJbtTmGDUYJ5OOBQBIy4z71H90DtUqtn61HLHgHP1oAgvZSqjAqv5rFQCeKssBxzRsj70AJAxPWphu2MDSQKuflGBUpOY+lAFOd9sXNQQHCljz6VanjDpyM47VCsTAYVTQAIjMjMBxTVGBnirQ3RRMuPmNVyoAIzmgBhPPIqzbr+9yOOKgIz6VYs03OzDOAKAEuvlCnGOabDMYp45F/gYMPwNSXoG1BkEiqsTYbkDFAH3BZeJUk+Faayjciz6/7QXFfIckzTzSTOMs7Fzn3NfRXgbTJpPgHPFO2fMhd157Cvm21kG0r1KkigC3uzyBU8D/vF3jjNVFbjNSb8EcdKAPavD/jA3GlRW9w4WKIAAZ7VZ0Tx6ul6xNJEy/Z2IDDPWvFYrx1UqGIHtSrOSeSeaAPpqXxcvi+0a2sYytszBG7lz/hXQaDo72RijQPHH97b2rzH9nvULUSywSsomydma96bDY457UAcT8Xby4tPBF69lJtlIwcHkivkd5CXJYksTkmvqH4v3SQ6PLubKupUivl+UcsQBjNACE56UxiGAHem78NxTSc8nrQAhPbNZ95OISzA1blkEaMxHPYVz905YsXPFAFO6kZw0jn7xrPkYluO1W5JVdNnpxVBsgHPQUAaFnMgDKRye9W4SMViWkmWOB34rbtVBxk0AT43LxRS8DhaKAGkEAgHtUSvyoPrUwO4nFQuvzc+tAEhyBla29IObT3rDZwCDnjNbOkMPs3XvQBpKAcZNS7QBwTULEZwKcuQue1ADlHHPWnxRlj8vNMVstWrpfkpcRs+MA0AdZ4S8C3Oq2xuGjIA55rqNK8EypK6BDnOOBXdeBNWs5dE8uHaGC4rptJnSINmPMh6EigDze68NXHh6EXXmAzDnZ61S1TQrbVdLub3V42XUAuY427+mK7HU4Li68SwLPmVGO7y15x9a0PFdhDeRl2jKSQgBRjFAHgvhSfWB4ntNOsI/sxMoDEDoufWvrSMEIoJ5wBmvI4NDl03Wbe/8oKsg4OOtbni3x9FoOml3K+dt4FAHoWaPxr5V1H4u69dXG+BzGoPAJra0L43apa4TUrdLhB6daAPpD+dJ7n8q5bwT440rxZbBrKYJcj70DHDCupOe9ABmvGP2qI0bwHZuwG5btcH8DXsvIPNeF/tU3i/2NpGnhhmSYykZ7AYoA+X5JCF2g8UROV3YFT3EKx4IOcjpVVgQMrQBKXyPcVNCefYVVDckN0Iq3DjaB3oAlZu/SmZOOeho3DvQrd8UAOUk5I4pkhYkEnmmgsSe2ac/wAvfPFADDjPzc0qsMEbc/WojKOncUeYM9Dn6UAScjBA5qQPj5SCaapJOf50m/5Tkd6AEY5bpxTt23BB5xUQdcE5zTS+RgdKAJWc55yT3qH7zkdKUtgY6+9Ng5fPagBXAHAq1ZqBHycZPSqj/M/y9M1dCeXHwR070AVr3Hm4XJAqO2iae5ijHV3VcfjXXfDvwRqHjPWlt7aNltVOZZscKK9n1H4PaVod/aTiUbIyGLHjkUAegag0Oi/Bxl+6kdjt49cV8XW135U7lidrkmvoz49eMLW28MR6Jp9wHaVQvynoK+aGU7iT0FAHRQuGxjvUzOAAB171g2VwYsBzla1VbPzZ6igCxvyeOKcpyck8ZqFScAH9KkUfLnHFAGroeqz6TqMd1aSsrKfzr6M+H3xNttRjW31J9soH3q+X92RgVraPcy29wGBIPtQB6Z8WPEg1Z7mC3JMYc15Gc8j1rqTbXuo2t9dWdrLPBbANOUG4xg5wxHXHB56Dv2rl3HJweKAISuCfSoyeelSucLx09aiYHr7UAZ15KSXB6Csq4i3E4JK4/WtMqWMu4fe6Gs26YwqUHU96AKBsz8rbsHvSz24K4JFRvK0koUMenNU5mmDspYkdjQBdt7VUIZccVdjUg+5qtbEB1HtV3kkdMCgCRQMUU0MRkUUANAP3u1KRuXPalJHkHHUGjqgwaAKsnzBhWt4ekzA0bdQayJkwSSTVnSZPKvAM8PQB0wwDwKlVscdRUf0605QGIoAUk5OBU0O8kEdKiIIPPapVYhcUAdr4b1mS0VUWYqTxwa9p0HV7U6WJbm4J2jOc89K+aIpTGMg/MDmrdprd2J4kMziLcCVzQB9b+EbF0he/uBmS45TPVU7UnjmVbPTGuyuQowa4uL4o28WkW6xxgSqgU56cCuT8dfEO41rSvs0URRD/AHR1oA7s+LLHWNNgigzmBd0jemBXjfiu1v8AWriW8dXFqpIQHuK7fwJoH2HQrU6hkG9fcwPXHpW54/js7PScQhVhVeMDHagD52ltwnSqxjwc9c1bvJg0j7ehJxVUsNpzQBNpt7daXepcWMzxTRkMrKcV9YfCfxiPF/h4SzYF9B8k6jufWvkB3JzivYf2YbuSPxRqdoW+SSAOR7g0AfShPNfJH7QevprfjuS3gfMFighBHTd1NfTHjnXIvDnhe/1GVgDHGdgJ6selfC+oX73t3NdTZLyuXYk+poAgumyAP1qHCnjPFOdgwyvfoBTI0B68e1ADJ12yfL0q2pUgdjiqkv8ArQKuxrgZNAAEAYHqKewG4AcetJncacy88NxQA0hV3Mw+UDNZ5naTcFAxmr5AbKt0IxVWK3HnkAkLjjJoArx7sAleh9amBO4MASfQVJJbky8SKuByPWpCq27x4JPmdfagCK3uFaZgwIOcc1aeI45GKlICsvyg55oCiaUjPA5oAy5FVXfHWq85Py7PXpV2+VUlyp4NVGIzkCgCRDuA9KmYhYhgdfeoYFJGTT3JJ9hQBPYwl2J9OlaNpaPqGpWtnEMySuEGPeq1sSke0c5Fdr8IoIo/FUGoXwHkQHcd3SgD6k8IaNpvgXwdEGWOFYog88nQs2Oa+c/ix8VbrxFfy2+lsYbSMlQw6mtb46/E/wDthBo+jybbb/loynrXh8aFwcGgB15cz3Uge4meSTHVjmoF756UMMd6b0bmgAI744q/ZT8qjnHpVKM/I2T+FOB54FAG8mOBUwKhSAax4LxkAVxkdjV6Ob3yKALSLkZxWjYkCJ2P3hWUsmehxipraUkMM0AepfATWjY/ESG3dsRahC9ufTcBvX/0HH416545+Euh+JPMuLNRpeotk+bAg2Of9pOB+IwfrXy5o+pyaPrVhqEWd9pOk6j1KsD/AEr6x8Q/EXRNL8Q6Ro9zOVXU4PMNyrYEAb/Vkntu557cE8UAfNXjbwJrvhKcjVLUm1J2pdw/NE/pz2PscGuOu22Jgda7r4v6Zr2geJZbbX9RvNQt3Jktbi4kZxIntngEdCB0+hFebzzNIGbGO1AAr5OT6cVmXyF7hlx1FXY3yQKp3b5kZ847CgDKC+XIfQVJ+7bBIpboDysD7xFFvBlI9xxk5oAsRKoAx1qdcgZx0qMqFPFPUkAj1oAFOWopyY/CigBuDnjpTos8inc7sgVGWJII4oAZMCUcMcHtVKGYpOjE4CtVuY8Enmsp3y7Y70Ad9A2+NTnqKnTjmsTw/c+dbbWPzLW0ucfNwBQBKMtRjGKapwCRS792BQAkhIABPWn28eZEB7GmkFjk1r6HYveXccMa5kdgo9qAOr8IaBda5dx7o2Fkh+d8cH2r0nxdoumabpentbKhIkXcMV3PgnTLfS/D8FqI1Dbfn461zurWcOpeI3t0UmBV+72zQBka9rQmFoLbASBegrgPiT4tS/s4ra1fLEYbHavYtW8LwTeE82cYS7A6/jXzl4q0j+yL14ZDukPegDnlkAPzdaSWRSMVE4ZTkjrTMFgeOBQApPFev/ssxI/iXVrh3AkWMKq9yK8clYLG59uK0/hd4rk8J+K7a/LEW7NtlX1FAHuX7SkPiC/0yKOzs3/syI7pGU5LfgK+YfmyVIxX6D2F1Z61pcVxCUntbhAR3BBHSvnH49/C6PS/M17Q4ttsx/fRKPun1oA8EOVfG7kVKOeTUPTJxUkRLL04oAiAJlBBrQHAB65qlAAZTx0q/jaAe9ADUJxSkkfSkGelBJGB1oAVyMls9aq3J2bSD8xPWpnPGcVDM7fKEUH6igCjiV512kh+1XrQSM264JJXgA9qWSVBjIyR3FTRshwV79aAJ2dRtZDlgOhqJt65IwN3JpwUbuD3omcLuXqaAKV24dx6AYqGcBThenc1KNpAz1BpjsDuoAfE/wC6DAY4pBk/jR0iUAcUqE7lGKANO0haSWONRljxWtqWpDTLb7HanDlfmIqLRZUhE078sifL9awL6Vprp3fqTmgCAsXcsxyepp8R+ZucLTOBjHek6cigBwUbSc1G4HBPentyMnpQigsM9BzQAFGSIBhyanjjCpk8g07aZQWYYUdKSRy7queF5oAhYAHg/wD1qIZSGPJzUbtubIp6RtsaTHHb3oAtLdkEbuTU6XydM49Kx2ZifUipImzgHrQBs/a1ccngU+4vpLuXzLiVpWCLGGc5IVVCqPoAAPwrPVdo9j2p4AXqKAPdPAmsWPxS8JP4I8STBNatUL6XevyzbR0PqQOo7rz1XNeJa/pN7oWr3el6rC0N5bSFJEPr6g9wRyD3BptlcTWV5BeWczQXMLiSKRDhlYHIINeu+P8AW/D3xD+Hlv4gvLm20/xdpxW3mg73QP8AdA5x1YH+E7gexoA8YgA5z1NULlB5jA9M8VpoPmwOlUL2MrOfegCnMmQPYYqULkJzjAxS4JOO2acQeBigAyAAM0oxnJpHHzAU4DgnFAAcdBRRgAdOaKAANj8aHIXA9aNvy5HXNVppNpO7PTigCrczbVKjrWej5lYEfSnajISRjjPeqJlZJflbIFAHRaFceXeoGOA/WuzV9+K8+tC5ljcDDZ7V3NrIJIEYelAFod/enqPmAqNOWBzUy8ZI5xQA4L0A55r034U6Xm8juWXOGBya81gI/iNer/D3U0RYbWMgNuyaAPcLmGVIlW1PzSDGKq2mnf2XcLcMd0rnbz3JqxpBnlf7RLJthjXAFYPifWM3UUccm1UO7Oe9AFXxLq97o5kilkBWQkgDtXz/AOObv7VqxYvuPU16d8YPE8Dx2ccLZZF7dzXiNxKbmZpGJ3E9aAITkjn60085HQ4p64L+wpGK845NAGfqTbIyo71kcknFXdRlDz7SeB1qvhcfeINAHtXwH+KH9gTJoutSE2Eh/duT/qzX0/cR2ms6W8bGOe0uEIJHIIIr8/DCFjEgfLcYFe0/Ar4pSaRcJo2tSlrOQ4jdj9w0AeffFXwrL4R8XXlkVP2Z2Lwtjqprl4NixEvn8K+qP2kNCt9Z8Gw6xahXltyCJF53Ka+VQjOoHAA/WgBtop3Me2atEMxz2FJEPlI7VKMD5R3oAaAAo55pmdpzTh1xStgHnFAET5z65p6KA3IyaFHzgHtTLokkFDQBFKwLngDFTKoC/Lgj2quFJbpnPWrsSA2/y9qAGL9wAdaa68Z/OpY1OMnORTZlBJCnigChIhRS4HXvTF+6TVjbkMCfwqIxmOTocHrQAgLGMCpIwNygjnNNUDyz1HNLGSXA6k0AdILUjwvLdE8mYIPpXOzn5+fSvbPhvo2n3mgWEWsDFrI7sSfUV5P4titoddvIrAhrdJWVD7ZoAxAD1pTwDnqaVcDPv1pCRkd6AFU89MipSmQD0FRoQpqWWRCgCjnNAEpO1QgB2jnNVZD8zYPWrSPukw3TFV9gkuH5wgPJoAI4w+OwHeiabfhF4VeBiieZcbIhhQMZquoxQBIMck8Z4pXTbgjmltxvbpwOtSFN0nJ49KAHxHIGc1MzZX5s5qMKA2D1FSZBHUZFADeo9hSH5QD/ADqRMHODwKYzEsSccUARrIQfUVDOQ5JJxg8VMeCcjHvVJjuY88UACkEdDmnOwx70iHB5PBp20ZBzzQBFv2t0qXduXpTD8z5pY84oAcvC+9FL2OetFADBkg+lU7wZVvpVtiQvFULs7lH60AYN27F9p6DpUIyX45NSXIxK2TzmkgUtKoAzQBu6arDk4Oa6PSZyC0THjqKxLJNqAkVbViH3LQB1KoduTTwxVjgdRVOzuvMj55I4NWlznJoAahYsK6zwjdiz1GOVm4yM1yyAc1btp2iO6gD6Mk8aWv8AY6pHIoPcZrzPxX4uLXf7hvlAxXCtqDlsBzj0zVO4lMrncaALGqX8t/MZHYkiqadCDjmkJ2jp1ppPPT3oADtwcCoLpxHCzA81Iz7ax7+cySYU/KKAK2XJLNzmlzzyKFLbuOtBLAds0AOGBwKfHu85NhO8sMEetNVWY4C1e8Pw/aNe0+EgnfOi4/GgD63vtPmg+BjQXrF5hZ7znt3r5Dbpgj6V9t/ENRa/DXUU6bLUJ+mK+I2cIxB9aAHQjgjoM09/v+wHFRxkknPSpHG49aAEByRilYbhSMuwYU0AY7mgB/l5PJ7daidP3Wcjg04/dAycU2TYI+OTigCE9QOxqwpZUwMnnmq9uDvBIzjoKt5cluiigCTBIHIXNRufn2jnIoGwjLOSfSnxSRoQSOR0oAqPH1w2MGmbixBJFTXGJGLBcZ9KiIUDnFACSp8u7IAq9ZRQW4WR3DMw+7VCZgFAPSmwMTN8ooA9g8WzSad8LtHntn8p5WONvoa8ifEuGLHOcnNeweMLYXnwS0a6UEtA2Grxzd+4xgUARnAYimjGaMZGT2pTgjpigAI5NIT82aMcEZOaQrx1oAPMKsDnk1JM+YwuBk8kiqk+QpYHpzTIJg2SeTQBbi6cjIphGc4pF37QQOM9KmdgFUgYPpQA63LDhcgd6kk+R15z71GSxy/rTfmyCxIFAFxMvz1HuKU/Kp6YqFJCMj+VSsNycnGe1ADUIyTQhXcc0uzA3deKgwSxIzQBJMRsLdOKztyhxtq7M+23KH7xFUYlHOe1AEuPmJ9KD60jNwMdaVlPl+5oAcBgk0nHBFNOR+VAO4CgCReue1FKCDwaKAK0jfucA1m3D7VPpVgS7od2eao3J8xCO/SgDKnffKzVe0qMGRTnk1nHjitvTEXarDAzQBrRgdMU5sKvBpglRFwTlvaqU16v2jy+Qx9aANWxu/Kmz/CeK6BX3IDnOa4qNgG3SSAYPArZ0vUVPyM2R2NAHQxY71OTkdsVVjkVkGDk+1O3fMBnFAEwG0bifYVFxuHNDtg44IqNnHNAEjsNufSo2xg89qimmCDlhis+4uywxEfqaAJ7u4G0op5PU+lZ5YEEe9BDNnrTNue9ADlI+bHfpS4waaAFznOadk8HHSgCWA4fGe1bHgd1TxnpLykeWLlM5+tYsQLMaktZGtr2OdDhonDj8DQB9u/FiUf8K91IjkPGBXw3emTzWWPjtX2hFeL41+EnmW53SPb7SB/eAr461GFre9uIZBh0cqfwoAhsC7IQ55FW3Uk5qraElyFHbmraht3pQAiqfLOOeaaQdp4p4yAB60rc4FAETduOtNIIOD3qdtu488Uxh1NAEEPDt1yKnfCsAec0iLjJyfelZVY8E5oARQN2D2FPwu/3qOBCZSSflqxty/SgCCQYQntmqwKknOdtaBGYyp6nvVDbgHngHH1oAhkALjJxmpbVTuPtUEuN3JxirlquELHqe1AHucaLc/s5zEj5opSa8Ei+4wxzjNfSWn2yL+zbdsB95Wf9a+brc4fHHIoAiweM0uffNPkU5INMGBmgBCMHOaTnccninY9Pxo69qAIZQuCBzxVMwssSlfvdavtjkY4rLmldXcBzjpg0AWreXdjDY55q+sO859a56ydluCjDqK37WcE8DgCgCyI1iA3cntVd8vIc02e7DDCctVeF3D/MOKAL8YPA4qbhm44I7GqqSBVyTzSqSSCOpoAuBG2HJwAM1VllCMMdaVpDgqTzVX70xYnhRmgA1AlUDYPNQx/M+TwMVLqBzHGPXmq0jbWULyO9AEy/M4PYcVIzDeRmo0IYADgDrTsA0AKzHk+1CjCjHXFJL1AB4FOQ8AmgB+AoHfIopM8cDmigDn2kKRDHFUbmV9wKuMHsKe8DyA7n5HaqvltzweO9ADDyc1p215GkWF++B8o9TVWO0ZwABye4PSta001IwCeW96AM8RXU8ucld3v0q7FppjcM5LE+tayIowAAMCnkKWH86AKbWiHnbk4pFszhSpxirp5Py9KH6ArQBHBdXEL7V+YCtD+0zGhMwxnvVKQkjd04rHvJ3kBPVQcUAdbZ3gu1YxsPl4rMn1hTJ5cbDeCRXO2qXuyVLWRxGwy4Bp9pBi6Vzz2yaAOiR2bG85NB6Hjmmqo4Ap3TgUAODY4B4oA7kUwY4zTsnBoAMjPTk04EjPrTBy3WnKpOTmgBVJ6g4zUj5J4HSmqegGOO9WFKlRjGPWgD6I/ZY1hp7bUtIlYlEG9VPp3rzD426CNE8eX0Ma4imPmp9DXTfsvz+X44ngHR4WNTftaKtp4i064zgywEH86APFrcqJPkBB71aJ7msDRXaS7YkkrW+ygsKAEHbNOOMHI5NIB82M807aT1GQKAGsOuKUHaOKUDIzjpTDwCBnmgBy8gYFJjJOBSqcLS9CCKAIEZlmGPunrVpeG61nTyH7ZGvQGrmT0oAlOCp5AxWVO5E5HPTitPcOQw4rMuyPtSjtg0AQz/ADSx+9aixnyhtHOKq20aN5bHsa67wRosniDxHY2VupZTIC+Oyg0Ae86hZjSv2dXgmG1mts4Pqa+U0+Uhh1r6l/aT1aPR/BNhokBw85CkDsqivlrgcDmgB8zbiGFR/wAfFSquYsHqKhA/OgBd3bHNGMjI4NPjAWQFuRTGPzHA70ABC4I71lXFuxndkGRxWnnJ9KZICDigChbWzmZWbgHoRWkkITIU5JpiLgAdMVOh2MOKAKos8MWZmwOTzSR/MxKA4Hr3q/d48oAHhutVyu0/u/SgCvIGByabDOyMT2z0NTTM23GOaqJG0j7SpHr7UAabkSQiROhqorCO0kbbyTitW2EaWzAqQAKzbjHlbFGMnJoAqTOfKQk5AODTA4z656Vdt7bKksxCepqpLHsk4PFAEqv8oUdfSnruI2nj3qvFkEHqRU8Z43MaAHdQR6VJEMpjvUYHBJPJ7VKh2rz1oAkQDNFMByOKKAOTMjq24v8AhirVnE8zjJOD196jitDcSZUnb1xW3a24gQA9aAH29sqMcLx71PtBfHam7sdM05pEC4JAP1oAVRhsZprHHFQm4RTjcCe2Karb0JOeelAE+4EcUx3wMDkVCxZBhQCKIhuGTxQA9XaQYHA6VVkiI3qfu/1q5GCAem2gBehI2+1AFKCX7MvyEMzDDcdKIMtKMDipmRA5yMDtT4FUOD78UAW1GMe9OHpmj19KXjFAAD09aXr+FKQMZHUU1cYyaAHoBj5hxTic9xmmckew6U3JDDGaAHIMHjuanjAB2561DC3z89KmTGCRQB6n+ztKbb4j24Bz5kbKcfSpf2vbkT+JbOAdYYsY+tVf2fCr/EqwyuP3bkflT/2m7Vn+Iy5BKGNW5+lAHk2j2ht7YMw+Zua0VPc0L/qwB2pV4bGOo5oATHIOeTVsL+7Y44FU8/NgDpShmwV3EDuKAHyODwvWj+EFqjOMUc+tADlPBBHWlIOAfak9CaVuSfSgCndQ7pRKMZWrSYKg9qaVLdqcnCYxigBdwOfWs+8BWUEjqK0lQ9RjPWql6C2DigCPT8sD2FfUn7OPhmKx0CXXLpB5s2djHsor5m0mDcY0Y8uwA/OvrrxTct4V+D8a2ShGW2VOO2RQB8+fHHxQPEnjS6aN91vbfuYgDxx1NecquBk9KdJI0kzM5y7sSTT5Cu0IB0GaAC2YM+D0pJ08vGMZNRQsVkBAxzT7jl85zkUAMOwoBht3rSohOecVGx7YpV+tAD2UDpUMh6bugqXlTmq90f3TZoAUEdOpzTwx4yazwzq3ymrCs4cBsHvQBo+bujKYBz0pgcIQCKYrgYHej5WOcZoAV9hbOM0NEWZSg2k9acgCnnrU0z4XjrigBlzKUURhhtA596plhsywwxPApzgkjJ680yRRs5oAR5GKqN3A6CoZEz0NRz7lA2g0RE5GTxQA8MU4xkH9KVepIyc0pO4Z7U8A5O3p1oAfGjE5A6UhOWORVi2fa3Q7ahlB3kgdaAHA5AxRUaHIx3FFAGL/AGtHCmLeIlumW4qH+2bg4+WP8qzafAAZAD0oAsNqN0Sf3pH0qJZPMm3zksT1qE9aO1AG5BtOzkL7ZrRAIXpx2rC0dQZSSK3pSQgAOBQAjtgA7fzppOAABxTCc4zSuf3dADgecdqX3Uc0R/6sUqcA0ARrlpPmPyipUwZhtHFROeTU9p9/8aALB5Pv2oIGOeooc8/jR1DGgCVVAHJxTQBuGPWo88AdsU9OMYoAc3HFJu6c0g5bmkYfL+NACjPbpSk7jgcU1+DgdKUcLnvQB6B8DtQFn8SNKZ3ADP5f512X7TQI8bWzEceQMe9eOeBJpE8d6UFcjE6n9a9z/ahRf7X0h8DeYsE0AeIJ/exScsCae3QVHuIdgDxQAYIx7UzeN4HXNEhIGPWo0A3H60ATfeGO3rTuw7mhP9XUi8r+FADQTkcUmc5IpzfeqJuCKAHk46HrSAAqCTzQ3AJ74oH3VoAeGyABx61Gy7+M1IKT+IfWgBbaRYL205/5ar/Ovrv4mwfb/hHIYxuAt0cflXx3dHEy47MCK+zrAm5+D8Pn/Pusec9+KAPiny8uStNO7PvVqcbLicLxhz/Oo5QNqnvQBFHkSDillGWIJ5pI/viif/WL9KAGMPmxmmjGcHrSkcUo5xQArDjg571FIC2R7VIfvU09DQBnSiSORjjdkYp0L4X5lI96tRfMvzc00qPMAxxQA4YLBhnbSLIV74GaQ/LuA6VCx+WgC8twh5cU5X80sVHGKx9zb+ta0Py2w28ZFAEW8tMV9KJpEDbSwFRRkm4aor0AupxzgUATfKyYBzTGiDgBcgis13YSHDEc0plkEuA7AfWgDRSIqpQ/gafGSuQc88U23kZwNxzRISACPWgC9GAUPOKa7ZcD2pq9B9KhLEknPNAETsIpSPWiobj/AI+k+lFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced maximum intensity projection 3-dimensional image from multidetector-row computed tomographic urogram shows characteristic papillary blush (arrows) associated with scattered calculi within the dilated collecting tubules. The computed tomographic demonstration is equivalent to the well-documented intravenous pyelography findings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Maw AM, Megibow AJ, Grasso M, Goldfarb D. Diagnosis of Medullary Sponge Kidney by Computed Tomographic Urography. Am J Kid Dis 2007; 50:146. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26912=[""].join("\n");
var outline_f26_18_26912=null;
var title_f26_18_26913="Patient information: Impetigo (The Basics)";
var content_f26_18_26913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15458\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/9/6290\">",
"         Impetigo",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/3/1087\">",
"          Skin sores caused by impetigo",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/55/8048\">",
"         Patient information: Impetigo (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Impetigo (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/impetigo-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H479239440\">",
"      <span class=\"h1\">",
"       What is impetigo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Impetigo is a skin infection that usually affects children. It can happen if bacteria (germs) get into cuts, scrapes, or other small openings in the skin.",
"     </p>",
"     <p>",
"      Impetigo is most common when the weather is warm and humid. It spreads easily between people who live together or spend a lot of time together.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479239447\">",
"      <span class=\"h1\">",
"       What are the symptoms of impetigo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Impetigo causes red bumps on the skin, usually on the face, arms, or legs. These bumps go on to form blisters that then burst and scab over. The scabs form a yellow, gold, or brown crust (",
"      <a class=\"graphic graphic_picture graphicRef59728 \" href=\"UTD.htm?6/9/6290\">",
"       picture 1",
"      </a>",
"      ). In some cases, the blisters leave painful craters with red rims (",
"      <a class=\"graphic graphic_picture graphicRef72412 \" href=\"UTD.htm?1/3/1087\">",
"       picture 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479239454\">",
"      <span class=\"h1\">",
"       How do I know if I have impetigo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will probably be able to tell just by looking at your skin. It&rsquo;s possible that your doctor or nurse will take samples of pus from one of your blisters. That way he or she can test the pus. But that is not usually necessary.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479239461\">",
"      <span class=\"h1\">",
"       How is impetigo treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on how bad your infection is. You might need an antibiotic cream or ointment, or you might need antibiotic pills.",
"     </p>",
"     <p>",
"      If you have just a few affected spots that do not go deep into the skin, you might just need a cream or ointment. But if a lot of your skin is affected, or the infection goes deep, you might need antibiotic pills.",
"     </p>",
"     <p>",
"      The antibiotic ointment experts recommend for impetigo is a prescription medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?5/63/6132?source=see_link\">",
"       mupirocin",
"      </a>",
"      (sold as Bactroban&reg;). You must put this medicine on the infected parts of your skin. Be sure to do this for as long as your doctor or nurse tells you to. Otherwise, the infection could come back.",
"     </p>",
"     <p>",
"      If your doctor or nurse gives you antibiotic pills, you will probably have to take them for 7 days or longer. Take all the antibiotics prescribed to you, even if your skin clears up before you finish the medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479239468\">",
"      <span class=\"h1\">",
"       Can I keep from getting impetigo again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The best way to keep from spreading or catching impetigo is to wash your hands often with soap and water. When washing is not possible, use alcohol-based hand rubs. It's also a good idea to clean the surfaces in your home with a household cleaner.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H479239475\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/55/8048?source=see_link\">",
"       Patient information: Impetigo (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/18/26913?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15458 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26913=[""].join("\n");
var outline_f26_18_26913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479239440\">",
"      What is impetigo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479239447\">",
"      What are the symptoms of impetigo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479239454\">",
"      How do I know if I have impetigo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479239461\">",
"      How is impetigo treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479239468\">",
"      Can I keep from getting impetigo again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H479239475\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15458\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/9/6290\">",
"      Impetigo",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/3/1087\">",
"       Skin sores caused by impetigo",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/55/8048?source=related_link\">",
"      Patient information: Impetigo (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_18_26914="Follicular pattern in KS";
var content_f26_18_26914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular pattern in Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This central plaque is formed by a confluence of small lesions surrounded by papules on the thigh.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26914=[""].join("\n");
var outline_f26_18_26914=null;
var title_f26_18_26915="Conivaptan: Patient drug information";
var content_f26_18_26915=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Conivaptan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     see \"Conivaptan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2473286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vaprisol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691940",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low sodium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to conivaptan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2790019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to make urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More thirst.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11476 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26915=[""].join("\n");
var outline_f26_18_26915=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2473286\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011242\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011244\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011243\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011247\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011248\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011250\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011246\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011251\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011252\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=related_link\">",
"      Conivaptan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_18_26916="Palonosetron: Pediatric drug information";
var content_f26_18_26916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Palonosetron: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34085?source=see_link\">",
"    see \"Palonosetron: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/57/36755?source=see_link\">",
"    see \"Palonosetron: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14877561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aloxi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       5-HT",
"       <sub>",
"        3",
"       </sub>",
"       Receptor Antagonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34085?source=see_link\">",
"      see \"Palonosetron: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents: Information based on small clinical trials: I.V.: Prevention of acute chemotherapy-induced nausea and vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Kadota (2007): A multicenter, stratified, double-blind randomized trial of 60 pediatric patients &gt;2 years [12 patients (1 month to 2 years) treated in an open-label fashion] showed 3 mcg/kg (maximum dose: 0.25 mg) and 10 mcg/kg (maximum dose: 0.75 mg) were well-tolerated and effective (no emesis, no rescue first 0-24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sep&uacute;lveda-Vild&oacute;sola (2008): A randomized comparison of palonosetron (0.25 mg single dose 30 minutes before chemotherapy) and ondansetron (8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 hours beginning 30 minutes before chemotherapy) in children 2-15 years, evaluated 100 chemotherapy courses in each arm and showed a statistically significant reduction in emetic events on days 0-3 in the palonosetron group and clinically significant reduction in emetic events on days 4-7 (up to 6 emetic events in the ondansetron group vs none with palonosetron)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prevention of acute and delayed chemotherapy-induced nausea and vomiting: 0.25 mg as a single dose administered 30 minutes before chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PONV: 0.075 mg immediately prior to anesthesia induction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic or renal impairment:",
"     </b>",
"     No dosage adjustment is indicated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aloxi&reg;: 0.05 mg/mL (5 mL) [contains edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse I.V. undiluted over 30 seconds; do not mix with other medications. Solutions of 5 mcg/mL and 30 mcg/mL in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, and D",
"     <sub>",
"      5",
"     </sub>",
"     LR injection are stable for 48 hours at room temperature and 14 days under refrigeration",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3137181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, and D",
"     <sub>",
"      5",
"     </sub>",
"     LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Ampicillin/sulbactam, atropine, carboplatin, cefazolin, cefotetan, cisatracurium, cisplatin, cyclophosphamide, dacarbazine, docetaxel, doxorubicin, epirubicin, famotidine, fentanyl, fluorouracil, gemcitabine, gentamicin, glycopyrrolate, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, ifosfamide, irinotecan, lidocaine, lorazepam, mannitol, meperidine, metoclopramide, metronidazole, midazolam, morphine, neostigmine, oxaliplatin, paclitaxel, potassium chloride, promethazine, propofol, rocuronium, succinylcholine, sufentanil, topotecan, vancomycin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fosaprepitant, methylprednisolone sodium succinate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe:",
"     </b>",
"     Compatible: Dexamethasone sodium phosphate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light. Do not freeze; do not mix with other drugs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of acute and delayed chemotherapy-induced nausea and vomiting; prevention of postoperative nausea and vomiting (PONV) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aloxi&reg; may be confused with Eloxatin&reg;, oxaliplatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Palonosetron may be confused with dolasetron, granisetron, ondansetron",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F205866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events may vary according to indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, QT prolongation, sinus bradycardia, tachycardia (nonsustained)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, flatulence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased (transient), AST increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, allergic dermatitis, amblyopia, anemia, anorexia, appetite decreased, arrhythmia, arthralgia, bilirubin increased (transient), chills, dyspepsia, edema (generalized), electrolyte fluctuations, epistaxis, erythema, euphoric mood, extrasystoles, eye irritation, fatigue, fever, flu-like syndrome, glycosuria, hiccups, hot flash, hyperglycemia, hypersensitivity (rare), hypersomnia, hypertension, hypokalemia, hypoventilation, injection site reactions (burning/discomfort/induration/pain; rare), insomnia, intestinal hypomotility, laryngospasm, metabolic acidosis, motion sickness, myocardial ischemia, pain in extremities, paresthesia, platelets decreased, rash, salivation increased, seizure, sinus arrhythmia, sinus tachycardia, somnolence, supraventricular extrasystoles, tinnitus, T-wave amplitude decreased, vein discoloration, vein distention, ventricular extrasystoles, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to palonosetron or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with, or who may develop, prolongation of cardiac conduction intervals, particularly QT",
"     <sub>",
"      c",
"     </sub>",
"     ; conditions include hypokalemia, hypomagnesemia, or congenital QT syndrome; use with caution in patients receiving antiarrhythmic or other medications known to prolong the QT interval (eg, class I or III antiarrhythmic agents) or medications known to reduce potassium or magnesium levels (eg, diuretics)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palonosetron may cause ECG interval changes (PR, QT",
"     <sub>",
"      c",
"     </sub>",
"     , JT prolongation and QRS widening); interval prolongation could lead to cardiovascular consequences such as heart block or cardiac arrhythmias; hypersensitivity reactions may occur in patients who have exhibited hypersensitivity to other 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonists (eg, ondansetron, dolasetron)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F205854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline ECG in high-risk patients, emesis episodes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palonosetron is a selective 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonist, blocking serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Adults: 8.3 &plusmn; 2.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 62%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized to 2 minimally active metabolites (&lt;1% activity of palonosetron)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 21-37 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine 80% to 93% (40% as unchanged drug); feces (5% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Adults: Total body: 160 mL/h/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/57/36755?source=see_link\">",
"      see \"Palonosetron: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Eisenberg P, Figueroa-Vadillo J, Zamora R, et al, &ldquo;Improved Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting With Palonosetron, a Pharmacologically Novel 5-HT",
"      <sub>",
"       3",
"      </sub>",
"      Receptor Antagonist: Results of a Phase III, Single-Dose Trial Versus Dolasetron,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2003, 98(11):2473-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/18/26916/abstract-text/14635083/pubmed\" id=\"14635083\" target=\"_blank\">",
"        14635083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gralla R, Lichinitser M, Van Der Vegt S, et al, &ldquo;Palonosetron Improves Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy: Results of a Double-Blind Randomized Phase III Trial Comparing Single Doses of Palonosetron With Ondansetron,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2003, 14(10):1570-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/18/26916/abstract-text/14504060/pubmed\" id=\"14504060\" target=\"_blank\">",
"        14504060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kadota R, Shen V, and Messinger Y, \"Safety, Pharmacokinetics, and Efficacy of Palonosetron in Pediatric Patients: A Multicenter, Stratified, Double-Blind, Phase 3, Randomized Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(18S June 20 Suppl):9570.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sep&uacute;lveda-Vild&oacute;sola AC, Betanzos-Cabrera Y, Lastiri GG, et al, \"Palonosetron Hydrochloride Is an Effective and Safe Option to Prevent Chemotherapy-Induced Nausea and Vomiting in Children,\"",
"      <i>",
"       Arch Med Res",
"      </i>",
"      , 2008, 39(6):601-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/18/26916/abstract-text/18662592/pubmed\" id=\"18662592\" target=\"_blank\">",
"        18662592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siddiqui MA and Scott LJ, &ldquo;Palonosetron,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(10):1125-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/18/26916/abstract-text/15139789/pubmed\" id=\"15139789\" target=\"_blank\">",
"        15139789",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA and Xu QA, \"Physical and Chemical Stability of Palonosetron HCl in 4 Infusion Solutions,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38(10):1608-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/18/26916/abstract-text/15328393/pubmed\" id=\"15328393\" target=\"_blank\">",
"        15328393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12965 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-5203FA14AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26916=[""].join("\n");
var outline_f26_18_26916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14877561\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060801\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060794\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205824\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205812\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060804\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3137181\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060797\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060803\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205868\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205866\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060807\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060793\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060792\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205854\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205819\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205821\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205831\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060800\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060791\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060806\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060799\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34085?source=related_link\">",
"      Palonosetron: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/57/36755?source=related_link\">",
"      Palonosetron: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_18_26917="Streptomycin: Pediatric drug information";
var content_f26_18_26917=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Streptomycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"    see \"Streptomycin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/48/40707?source=see_link\">",
"    see \"Streptomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14595275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Streptomycin for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Aminoglycoside",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitubercular Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V. (Reserve I.V. for patient who cannot tolerate I.M. injections): 10-20 mg/kg/day once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Congenital tuberculosis: 20-40 mg/kg/day (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"      see \"Streptomycin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V. (Reserve I.V. for patient who cannot tolerate I.M. injections):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants: 20-30 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tuberculosis: 20-40 mg/kg/day once daily, not to exceed 1 g/day;",
"     <b>",
"      or",
"     </b>",
"     20-40 mg/kg/dose twice weekly under direct observation, not to exceed 1.5 g/dose; usually discontinued after 2-3 months of therapy or as soon as isoniazid and rifampin susceptibility is established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Other infections: 20-40 mg/kg/day in combination with other antibiotics divided every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plague: 30 mg/kg/day divided every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tuberculosis: 15 mg/kg/day once daily, not to exceed 1 g/day;",
"     <b>",
"      or",
"     </b>",
"     25-30 mg/kg/dose twice weekly under direct observation, not to exceed 1.5 g/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enterococcal endocarditis: 1 g every 12 hours for 2 weeks, then 500 mg every 12 hours for 4 weeks in combination with penicillin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Streptococcal endocarditis: 1 g every 12 hours for 1 week, then 500 mg every 12 hours for 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tularemia: 1-2 g/day in divided doses for 7-10 days or until patient is afebrile for 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plague: 2 g/day in divided doses until the patient is afebrile for at least 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Administer 7.5 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer 7.5 mg/kg/dose every 24-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 7.5 mg/kg/dose every 72-96 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Inject deep I.M. into a large muscle mass; administer at a concentration not to exceed 500 mg/mL; rotate injection sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: I.V. infusion through a peripheral or central line; 12-15 mg/kg/dose is diluted in 100 mL of NS; infuse over 30-60 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F223228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Esmolol.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Streptomycin injection should be stored in the refrigerator",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination therapy of active tuberculosis; used in combination with other agents for treatment of streptococcal or enterococcal endocarditis, mycobacterial infections, plague, tularemia, and brucellosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Streptomycin may be confused with streptozocin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F223227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drug fever, headache, neurotoxicity, paresthesia of face",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, exfoliative dermatitis, skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity (auditory), ototoxicity (vestibular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Azotemia, nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Difficulty in breathing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Drug reaction with eosinophilia and systemic symptoms (DRESS), toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to streptomycin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing vertigo, tinnitus, hearing loss, or neuromuscular disorders. Use with caution in patients with renal impairment; modify dosage in patients with renal impairment; monitor renal function carefully during therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Parenteral form should be used only where appropriate audiometric and laboratory testing facilities are available",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminoglycosides are associated with significant nephrotoxicity; risk of nephrotoxicity is increased in patients with impaired renal function, high dose therapy, or prolonged therapy. Risk of nephrotoxicity increases when used concurrently with other potentially nephrotoxic drugs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; renal damage is usually reversible. May cause severe neurotoxic reactions; risk of neurotoxic reactions increased in patients with impaired renal function",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; neurotoxicity is manifested as disturbances in vestibular and cochlear function, optic nerve dysfunction, peripheral neuritis, arachnoiditis, and encephalopathy. Headache, nausea, vomiting, and disequilibrium may be indications of vestibular injury. Loss of high frequency hearing is indicative of cochlear toxicity. Risk of ototoxicity increases with use of potent diuretics. May cause neuromuscular blockade and respiratory paralysis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; especially when given soon after anesthesia or muscle relaxants. Aminoglycosides can cause fetal harm when administered to a pregnant woman aminoglycosides have been associated with several reports of total irreversible bilateral congenital deafness in pediatric patients exposed",
"     <i>",
"      in utero",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5722065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Streptomycin crosses the placenta. Many case reports of hearing impairment in children exposed",
"     <i>",
"      in utero",
"     </i>",
"     have been published. Impairment has ranged from mild hearing loss to bilateral deafness. Because of several reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy, the manufacturer classifies streptomycin as pregnancy risk factor D.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hearing (audiogram), BUN, creatinine; serum concentration of the drug should be monitored in patients with renal impairment; eighth cranial nerve damage is usually preceded by high-pitched tinnitus, roaring noises, sense of fullness in ears, or impaired hearing and may persist for weeks after drug is discontinued",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1049988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic serum concentrations: Peak: 15-40 mcg/mL; trough: &lt;5 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial protein synthesis by binding directly to the 30S ribosomal subunits causing faulty peptide sequence to form in the protein chain",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into most body tissues and fluids except the brain; small amounts enter the CSF only with inflamed meninges; crosses the placenta; small amounts appear in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 34%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (prolonged with renal impairment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 4-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-4.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 30% to 90% of dose excreted as unchanged drug in urine, with small amount (1%) excreted in bile, saliva, sweat, and tears",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use by patients with active tuberculosis that is resistant to isoniazid and rifampin or patients with active tuberculosis in areas where resistance is common and whose drug susceptibility is not yet known. Pfizer will distribute streptomycin directly to physicians and health clinics at no charge. Call Pfizer at 1-800-254-4445.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 21:9-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      1992, 89(1):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/18/26917/abstract-text/1728006/pubmed\" id=\"1728006\" target=\"_blank\">",
"        1728006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arguedas AG and Wehrle PP, &ldquo;New Concepts for Antimicrobial Use in Central Nervous System Infections,&rdquo;",
"      <i>",
"       Semin Pediatr Infect Dis",
"      </i>",
"      , 1991, 2(1):36-42.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/18/26917/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorin MI, Hsu KH, and Jacob SC, &ldquo;Treatment of Tuberculosis in Children,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1983, 30(2):333-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/18/26917/abstract-text/6602321/pubmed\" id=\"6602321\" target=\"_blank\">",
"        6602321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12807 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-393BA8AD0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26917=[""].join("\n");
var outline_f26_18_26917=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709418\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14595275\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049985\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445115\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049978\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223184\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223168\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049990\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223228\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049982\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049989\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223230\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223227\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049993\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049977\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049976\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300082\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223177\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223180\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722065\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049984\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049988\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049975\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049992\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049994\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12807\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12807|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=related_link\">",
"      Streptomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/48/40707?source=related_link\">",
"      Streptomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_18_26918="Growth plate anatomy";
var content_f26_18_26918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Anatomy of the growth plate (physis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 406px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGWAh0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArGvNQniuZEQrtU4HFbNeU6p4/0y28WajpepB7VoJtgm+8jdOuOR/nmuDMJzhBODtqd+Aws8TKShHmsrnb/2rc+q/wDfNH9q3Pqv/fNZdrcwXcKzWs0c0TdHjYMD+IqavH+tVv5mbujBOziXv7VufVf++aP7VufVf++ao0UvrVb+Zi9lDsXv7VufVf8Avmj+1bn1X/vms92VFLOwVRySTgCsa58VaLBJ5Zv45ZP7sIMv/oINNYmu9pM0p4X2nwQv6I6n+1bn1X/vmj+1bn1X/vmuQ/4Sqz/ht7wj18sDP5mq/wDwnGjK5Wd54SOu+In+Wat1cSurNlltR7U7/I7f+1bn1X/vmj+1bn1X/vmuY07xNouo4+yalbux/hZtjH8Gwa2B0qPrNZfaZhPC+zdpws/NF/8AtW59V/75o/tW59V/75qjRS+tVv5mR7KHYvf2rc+q/wDfNH9q3Pqv/fNUaKPrVb+Zh7KHYvf2rc+q/wDfNH9q3Pqv/fNUaKPrVb+Zh7KHYvf2rc+q/wDfNH9q3Pqv/fNUaKPrVb+Zh7KHYvf2rc+q/wDfNH9q3Pqv/fNUaKPrVb+Zh7KHYvf2rc+q/wDfNIdVuACSyADkkiua1rxJpOjIxv72JHH/ACyU7nP/AAEc15tqvjPVfFt42m+HdPla2Jww/vD1kPRV9s8+/SrjXry+0zuw+VSrrnceWPd6L/gnQ+I/iVrkmrRWnh1oD5ziG3R4gzStnl/Zf8M16RZ6lfpaQrdSxy3AQCR1TaGbHJA7DNcT4M8HR6JK1/fSi71aVcNLj5Yh3VB6e/f2rrqdTF1NoyYY1YaTVOhBWXW2rMjxF4r1XT79Y4WhEbIGGY8+o/pWX/wnOs/34P8Av2Kg8asPt8C9xFn9TXO1pDEVWviZ8Njas6deUYy0udT/AMJzrP8Afg/79ij/AITnWf78H/fsVy1FV7er/Mzl+sVf5mdT/wAJzrP9+D/v2KP+E51n+/B/37FctRR7er/Mw+sVf5mewyarcrGpBTOM/dp2gapcX19cRTFSsagjAxzms+44QD2pfBQLahqbnsEA/wDHv8K94+gOtooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvO/GHhHRddvrh76zUXBP+vi+ST8x1/HNeiVzWo/8fs3+9Xm5m2qcbdztwNSdOpzQdmeUy+A9c0qUy+H9WWVeyTlonx6bl6/jiozqPjrThifT7uUDvGY5gfy+avUqK8f2r6q57qzOpL+LFS9UeVP4w8X42poN9u9Tp7/zziq5uPiPqz/uoZ7WIn+IRw4/P5q9drn/ABtrC6RozOHKSzHy1I6gYJJHvgce5FNS5nZI2o43mmoUqMbvurnjV/Ya9qOuDSHvH1O9P39szvHH65Y8DHfHHbrXe6R8L4IolOq6ndyy45S3by0Htzkn68V1XhDQ00fTdzoPttxiS4b37IPZeg/PvW9RKo07RNMZnFWf7ui7RXbr5+RyUXw98PIPnt7iU+r3Un9GFMn+HPhqUHFnMh9VuZCf1Y12FFRzy7nm/XcRe/tH97PN7v4V2qBjpOqXdsx/hmVZV/of51nx+HPGuigpp88dzF1X7PceX/44/wAtesVi+KPENp4esfPumDSPkRRZwXI/kB3NVGpJ6bnZRzHF1Gqfx36NXPOr/wAS+ONKgMt5aSpEn3pJooyv5risyH4ieKb1/Kso45ZP7sFsXb8ua6y38K33iu7i1HxRLJHZj5orNWKkg+uPuj2HzeprvNPsLTTbZbewt4reBeiRqFH19z71UpRXTU7KmOwtGPK6UZT62Vkv8zzC0h8f6yn7+MW6N/FdS+WD/wAATn8xUkvw712ZSZNU05ZDzhbc9fr1r1Wip9tJbaHA81rJ/u0o+iPHH8CeMrQlrLVYOBwIbmSM/wAsfrSpafEOxXbJHeXK/wB5LxW/mc17FRR7V9UjT+2Kz0nGMvVHj41nxrA206drWR6RLIPz2Gpote8cvwun6j1532qL/wCyivWqKHUT6IX9pw60YfceT3ereOktnlltpoIEG55JDBGAPckVzunTeLfGExhs7i7a2zh5XlZIl+pHX6AE13vjhn1vXLLw5CzqshDzMOy4yx+oXge7D0rtbG0gsbSK1tIligiUKiKMACqcuVJ21Ot5isPSTjSipy1Vlsv+CcBovwr0+DbJrF1LeydTGn7uP9OT+YrvNN06z0u1Ftp9tFbQg52RrgZ9T6n3q3RWTk5bnkYjF1sS71ZNhSUtcz4k1tEie0s3DSN8ruvRR6A+tJK7sefiMRDDwc5/8OYXiC7W81WaRDlF+RT6gd/51nUUV1JW0Pi6lR1Juct2FFFFMzClAyQPWkp8A3Txj1YD9aBo9Ru+9T+ClwL9vWRR+QP+NQXner/hBR9iuGHeYj9BX0Z9Kb1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwGv+IrS01W6haOZpEfBwBj+dZvx11u8Onab4M8PyFde8Tym0V1PNvbD/XTHHYLx+JI6VzesWKaXqMlhHLNMlqFhWSZy7uFUDLMeSTjk15+YxUoK/c58Rip4aPNT3Zuy+LD/wAsrTj1Z/6YqBvFdyR8lvCPrk1zTuqDLsqj1JxUDX9opw11AD6GQV5PJE5I4zHVvgbfov8AJHUHxTfHpHbj6Kf8a4vxprFzqOt6LHcumyOUPgLgcsvX8qmn1azhQnzhI3ZI/mY+wArPh0mTVpZrrUonjeRdkMSn5olHOf8AeqlBLoetlmJr4Oo8TjXKMbNLu21bRO17XvfbTe7R2ja/qZ/5efyRf8KjbWtRbrdyfhgVy4i1uwYLIYruIf3gUkx/Kr1peR3OQMpKPvRtww/CjkXY8yvRxMYupCrzxW7Unp6p2kvmrGu2q37DBvJ/wcioWvLlvvXEx+rmorXTJtWvIrW1MvnPkKEfb7kn8q2H+G928hgOuRvcYybYXWG+nCg1pToTmrxRjQpSrx5nN6eTf6nN3uqpA2xpmknP3YlYlifpWBZW1xqHiKSXU8FrdVYRg5CE8qP6/Wuol0EaDdSW8lmLefHJPJYeu7uPxrDu5JNL1ea7aF5LO5VRIyDJjZeASPTFS1bQ9TAYmFP2tDCK05RaUpaSburpdI6Xsrtt216HQCaUdJHH/AjTxdXA6Tyj/gZrNt9Rs7gAw3MLZ6DeM/lVpXVwdrBvoc1Njw6lKvR0qRcfVNFoX12Ol1OP+2hpw1K+HS8uP+/rf41UzRmiyM1VmvtMvDVr8f8AL5N/30aeNZ1Ef8vcn6VnDrVkWF4RkWlwR6+Wf8KFG/QpV63ST+9loa7qQ6XTfiq/4VIviHUx1uAfqi/4VlyxyRNtljdG9GGDUMsqRRtJKwRFGSxOAKXKuxccTiG+WM5X9WVLLXLuD4hXV0/lPLLbbV3Lx0TsP9yuyXxXc4+a3hJ9iRXmRtbnWL99StH+zpGAtuzDmQjufbrWjFrixDZqNvNbzr975Cyn3BHahxTPqMxWKq+z+qz5pxhGM4rVqSXbr52vZ3TO+HiyXHNqn/fZpD4sn5xbRD6sa4u21jT7htsV1GW9Cdp/WrysG5Ugj2pezj2PDrYjMKGlbmj6q35o1b/XL29Uo8gjjPVIxgH+tZlJmjNUklsedUqzqvmm7sWimPIiffdVx6nFKrKwypBHqDmmS4ySu1oOopM0ZoJFqfT13X9svrKo/UVXzVzRhu1exH/TdP8A0IU4q8kVDWSPSdQ4BNX/AAXzo7N/emc/yH9KzdRb5G+la/hBdugQH+8zn/x419EfSGzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVFdXENpazXN1IkVvChkkkc4VFAyST6AVLXnvxo0nX/Euh2HhvQYnSz1a7WDVL1XUfZrUfM+ATklsYGAR1BxkUAW/Ak+geNmtPH1jpVxBfTW8llBcXQKu0AkPKruIAJBIOAcE9jXF+MsnxNqQyR+8PI+lexaXYW2l6ba2FhCsFnaxLDDEvREUYA/IV474x/5GfUf+up/kK4cf8C9Tz8w+Bepz1tpVg95E12nmAsA0kpMhUZ5Iz0/CvTLzRbOz1S1sdN8EW9/p0oUvfCaNQgPU4PJwOfftXndWEvLlIfKS4mWI/wAAchfyrjw9eNK/NHmMMPmEqbftPe9W9DU8YWWlWGsNDoqqkSqPMVDlVf0B/Ktq21iJfCkFnoeqW+jaopBklntvND9c+3PByc9MYo8E2dnNo2oXENpb3+sRhjDbTsApwPl68cnv/KtfQ7e6vrO7bxl4e0rSoVA8to5VZj1zkjp2712YalNXrwsvI6cNSqa4mLj6MyZddRPClxY61qsOt6nJu2SxW3lqgOMdgMjk5FeZ+Io3WzF5Ads9sQ4I7rnkH27/AIVs3AjE8ohJMQY7Ce4zxWZrjMbBoI8GW4PkoPr1P4DJrhr1pVpc0vwIweKnUx1Oo7LVX7W638rXv5G14f1aTT7211G2AYgbtrdGUjkfka3Re+Dzrg1tvD0i6sJPO81ZDjzM53Y3YznnOK4O1mk02Bbe9RjFGNqTopKlR03Acqf096txX9pL/q7qBvYSCnRxNWimoO1wccThpS+rXcG9GtU1/wANunr3R22oyyeLLm51K4eLT9NsYv3ksh3bF5P4nr/nrV8P6ToniY3Mfh3XvtU1uAXD2rxjnpyf/r1naNrd7pJk+xSLslGHR1DK34VoP4x1byTFbvBaoe0EQWtYVMO4t1U3JmEKuGcG60W5s4fXdDj0vVJbgwxboGZLiMAFWx1Ye9I2npKEvNKnaCZhkHJKOPRh/hWxITIWMhLFuWLc5z61jWLrpMxsbhgtszE20jdMHnYT6j9a42+x6FDMMRXockJtzhst+aHVNbS5d9tr9Ejc8KRPruopYO8dpdA7ZA54BxnI9c9q2NZsdB0bWE0rUPEXlX7bcRfYZG+905GRXNXFuWnS5t2CXMYwD2Yf3T7e/auhsvF2uLbKou5UxxiVFZh/wIg5/OuihKhH+LFv0ZxxlhP4koOz6J7P/Lt9z7vZutCl8I3tnqc8kF3AkuPL+6xOD0B9OtQeJdTttcv47u18SeIdI2qB5EGPLyO+Awz+Oap20F1r63V9q2prBZ2igy3Fy3ypnoAOn8qdJodlcaJcapomtW2pW9udsuxdpU8cdT698V0Up1qSdShH3fPUdGpXoxdXDxtHz1L3i7xNZahodtap5s80ADSXUyBCcLyQAe/XHSvPWtl1Zo5bjcbVTlI88OfU+38/p1j8U3i22mtFuAkn+Qew7mtW3jWGCOKP7iKFX6AVxVKrqS5pbm7qVcPhljLWnUbSfZRtdrzbdr9LOx0egWVpLpd1MiW11qcbBYbO4uPIjK8fNu79+Pb3rSiWE6Lff8JNY6LY3Kj/AEUadPvkY4PUfXHf16Vxtdhr9tp3h9LBD4Z1TWLWeIO99ZMzlWPbYOPfnA5713YW9WDpQgr92Y4PmrwdGnCLfd7mJa6Fp9zoVxq2rJPLbRSCIpbW3nyDjO4jsOazbjw1DfaFJrXhbUJ/ssL+W4ljaNkbjgq3Ucjoe/Sut13SpPD9laapo91e28NztBilykiEruAYD8cg9KxNQ8Q6pqFr9mvLx5IMgldqjOPXA5/Gsp+ypwdOcXzd7mlPGywUHSV1Jed4v1i9GjkU1swsbe9t5/tifeWGMuG9xjtTjcalfMFtrc2cB6yT/fI9lHT8akv12axp0y8Fi8Te42kj9RXTaboOp6lF5tnaPJF/fJCqfoSRmuSMXJ2SuXVrUaXs6uHormmr63aTu07R23V1e+5gR6TbylUkiNzIxx+8+bJPoOg/AV0A+Gt3GSbeCKG4A3bIbna/5Zx+dXbTw/rlhdwXaac0hhdZAFKuCQc9jUck3h2DXDq48M+VrSSmUubqQKJc5LFOmc9sV1UadLX6w2u2hFHF1XzPFVZpv11MBYLi2leK4kZih2lXTDgjrnHH6U/Nay2Gq69dT3cNpLMZXLM6rhMnsCeKqalpt3pkwivoGhdhuAbByPYiuZwa1toeXU5pPntp6W/LQqZrR8OLv12yH/TQH8uaza2PCS7vEFr7bj/46adJXnFeYqKvUivNHc6kflb6UzSfBmmXmnw3M9zrySzAuywa7fQoCST8qJMFUewAFGpH5G+ldVo67dJsh/0xT+Qr3z6Mwf8AhA9I/wCfzxJ/4Ueo/wDx+s+y0qPQfiTpNrYXmrvbXWk38ksV5qlzdozxzWYRgJpGAIEjjIx9413VcjrM0dv8TNCmncJFHoeqO7N0UCaxJJoA66ivPfCHxEu/E72V5beHJ7fQL1n8i+nvIlkMY3YlaDO4ISpHUnvjHNXrb4oeDrmK+ki1pPKs7c3crtBKqmENtMiEqBIm4gbk3DmgDtKK4m/+Kvguxsobu41yP7POJWiaOCWTzBHjeVCqSQMg5HbnoDVe9+Kvht9H1W80TUrO+k077O0qTPJBHtmkVFYP5bbgd3BUMM4BIzkAHfUVx918SvCNrr66LcawiakboWXlGGTCznohfbtBOeMkZqK/+JXh+E6nbWtxLLqdna3NylrNbzW4uPIUlxHI6BWxjkqWx1oA7Wisrwnq/wDwkHhXRtZ8j7P/AGjZQ3nk79/l+YgfbuwM4zjOBn0rVoAKKKKACgkAZJwKK828S6rJql88SSH7JG2EQcA+59a5sTiY0I3erZtRouq7I9HSRHzsdWx6HNOryiC2ljdXgdopB0ZDgiuq0jxJJCBDrIx2WdR1/wB4D+dYUcwjUdpqxpUwrirxdzraKZFIk0ayROrowyGU5Bp9egcoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU9Y1K10fSbzUtQlEVnaQtPM5/hRRkn8hXCfBG613XNF1HxT4gubgR67dG50+wkbK2lqPljAHYsPmOODwepNX/GMnhrxlqd18PNWku5LmW1S/nityygRiQYDOvAyQPlPUEe1drDFHBDHFCixxIoVEUYCgcAAelAD68U8Y/8AIz6j/wBdT/Kva68T8Y/8jPqP/XU/yFcOP+Bep5+Y/AvUy7eCW4kEdvFJLIeiopY/kKlurC8tP+Pq1ngH/TSMr/Oui8A6xa6ZPeQ3cnkG5UKlwFzsIz1/P9Oa6HQW1DT7e/XxT4g03WNKZP3MgRUlPqCF4PH1Oa56OFhVpufPZ9jmoYSFak586TXQ8zBwcjg0rMzfeYn6mh8bjtyFzxn0qzpUltFqVs9+hktVcGRR3Fca1djhWrsRx208q7o4JXX1VCRVDyZGvzJMm1YgVjB6knq39Pzr0XxBqV3fahbS6B4wtNJ0xEAa3NkHfI9iOeMDHFUfHuuafqxtlsAZJIs75ym3I9BnmuuthoU4cymm+x6M6MMPTcoVE21bzXf8NOulyl4J0W31rVHiu3YRRJ5hVTgvyBjPpzWxpHkahrpsn8B3Fppqbg9/eOEwADg7T1z7E9a4q2uJrWYS20skUo6OjFSPxFbWg6uG1u3l164nubQE7hKzSKDjgkd+aeGr0oLllBNvqycJiaVJcsoJt9X0KGt21tbateRadg2iSEIV5GPTNUK9Ej1We38Qm8l8X2b6HliunpYjcFIOF3D5uOOe+Olch4ovLS/1qe40+Ly4GxgbduTjk47VOJoQp6xmnfsRi6EKfvRmpX7GVU8ul3M0BEtjNJC3XdCSp/Srfhq4tbXXbOe/GbZHy3GccHBx7HBrtr6/12XxEl3p3iTQE0DchME3+s24G4Z9euOR9KeGw0ayblK1h4PDRrXk58rR5ZDCbKYRLn7O3Cqf+WbDt9P5fjVuur+Id9p1/qUD6c6SOqESyIOGOeOe/fmqfhTRINWF7Pe3DxWtonmSCNcuRyeBg+h7GsfZN1PZw1IrRlWrcq1l37+fr37+ph2WvtpbTJHP5Ucg2yLNF+7kHodw2mpNT8YNJp/2MT24tyci1s41G8/RR649q3dN0nRPE1nPN4Q1Y3UsP37e4Xa/8h+eMe9P8E+H7DUVv571ZG+zAHyIRhn4PpyemMetbOjXhL2LurnWqUqU1QqRlr05rJ/gcFa6cbnzbjU0V5plKiPtEn90e/qaLaWbTCLe93SWw4iuAM4H918dPr0rvtPsvD3im2vz4Ynu4b2yAMtrdIVI68c9OhHU9K5esq9CdCXLURWKr16c3TxUbxfTa1tuXtZff1uMhmimXdDIki+qsDWrY65qdhEI7S9mjjHRM5A+gNXLzwxpekmGfxHrdhpd3IMqjYaQj35BI/MVf0zTLLQ/F6W2syRS24TfFIw+Qk/dLA/j+NUsPVhaTVk+pySw1Sm4yScU+r/r/IwdQ1DUdTRXvZ5p0Tpu+6P6VQrvrGfxpHryTalq/hyPQkkyyRn70Wei5GQcep/Ouc8ZXFjc69NLpm3yCBkouAW7kCtMVhvYpS51JsvGYT2CUvaKTZy98ub7Tm7CVv8A0W1dLZeILqDTJNNuI4LzTpFKNbzrkYPUAjBrDkjWTZuH3WDD2IrW0zSWvLS5vJrm3s7G2x5txcPtVc9B9a56Lqc69nuZxq1J+zjSvzRVvxb/AFG6M+g6NqEd9pvh2GG8jOUcXcxCn/dLEUmt6pNrGoPd3CRo7ALiMYGB/OrWm6LBrQmHh/V7DUpIRl4o2KuB64I6e9YxBBIPUVtiZ4hvlrt/MeMqYpvlxLfzNwapZ3/h+PRtYS9W3iYtHLYzmJ+/DDo3U9aq6nfW8thY6fp8MsVlZKwjM0pkkYscklj/ACrMorOWJqyp+yb0M5YurKl7Fv3Ra3/BKbtbB/uxsf6f1rn66jwEmdRuX/uw4/Nh/hSw6vViThVerE6PVD+7f6V2lkNtnAvTEaj9K4nU8lWUdTxXeAAAAdBxXun0IVyOswx3HxM0KGdA8Umh6ojq3RgZrEEGuurldS/5Kn4e/wCwLqf/AKPsKAOL0n4I2VjrWjXE2szXWn6Os0VlbyWsYmWGQMPJecfM6LvcqCONxqtafAm0tdF1HSotYj+zXFk9jFL/AGbELhEZlI3yjBfG3H8OepzXs9cR8YvEMvhjwRcanbahcWVyjqsP2e3SZpnIOI8OCqgnksegB+lAC+J/AMWu6lY3b6g8JtdKu9LCiINuE6Kpfr1G3OO9c5f/AAZt7vSXsTrUqhtH07SN/wBnB4tJVkD43dW24x2z1NcnqvjjxZaaHo7S+KFKyaVdXX9qWOmLKl5qCuAlmFKEAY4yArNjgjsnifxr8QUsvFWpQ3v9ly6FYaTeHTfsCSiSWdMzRFmG4ANkccj1FAHoN98MIbv+1c6pIv2/XoNcP7kHY0Wz9315B2dffpWBafA+GDWZL+TX5J5Giv4fMks0M7i6QrmWbO6Qpu4zx2AGTnNufG3jJfi4+lzXcFhYR6vFax6fPAcXVm20eahEJZnOSdwkCrjDADmvdqAMvwtpC6B4Y0fRkmM66dZw2glK7S4jQJux2zjOK1KKKACiiigClrc5ttJu5lOGWM4PueBXk8b4fNek+NWK+HLnHcqP/HhXlyMS/sK8TM5fvEvI9LBR9xs6jTmDAZq/PbpNEQRkVh6dLwOa2IZsDk1wwmtmbzi73RmQ3GoaNMTZTN5WeY25X8q2LTxuQyrfWRA7vE2f/HT/AI1FIEk6gGs66t4iT8lawxVWjpF6EOlCp8SO5sdc069A8m6jDf3HO0/ka0gQRkcivJH09pWwoIFT2tnf2g/0a5niHojkD8q7IZm/tx+4wlg19lnqlFeepqmuwLxdFwOzxqf1xmpV8Ta4g5htX+qMP610rMqT3ujJ4SfSx3tFcPH4r1Uf62xt2/3Sw/xqUeMp0X97pwz/ALMv/wBarWPoPr+BP1Wp2Ozorjh4145sGH/bX/61H/CaE9LH85f/AK1P69Q/m/Bi+rVex2NFcYfF90w+Syj/ABYmn2/jBw+LqyCj1R/8aSx9C+4/qtTsdhRVLTNTttRj3Wz5YfeQ8MPwq7XVGSmuaL0MGnF2YVX1K5az066ukgluXgieQQQjLyFQTtUdycYFWK801XxNqusfGPTfC/hu6EOn6REb7XZQitu3riK35HBOdxxzg5ByKoQnwO8O6haaVqPinxNC0fibxLP9suo3BBt4hkRQgHkBV7HkZwelemUUUAFeJ+Mf+Rn1H/rqf5V7ZXiXjL/kaNR/66n+Qrhx/wAC9Tzsx+Bepj0Vas9Nvr1S1paXEyjqyISPzpLvT72y5u7W4gHrJGVH615fK7XseTyyte2hWopKKRItFJWzZ+GtUurdZ1gEcTcq00ix7voCc1UYSk7RVy4QlN2irmPRWhqGiajYR+Zc2riL/nohDp/30MiqEaPLIkcas7sQqqoyST2FJxcXZoUoyi7SVmWbDT7zUJCllbSzsOuxcgfU9qdqGmX2nEC9tZYd3QuvB+h6VseMdH1S98m30fW5NC04IP8AQmXyX3dyzBsvn3qDw1pOpeGVnk1vVb/VdKmiZWtWt2eJj2YOzYUg9xXqPL6apc8qmvoz2HllKND2kqvvdrMwqKStu+uNTsfDunz+DNNtdQvCX+3b4xNMmMbQqE52kZ6A9BXDhsO8RPkTS9TzsJhniqipppepi1d0jVLrSbwXNlJsfoQeQw9CKm069bxHod/c6joraPqlhtLukTRwzgnGNrdG9uf8MunXoTwtTkluPE4epg6vJJ6rsdUni1bc3M1ho+n2d/cLtkuYYwrN7njk/UmufsL+60+5FxZzvFMP4h39j6/jTvEOt6B4Xvo7DUNH1K6YxJJ9qEwRJNyg5QdwM4/CpIptB1zR7jUfDtxco9sVFxaXagOgY4DAjgjP1/CuqvhMXyKtPVI7MRgsb7NYipql1uatx4z1Se2mhIt0aZdjypHhyOnXNc3SUVwTnKfxO55k6k6msnc6KfxLHdvDcahoulXuoQoES6uIAzgDkfqSeKyNTv7jU7x7q8ffM/U4wAOwA9Kt+FbWzvdct4NRYiBs8btu444Ge2TVDVPFs1jeSW0vw7kiVDjbI8m4j13Bcflmu6jh8RjY6Sul3Z6WHwuKzCNlK6XdkNFa2LTUfCw1ddJu9FuPtHkrbTOXWUYyWUsAcVkVx1qEqE3Ce5w4ihPD1HTnujdk0OCws7a61/VrLSo7gbolmbLsOOdv4j86vwQSabok+p+HtZtNS01mEVwFUMpPHDKcjuPfms6fxFLeWkFvqmnaXqSwDbGby1EhQe35Cq93rU8+niwhgtLKxDbzBaQiJCfUgV08+GjTvC/OdXPhIUr0+bn7ksXiC8t45EsI7OwEgw5tLZIi31IGatanpmg6DZWk3iPXfssl1GJEjjgZyQfTGc/XiudrWsvEWqWdukENzuhT7qSIrhfpuBxWdKtBzviLyXqZUa8JTviryXqP1vSoLOzsL7T7s3dhfIXidozG2BjqDz3rHq5qeqXuqSK9/cPMy525wAPoBwKpVhVcXJuCsjnquDm3TVkLXXfD5PnvpPRUX88/4VyFdx4DTbpd1L/el2/kB/jW2EV6qN8Cr1ka7L5uoW8fZpVH6iu3ri9P/ea7aJ1+Yt+QJ/pV648JefcSy/8ACQeIY/MYtsjvcKuTnAG3gV7R7x01crqX/JU/D3/YF1P/ANH2FH/CG/8AUx+JP/A7/wCxrKtNG/sj4p6J/wATLUr7zdG1H/j9n83Ziex+7wMZzz9BQB39FFFABRRRQAUUUUAFFFFABRRRQBz/AI7OPDk59GX+deWRyACvV/Goz4ZvOOy/+hCvLYLcMQTXhZkv3q9D1ME/3b9SW0nZW4zW3bSs+Kq2tmDjAxWnDCsY5rzjpbJolNSiNSfmqB7hUHFVnuz2NImxwHgL4u23iHT73UdQ0+y06wtLSS7l8vURczoEYL80IjUgEZOfpxzW5e/EzSDZXL2LtDcQSW25L+2li3RzOFV1G3cQckA469cVyUPw6l0jwZq2iaRrF1cxXFjNawW90saxoznduLKgbrnqT16dKu2/w8tptPkGralfXV/OtqrzsYx5aQMGWNAqgbcjk4ya75SoXbW1znUalrM6+H4heH7jWV01XuhK17Jpwma1kWH7SmcxeYRt3cHHPasPwP8AFfSdb0ezl1a3ubK/ms5rwotrIYnWLJcROR85CgEgZ9OvFZXhzwNLFrF3fa3fzSQJrlzq1pYxMvkh3J2SMdoYsATxuwPzzqaD4MsNG/4RkRXVzKugxXMUAk24kE+N2/jtjjGKXNQWm/8AT/4ActRm5efEfwpBaS3JvXeKO3t7kmOB2yJ/9UvA+83Py9eOcVSufHWlJeWb3G6ysZLW5uZVvbaWOZVhCkkLtwRg+vPGM1y/gz4ex6d4Iv8ASL6Zbe5v7s3MvkhLhVRTiOIiVCrqFA4K9TVvTvhxpOmQ2sdnf3yGCG6iDAx8m4xvIXbtXGBhQNvqDzTm6F9wjGqdl4X13S/E1tJPYW95HEu0hrm2aIOGGQVJ4YfTp3ra+xwk8KK4TwP4UsfB/wBvaxnlllvnR5iY44kG0EALHGqovU5wMnvXXxXuDg1zVHHm93Y2jGVtdzUhtI1GFwKZdWKSLyKjiuQehqcTEipco2FZpmLEJtKv457duUOcdiPSvS7eVZ4I5YzlHUMPoa8+v4ndWYV1nhGZpdCg3/eQsn5GvRyuo+Zw+Zz4yN4qRL4l8QaX4Y0iTU9evI7OxjZEaVwSAWYKowASeSP59Aay/A3g2x8J/wBrzWs9xd3erXr31zdXJBkcsflXIA+VRwBjufWuJ8SWlx4++Mtho08EyeG/CgTUbrzEIS7u3GYVGeGVRk55H3ga9er2jzwooooAK8R8Z/8AI0aj/wBdf6Cvbq8R8an/AIqnUf8Arr/QVw4/4F6nnZl/DXqZ/iLQ9L12HTP7W8TrpLLbqqWjtGyAAn58GRcbupyPxq9oXhl/Den31zba3d6zpslu0XlQqhgDHo7bZWxjqOPxqr4qv/CelXMOjeKrK4vb6CJN8kVqo2BhuC+ZvVmA3f56Uuh6b4dtbW/1bwbPNdZgaGaNrgqYEfgloiu4+gO4jv2r05SnHB2ldadk0ezKVSGAtNyS5f5U1t5aom8NmyGpg36RyKI28tJW2o0mPlDHsM96r3F58UftTDT9HtbOPPy/ZLeAx49nbPH41Y0Dyj9sHl2ct95P+iJekiFpMjhiCO2cc4zVdbjxgJmhvfAVnMhPW3Eka/XeshXHvXHlakoNxjF+r1ODJoyVOUoxhL/E9S/r91LL/Zj6j9lk1eOEC+Nvjyy+44HHBOMZxxWZ4w8Gy+Mtam1mz1GaJZ1U+Td2spWLAA2q6BgV4z0HWtK/0oSa59k0aJrhgiu0SsHCNjLLu6EA8Zq34u0LxHq182oWPiLVNLjOMWpEghhIHQNCSMe5ApYGrONac+ZRv5XQstrTjiKlTmUL+V0ZPgLSR4IutRlv9agu45rdovsFushWRjjBbcoAxj680aAZhrdi1tEJZlmRljJxuIOcZ7Vd+0SQeGpbTXtWg1zVGceRNHGf9HQdcyEAtn0NUINtlpF3rD293dm0dAsFo+2TJz85bB2qMdcdcVji5VMTiVFNSfloc2NnVxmLUFJSfRrT8zK1rwToWtaxe3eneKrOKWeZ5Gtp5IyysSSQGMgLc+1dH4M8KyeDrPVbufUbm9guLV4RBbxEw5PR2OSOP6muUvfEHgbxHI76zY31leOcm6RVLE99xTAJ9yhNbfh/TtL8KKNV0Yy38WoQSRQzvc7oiucNlNinIPY17GLqzp0GqkmvVJ/ij6DHVp0sM1VlJaW1in+KI7K1mvbuK2tl3zSttVc4yauyWmmWtwYbnxPo0F2hwUE5Ow+hYDANT+HIBbpNrVxqMOnWlgy7p5UL/MeANo656fjVP/hHvAGsXTSWV5pjSOc+VHfPaAn/AGUkDfkDXj4HCU6kXOsnbyPn8uwNOrB1K8ZW6NIm1m0vLeC1mnvY720mBME8M/mxtjrg1X0ezW+v0gkZ1TaztsXc7BVLYUd2OMAVoeI7aXTLLTtNj01NP023Vjbqkvmh9xyzF+5/xqn4csrjUNZtre0m8iUtuEo/gwM5/SuOpGKrcsU2r9dzgqxgsRywTav13Cx+IHhNrU2E76olup4j1K0iuYgf90cj6CrepyxNpKT6J/ZR0e5kwZNOthAHdRnbIuMgjOcGtLUZvCN7Oy6nqvhTULvo000AjZj7yK2DUWsWcsfhxI9IttIGhxS+az6XJ5ilyMbmOc9D/nivWxigqNoRlHy6HuY+MI4e1OE4+XQ5aikzVvR5YIdVtJLxd1skqmQYz8ueeO9eCld2PmkruxseErO2NxPJqNqJB5LG2E5McTydgX6DNQt4s8c2U5hfwVK1sDgLaGcjHs6MR+OK0/E1x8SItTmu/DlxY6no0jFoUhSI7U7KwOCT24J/DpT9G/tPWNH1WbxH4fOhXVrF5kdzAxiWVsHIKZ9hzz1r6KjQWGpOVozXrZn1VDDLB0XO0Zr1syPVrVdS8OnWL+HUdKvlbaLPUJvML8j7mfmxz3A6HjvWPo+g3eqW8txE0ENtEdrTTybFB9M/l+dZWZJpAPmeRjgdyTXWXPhJb7QIdL8TpFBAspuImS9WKZCRg8EFT079K8unGGJrXcbR8tTxqUaeMxF3Fxj5alUeEruXIs77TLx/7kFyCf1Arn54pIJnimRkkQlWVuCCK14/hp4e00rqNo2u3n2ZhL+4uYCARzyV+YD3FUNYv31PU7i8kQI0zbto6D2p46hRo2VJtvzQ8xw2HoNKjJt+asLo9g+qanb2cTBGmbG49AOpP5Ci/wDFPgTSrmS18nV9SliYo8ibUQkHBxyD+lX/AA9pN1PGdTS9ttOt7eQAXNxJsAbrgf8A166G2/sS6uCYtQ8D3d+x+8YIy7t65Dcn8K1wFKHK5Vabkb5ZRp8rnWpOS6HOOdD1rwyda8PLeQJFOLeWG6AzkjPBBOfz/Ksauh8Y3OrJcrp+qCGOKL544oFCxkH+Ifr+tc7muLEuDqP2cbLsedjJU5VX7KPKuwtei+E4/K8NQk8GRmf9cf0rznNeo2cf2fRbOLoViXP1xz+tbYFXm2dGWxvUb8ix4dXzNez/AM84mb9QP6119cv4QTdd3sp7KqD8cn+grqK9U9kK5XUv+Sp+Hv8AsC6n/wCj7CuqrldS/wCSp+Hv+wLqf/o+woA6qivBvAnx3uNXS2udb06wFnPpl5qcg024Ms9olsW3CaNgMbwvy885HrXbP8VtK+xafNBo/iCefUBJJa2i2YSaWFI0keYB2UeWA4Gc5JyADQB6HRXjfiX4vG2uby40mWz/ALDXw3BrcF1JavLJvkuvKwyCRMjH8OQQc89qnvPixPpvjfxfBq9oLPw14cSFZJTbM89xLKF2BW8wKu4uNoKnKgksuKAPXaK8xsvjT4cvIYfIs9Xlupbx7EWkMCTyiVY/M/5ZuysCvQqSOucYq5efFfRLHxhZ+HL2z1GC+u5EhiLiHl3QMqlBJ5g64yU254zQB6FRXkvhn4sTa/a6FNJpk2lG/wBYfTds8HmrMF8zhHDrtYeXySGAPGD1rWtvi/4XntVuC17Ei2VzfXAkgw1rHBIY3EgBJDFxtAGc0AeiUVxvw++Iuj+OZtQg0uO6gubERvLFceWTskBKsDG7qRwcjOQeCBXZUAZ/iGA3OiXsQGSYyR9Rz/SvK7MA4r2TqOa8d1ALp2qXVux2rHIyj6Z4/SvIzOn8M16HdhKsYRak7I1o5AicVC9w2etZEmqooxGrN9eKqS6lM4wu1PoOa8pU2yKua4an9q/obrSE9TUD3MSDl14965+SWST77s31NNRWc7UUsfQDNWqfc4J569qcPvZtvqcKngk/QVA+rc/LGSPUnFVIdPvJj+7tpm99hAq5H4f1Fz80Kp7s4/pT5YowePx9b4Fb0X+dyP8AtVv+ef8A49/9al/tXjmI5/3v/rVYHhq+PeEf8CP+FOXwxeH70kA/E/4UWgNVsz6X+5f5FM6o2fliGPdqcmpgn54z+Bqy3hm8A4kgJ9Nx/wAKgOgaiOkKt9HFHuE+3zKLu7/d/wAAlTUbc/e3L9RVm3urd2wsi59Dx/OsibS72H79tJ/wEbv5VVdHT76sv1GKOSL2K/tfFU9KkfwaOvEm0cVPBcnGGNcZHcSxf6uRlHoDxVyLVZl4lVXH5GpdNndSzqjPSomvx/r7jrJLkBPWofFPjBPBXwyu9UhQTag8htrC3xkz3LnCKB355IHZTWNDqUL8Fih9Grdi8DLruueFNd1C9LWWjrLcQaf5fytcOfkmLZ52qBgY4IBz1FduWxaqt+R0169OrTvTkmdp4Z/tT/hHtN/4SBoW1f7On2swrtTzdo3YGT3/AMjpWlRRXunEFFFFABXinjBA/jC+QsFDTAFj2yBzXtdeJeMkMnjG+jBALShcnoMgVxY74F6nnZl/Dj6lbxH8RbHRNZudJm0vULw2bmAzzXSozbeMhdh49OelWtG1PRNU8P6tq+i2Pk3aoLS4M8SxvtkIPDJhX5UdRuGOvrX8ReP9K8O6hPo7WOoarNZN5LyXE4jUsOoX5SdvpUlvrsPi3wfdX1pZz6cthcIklv55kifcOGGQPmH9fevRxFNwwzkqbjp3/Q9bF0pU8G5xpOOm/N+hV08lLK9mtbezu9RQKLe3vJfLjbOdzZJAJHGFJGc+1Z6QfEG+Yf8AIK062J7fZVRfwGWP61o2x1OLQL248N2P2zWfMSNCEDtBGQxMiqepyAM4OM1k6dp3j77bFda54gv9Ig3hma4vGLkd9sIJJ+hAFZZdCMcPzy5V66syyiEYYX2s+Rb6vV/mdZYW4vtR1a2trOS8064gNvcm3xGQCBlkzgD5gSB+lcu/w81fQrs3Xh7xAbLnP+lCS0cD0JAKN+eK6DVEsPFWlazphnmsHubz7XDIsbOpxkBZAvOOc+xwe1c3ovh7xR4cnB0vxXpMcKnmI3bmNh6NGU/pTwFRQptxqpXb0a0HllVQoyca0U23o1ob3iZ4mms/9Ihur0WyC8ngGElmx8zD/GjXrvV9Hi0y58J6LaanZfZleeZYnlmWbJ3BtjBlA4x2qDxDJZS6mXsAgjZFMnlKVTzMfNsB5C56Zql4+8W3nhvXhaadoemJpoRHtriWBmadSoO7eGGeSenSuXAQdbETajF/l8jiyunKviptRjLye3yFi8bx6hcxx+IfCV0JGOPNhiEzZ9kmRs/99VpeK45rbV5LOWczJbqqx/IECqQGxtHA69qg8E/EYa7q1rpN5bXtjcXTiOOewu5CoY9MxuTge4NVdSV49RukllM0iSsrSMclyDjNVmycEouHL87orPFKmowcOX53X3HRWthBYRz6fqeq+HpY7pFFxpt1eBGPRl91YdQaxtS8C+GliNw+k6pDbg8yWN+k8Y/EqcfjVbXdI8OeKJRe3815pmqFFSWSFBLFLtAAbaSCDgDvipvCljo/g+W7ubHUb/Ubi4gaDyzCIYsHuw3EnHatKdWjRo3o1mn28zalXw+Hw98PiHF9vMlnm0+10Gz0fRkvBaQSPLuu5A7lm7DAAA6/nWh4ch/s1rbWb2/sNPtC5jQ3km0T8YZQPTGea5zNbK3Gl614cGgeI0kS3jcyW13CMvAxz27jk/n9CPNo1I1a/PiH8zx8PWhXxKqYqW/Utal8PvCTW7aha6fd3FoxyX0y+WaNfzGcVBpV/o/h3S76y8OaZJF9tXZNPczeYzDBA4xjjJ/Osrwf4Z1Lwr4ogvdJ8TaS+llx55aYoZYs8hojzuxnHXB71a8Rz2dxrl5Npq7bR3ygxjsMnHYZzXoZjXnBJQq80Werm2KqU4qNKvzRZn5qW0MQuoTcDMIcbwO655/Soc1r+EvI/t62N3aS3cC5Zo44y56cEqOoBxXixV5JHzkFzSSNTxNJ4sttUmfwto2g3+jnBhMMaM+3A+8NwbOc9Kh0LUbjxE0+meIvDl/o16IXkW6USrBlRn5lfgDjrk/hWPrupfEOxuJbg2dhqenqxwtvZRyxqvoVA8xeP71XtJ8SL4r8Mak8EVxpl7YbDdW0crG3lVjjhSflOR0/n2+lr07UHJwjJJbo+xxNLlwrm6cZJLeLM/TLl7TUbW4iTzJIpVdU/vEEHFa/iv4f6XrWpzane/2rp11dN5jpJcW7Lk/3d7hgPbt7dKxtLmmh1K1lto/NnjlV0TGdzA5AxXR618MLHxDqU+qXdrq1hd3beZJFHPDIm49SNxBH07e1edlc+Ry95x9Fc8nJKvJKXvuPorkfhTwTpvhW9XWrKPW9QngDbfLeHyzkYO7YxJH+cVzt1KJrmaVUWMO5YIvRcnoK19M8KaJ4F1m31FpfEP2uEkxxssaRycYwzDOR9DWPeTm5u55yqp5rs+1egyc4FTmdRVJK0+b5WIzmsqk1apz/ACtYv2E1pd2L6VrGmf2nYNJ5yxqzK8b4xuUjnp2pn/CGeDA+5tM8TDvsyuB/WtjTbq/fwk9n4Vv7DT9cM+6V7nCtJHjgIxBGf/r9KzEsvilauJX8QWaqOSZbmIr+IK114FVfYpxrJLsd2WxrewThiFFduwuvX9vcrZWljBLDaWMIgiEzl5CB/eP9Kyc1veL78X01i00trPqCW4S7mtQRE8mT93PX61gZrxa9/aSu7+Z89im3WleV3ffuWLKE3N7BAP8AlpIqfmcV6pekBcDoK888HQGfxBbekeZD+A/xxXfX7YRvpXdgI2i5HpZZH3JS7s1vB6f6DPJ3eUj8AB/9et6snwrH5eiQk9XLP+prWrvPTCuV1L/kqfh7/sC6n/6PsK6quV1L/kqfh7/sC6n/AOj7CgCvoPw50DQ/Adz4SsIpV065tprSWYlfPdJS+7LheSN7YyOOKdrPw90jVLDRbcz6haTaRbm0tbq0uPLmETIEZGOMEMFGeOoyMV2FFAHn2qfCPwxf2ctpsu7e2fSYtF8uCUALbxy+auMgndu6k5z+taOqfDvQdVk8TNqEdxMPEDW73a+aV2tAoWNoyMFSNoPU8j8K5747NrLWOkW/h1PEiXk8zI93pBkKWsWU3vIicu2OEU4GS2TgHPKa/beOP7d/4lD+Knby9L/sOV5CsAjAX7Ub5cgGQ/NneM9MUAejad8ONMs7/S72XUNXvbnTrlrmB7q4D/MYzHggKBjBPTBz1JqvL8K9BfxKdZW41OOQ6omsG2W4/cG6Vdu/aQTyCe/fjFcRb6b41TxFb6ubzxKzDxpPataNK5thpTFyHMfTZwoDHpnik+FFv48i8bwSeLLrXfNP2lL+GSF3spDkmN43MpjUDAAEaAnOCOpoA7zT/hholhcWkkFxqRis9TbVba3ecNHDM2/cFG3O0+YxxnPTmn2nwv8ADFveeKbg2ck3/CSArfRyPlQpLFhHjBQFmLHB64Pau3ooA5rwd4PtfCvnC01DVLxZESMLe3HmCNVzgLgD16nJOBzXS0UUAFeS/EO1aLxPK4BPnxpIAB7bf/Za9ariviJBh7O5A7NGT+o/rXHj1+5b7EywyxVqbdjgINMupsEIFHqxxWpZ+GnkOZ7gJ7IuasWkvTmt20bODXge0Z0QyfDw+K7/AK8ira+HrCAAmIyt6yHP6dK0o7eOFcRRqg9FAFWE5rzH48aFqGvQeFbXSfOS6XVBIk8aFhA6xOUduOFDheTWtOn7R2bOqNOnRX7uKR6Wq0jrXz1Yab440HUPiHf21tcS+IbuGynMkERdcu5MiQ5BDbEbaOp+XoTxT9THiLUNB0q6vNU16ezsvEMEhmt7KbzoLdo23Md9urSFGxghCPnIO7jG31T+8P23kfQSLTJ3jgieWZ1jiQbmdzgAepNeI3Gv+LE+IYFqddhsVv5LaaC5gd4jB5ZKzZ8oIgJAI+ct1z6VhWer+J/E3gq7MdzrWqwXXhy4bUBcWeyJbjpEsBEa7iRnO3cCO+aX1R2TbH7byPoobXUMhDKRkEcgijbXirL4x0fT9etbHVtSkW20O11K1lu4U2xzKSZIVIUDBVcbTyMg+5q6h4g8X6h4L07Xoby/t49VvZ7pLSC3kZktQMQxCWKKQqTjdkrhs9Rio+qt7ND9t5HtoeJ5nhWVDMgDMgYFlB6EjtUc8QZCrqGU9iM14tcX/i4W+rzxLqWmXT6dpuJp7EzTBiX80O8URYnHUhDtz91e3oXwvutSvvCKT6zBqMNwZpAv29t0joD8rD5Ebae25QcdfWonh3CPNcqNRSdrF250q1kyfL2H1TisufSCuTHKD7MMV1M6gVnXQINZKbRjUy7DVd4/docy1pOJFTyySxwMc17tbQrb28UMf3I0CD6AYrzbw7bC61u2hOdoJckdsDP88U34O6/qq6n4k8G+KruW71zRLoyRXUv3rq0lO6OTjjIzg44GVHavZy1Nxcmee8FDCTag73PNvh9Y+KtZ8S6lqtndahHp9jrWqR311PqbvHNAAQlutuWIyCc7sDGe+AKf8ONc8a2HhvwrpemarbXX9reHrq6sYZLMZgmhIKAvuJfdnBz68AV9K02WNZYnjfdtdSp2sVOD6Ecj6ivTGfP8XxS8Uav8OtS8WWUthpdpLe21lZpeKEKhYx9pYO3yZL7gpfCjac8kVR0P4g6xeX8uqK8H29PCl3cxXepWoj+ZbxUXPlEq0f8AtLwcZ4Ga9+8OaHp3hvRLTSNEtVtdOtVKwwqzNtBJJ5Yknkk5J71pUAeY/AvxbqfizStVk1a5lupLWdYhN5UPksSuT5csRKyDPsCOAeenN+L98vi3UlUFnM+1QByeBgV7lXhPibUFs/HF/Ojp5kF2HXJ7jB/pXFjvgV+55+YwlOEUlfU0dVXwn9pU+N59FfWkVVk4leTgYAl8s43AetRa6Zho9sdNbTj4eL/uf7MAEW//AGh13fWuW1bQfCut6vd6i+sX1i91K08kLQLKAzHJCsGHGScZFX47rRtH0F9G0Fp3gllE09xdMN8jAYACjhR+tb4uph3h1GFRt9jsxyoywijTqSb7alq3NzZ6Dc6npekrq9/FMsfkMrOsSEE+YUXluRj0FL4fvPH91cxX2r3iaBoyOGcSW0cW9R1VI9u5iff86yIL/wAh98FyY3/vI+0/pUktzNdMJZpJZiR99iW/WuXD4+NClyRppvucWFxs8NQ9nCheXdo620u7jUdJ1u18N3iaXrVxc/aLbOF81M/6oE8A/wCema57Rb34lf29a2OsaVNf2zyqkovLJWiC55PmgYHGec/nWWbiIHBkUEe9WxrdyIjENRnERGCnnNjH0zVYfMVSp+znBMrCZjUoUnSqUeb5G/qehSXmv6hFoFuZbOGTG8MAiccjcTjg571bsLTXorJ7O1ax1G1HLWhkiuAP+Akn9K5ae5stV8MTaFe30tlG1wLlJ4hvG7bjbIuQSvQ8dD61gWngMxTx3EXi3RIVRgwlSWUSL7hdgOfxrTCUMPUj7SVXll2NsBl1CtB1ZVHCfa1rHYnVLnTbiRbXT9P0u6GVdraxjhkHqMhcisgsSSSSSe9a3i7W7LULq0W2uTci2t0ge6kG17hh1cj3rP0W+sbfVrSW9KSWqSKZFPOVz6d686tJznZyv5nj4inWnV5ZNyXd3LcOh6rNAJ4tOu3iIyGWJjkeo9aoSo8TlJUZHHBVhgj8KZ4uv/HK67dXel6xPdae0rNbmwuQUEZOVBjByMDA5H51ueH9X1HV/DOqR+OUjjuLWINZXcoWOZ25+TA6jgdu9ehWyyMKXtI1Ez1sRw9OnR9tCdzEzVnTI4Z9StYrp/LgeVVkf0Unk1n/AGiL/nov51d0m1bVLgw20kIwMs8jhVUe5ryoq70R4UKFZySUG/kzQ8d+OL7wh4ml0m18O6WumRBfL+0QFjOpAJbdnB9O/vUnh3UtG8d294LSybSNYtYWnaNPmgkUdwf4T04/nW3Z3Oo2lstqNc0C+hGAsE86yY9hkA/rWLr2ualAr2Nw1tZwSD5orRURHH1Xr+dezXxFB0eWVKzPpMTVpPD8k8NJS72MTNdH4Wa9fS9dttDuFt9clt1+yM2MnDZZRnjJHA9OvauV+0Rf89F/OlS7jRgyTBWByCGwQa8mjU9lNTtex4GG9rQqxqcjdvIk0v4l6zo93/Z/jXT5boodplZTBdxD/ZYYz+mfWuw8ZzXyWNiw1Ga50u/jE8KyoEk6A4fgEnkdaw4vGOqxqoGqOwXp5m1yPxYGs/UNYl1Gfzr67M8mMBnbOB6D0rvxmNpV4+5DlZ6mYYuOKh+7ouMuvY6nwBYai2qR6lZWazwwEqxdwgJIxgE9+a5zxd8L9RudTub6DUpQ0jmTbqKPuXJzjzUDKfzFWJreHxN4ZtdKi1mTTri0neXCxO8cqsBjcV6EEHr61St/DXiXS9ptfGcqRL0EMlwR/wB8YxXblzhRpc0aiTe6aPSyik6FBThUs3umjY8KL4itNC1XTPEd1ZXmkrbNJbzG8jmdJVxtVcEtg+hHH6ViZrT8S6pZXX2HZMJr2KEJd3HlCLzpB/Ft9fWsX7RF/wA9F/OvKx1f29Xm0+XU8PM51cTWcuTbTROz8zbcaHpWgwan4gvLpBcSvHDb2sYZ324ycngdR1qlb+JPAdzIqfadds8nHmXEMbKPqEJNb9hB5Onraajd+HJraUiX7FqMoJUkfeA6qcehqKax0+1Jm07QvDEkkfzboXEzL7hS39DXbQjhY0l7WDuejhsNh40F7ehPm9GZ+v6adJ1OS185ZlAVkkUYDKRkHHbrWdmi/wBUa/u5Lm7uBJPIcsxIqD7RF/z0X868iVm3y7HgTozcm4wdvRnc/Dq3+e9uyOiiJT9eT/IVv6pJtic1neE7mzsvD0Ie4iWSUmRhuHfp+gFST31nc3MEP2mLbJIqn5h0zzXsYdKFNI+iweGqQoxXK/uPQNMi8jTrWPHKxqD9cc1Zqj/a2n/8/kH/AH2K5p/iX4bVipbWSQcHGh3xH5iGt+ZHT7Kf8r+47OuV1L/kqfh7/sC6n/6PsKq/8LM8Nf3ta/8ABFff/Gaz9N8Tab4j+KWjHSzekW+jah5n2mwntvvT2WMeai7vunpnHfqKLoTpzSu0z0SiiimQFFFFABRRRQAUUUUAFFFFABWV4osjfaLcRquZFHmJ9R/9bI/GtWipnBTi4vqOMnFpo8ZtZPmFdDYS5UVleILD+ytbmgAxETvj/wB0/wCHT8Kn06XDAdjXys4OEnF7o9u6kro6a3OcVbxxVC0bgVorytdFLVHNPRkJHNHbFOcc02k9xjCiurI6gqwwQe4qDT7C10yxhstPt4ra0hXbHFEu1UHoB2qz3pTS6DKmoWkF/ZzWl5Ck9tOhjlicZV1IwQR3BotreK1tore2iSKCFBHHGi4VFAwAB2AFWCKbipe1gDHFV5qs9qrz9Kh7FIzLl8cmqEnzAsat3PLYNUrpgqYFZmqOg8AW5e6vLojhQIlPueT/ACFO8Yaf4e0HXI/iHrV1cWMmlWT2k0sQLJLC7DCyKqlmwxyMdzk9ONXwTB5OgxMRgys0h/PA/QCtPWNNtdY0m803UIhNZ3cLQTIf4lYYI/I19Ng4clGKPJxEuaoyxbzRXNvFPbyLJDKodHU5DKRkEH0IqSvMfgQ2qaXo2qeD9cS4e48N3RtLe6eMhLi1YboWDdCQpxgdBtzXp1dJiFFFFABXzb46H/FZ6xjqblq+kq+a/Hhx4y1n/r5auHHfAvU6cNuypePo+iymDVpZ57wAFordeFzyMk4p0cem6pp1zeaRJOht8GWGcDIB6EEfQ1Vv5LDVJln1Ozd7kKFaWGXZvx0yMHmkjngtbOW1022FtFMQZSXLs+OgJPb6VhJ4f2dlue7OWD9jaKfMQoQGUsMqDyKn8QPrV1q0lxo98/2MhfLSO5EWwYHBQsO9VM1ray2sSw2r6FchLcRKrWylY3Vh1OD97NGCk1JrT5iy2bjNq6XqQ2x1OayuTrzW52IDDJvQylsjj5TyMZ61RrR0SPWpbgt4giQaciMZHmjRW6HG0jnOcVDpmm3Gou4t9oVBlmc4ApYuD9p017Cx9N+1VrXfYs65qUmh2dlLpunWk1rLGC1zMhc7+6nkYpdG1iLxJb3lvcafDBcQwGZZohgcY49R+Zq/p9pqVojpY3Nldxn70KyBwfwOKz9Q1K7RZLVraGyDcSJFFsLfWtHVhGnyyhqbSr040eSdOzMunxRvNIscSlnY4AHc1FmrOnXbWV7FcIoYxnOD37VwJa6nlLfU0v7EuYObi7tLU/8ATSbBpYtEa7LC21GxuZAMlUm3Gsu90TSdTu5rlNUmtZJnLlJot+CeTyD0qxoPh2z03VIL2TXIGWE7gsYwW9jz0rvVDDuN+Y9ZYbCON1PUqzxPBM8Uo2uhKsPep7WeM2d3ZXDSJb3ShWeL7y4OR9R2IpNXuEudTuZoTmN3JU+o9aisYluLyCF22pI4Ut6AmuKLcJXieZGTp1LwexTXwxYEknW1C9v9Gbd+Wf61q6hdiW3s7ZJZJo7WPYJZBhnPc4/AVJ4g8QjQtUk0+DSbVoIwPmlUlpMgHOf/ANfSk0e707xI8lvFamxvwhdAjbo3x/KvRrwxFSF5bHsYqni61K8rNGdWq8em6Xpdveaw07G4J8uOEDOB3/yayWBVirDBBwRWtbSpqljHp97p73scRyjREh0/EVw0OTn/AHmx5eFdP2n71aDLaTQNTkEVjey21w33UuVwGPpn/wCvVO8t5bS4eCddsiHmrk3hXTlCuNP1hdpztVlIP6E1DrN81/fvM0flcBQhPIx61riY0lZ0zfGxoKzo7j7Rftem3dgt79illKukm4qrEZ+ViOxzWdB4c1+2cPFfxQqD/rBd4H6UZozRRxcqUeVIMPmE6EORJNGrrtxFPNb7JBNMkSpNMBgSOOprMpua0dHgil+0yzQS3Jgj3rbxnDSc1hZ1JebOT3q1TTdkF/Fp+sMsupCeK7ChTPDghwOBuU9/cU7S7LSNHuUvILi8ubqPJjUqEXOMc96qSeKrRJWRtAiVQcFWmbcPxxWnfwW0mlWWpWcckEdzkGGQ5K4zyD6cfyruqfWaMNXoerVeMw9L3noZzNuYk9Sc0saGSREUZZiFH1qPNanh2DztRVj92Ibz9e1efGPM7HkQi5yUTp3AjiVB0UACjTY/M1BG/uAt/T+tNuG5qzoS5eeTsMKP8/lXontGvRRRQAVL4T/5Kbp3/YHvv/R1nUVS+E/+Sm6d/wBge+/9HWdXT+JHLjv4Ev66nknw6uPGEmifCP8AtC4UaXLqlyqOjSm6Pzy58/d8pXPT2xXV6Z8QfHFxovjWW8mjgn8JaZcQXMv2ZNtzfiSQpIvBG0RIpI9W9MV9CVhJ4R0JNJ1fTF0+P7Fq0ss99HvY/aHk4dmOc5OB37V2HzJ4bP8AETxqNJ1e50S+l1nT0WwMmpHTwn2F5CftCoFjIcINpyVfbu5zWloHi7xtq8/hfTIfEFmX1DUdQtn1GKyEwMMdussZYFI1LgkjKAKTjrgivWvEXifw/wCCbC0XWbo2Np5ZWIiGSRVRAoOSqnAAI61Um+JHhOG9srWTWEEt3HBLGfJkKKs3+q8x9u2Mv2DlSaAPHpvEPirw7e+PY4PEF1LqketW629vc2YdVgleFfNUEfdwxXaCB3681sfEHxT428NatPYJrEr3VtYwzaesWlK66zcPMQ8RAB2bV2jajA87ia9Hi+JXhGXxEmhR6wh1N7qSyEXkyBfPQkNHv27Q2QeM89s1Z0Tx54a1vWm0nS9UWe9w7IvlSKkoQ4cxyFQkm08HYTigDynWviB4nXx5qumafqbfbLTWbO1tdGjsklFxBJGjTb5AuVChmbdkYxz1FZPw9vvEuhQeHkhv2fRdV1TVrafTZLJMJtMzrJ5mN2Sw6dMHGK+g9O0bT9Ov9RvbK2WK61GRZbqQEkyuqhQTk8cADitCgD500PxbrVp4d8H213qjeFNFl0I3X2y00pJVluxKR5GzYyqAgDbQAWzgGvoe3YtbxMzFiVBJK7c8enb6VJRQAUUUUAcn8QtPE+nR3qD95bthj6qf/r4/WuMsX6V6zeW6XdpNbyfckUqfxryQwvZ3kkEow8bFT+FeHmdLlmprqelg53jyvodPYSZUZrYiORXO6fJwK3rdsqK46MraGlREjio6mbmoTwa0luQgNHag00ms2ygph60pam5qb3GLUEvOamzUEh61EmUjLuQA5rIvSWbC9ScCta6PJNVdKg+1a7ZRdQZQx+g5P8qIR5pKK6mjdlc9KsLcWtjb269I0CfkKsUUV9YlZWR4bd9Tz/4weKtW8FWOja7ZpFLoUF8kesoYy0iwP8odTnjaxGRjJJXoM572GWOeGOWF1kidQyOpyGB5BB9Kqa5pVprmjX2l6lEJbO8heCVPVWGDj0PPB7Vh/DywTw34esfCtzrkOralpduqueElERJ8vcm4kAKAoJ67aYHVUUUUAFfOnie3W7+Imo27nCvdsD9K+i6+dvEtpc3fxD1VLM7ZVuWfeei4PWuPGK8Y+p1YRXntcz9Y1vRNJ1WWwk0hpPJwGcN6gHgH6+tWrCLQfEEcq6S0kN0ib/LbIx9c5GM+hq7cWGn6xdtBejT7++gHz7HaJwPfGc1XuPsfhySWay0lra6mTyxJu3Jj25P5cdKmaoqGsbM+lqrDKn70bMwLCRbTUoXuF+WKQbhjOMGq92fE0UzvbX897Ex4aKTeD/wA8j6YrpfDwis9IvtYljM80W4hRyRgZ/AnPWs7TfH8Fw5TWrFNp6PEu4D6g/59qWEhOMXKKuhZfTqRg5RSaZDGt0+hyza1bJb3hkUQHyxG7j+Lcoxx74qTS5YZdP1DTrif7Ot0gCy9lYevsa17qy0nWrKS50WaLzkXcVjOM+xXtXO6fp91qDlbWIvjq3QD8a56rlGrzJWOSvKcMRzqNn2Rnf8ACH6mkgaGezYA8SJcAD6+tdRexvqP9mafFMt1eQx7ZpxyueO/fGOtQt4X1MKSEjJ9A4q/4MCWt7dwXP7q7IUKr8HvkD9K0qV51rQmrG1bFVMTanUjZFyDwrY4KSXEzyD721gMfhg1l614eW0tnuLOcyxxnDq2Mr+IqrZeBL19RuZNR1AiOQE+ZAx3uxPcEdPWtGx0iPwx4e1GK5uUlluchccZ4wOPXnJq6tClGLszSvhKEYNp6mb4pvNVgjtZtAymmtGM/ZkBKv3DcZHasWx8Qa28qpc2v9oRk4Mctvk/gQMg10mlaDqnlrPDOLXeMj5yCR7gVYvbLxFEpxcyTKP+eUnP9DThiLQtKA6eMtTUZ0rmLrkEdtqk8UA2xqQQuc7cgEj8M1JpOj3WphmgCLGpwXc4GfSs6YSLK4nDiXPzB+ufeui0LUj/AGNcWEcz21wc+VOIy4XPsO9cMFGU9dEeXSjCpUtLRGg+j3jQLFqBsb6IHCrcA5B9mxmsp4ovDty09toqW07gqspmaRefSqsuhQ3QRtZ8STyspyqlWAX6bv8ACtnxLq9lPpX2S3mM8hK/Ng8Y7k+tdlRqEbQmejWlGlTtTqHJuxd2ZjlmOSa27qXUz4ash4dJEqswuVixv9jzz+VZ2jWq3uqW9vISEdvmwewGf6V0moal4f0zVU026tFjfCnzTENoz0y3X8axwsZc3Mlc58BCfPzxV7HFq3jAS7h/a+73D4/LpXQa88k1jpj3sapqbIfPVcZ7YyB3rcitNG1qGcadNuaM7S8bthT268GuMXNteDcMtFJyB3wa1xVVyXK42N8fiJSioSgkdFa+GYwqf2heJDK4yIgRkfnVm48JRBSILthKR8qyAc1X1Tw1pvia7OoW968crgCRQA3QYHB5HSo9L8M23h/VY9RvtX8xogQiMu0nII9STwe1UqFHlvctYXDcl7/16mEttM919nSNmn3Fdg65FbFr4d1aN1lj2wyLyD5mCPyqxpeoW03i+SdBtimBVC3HOBz+OD+dYmo3fjSznnZvtOwseYoldQPbAOBWNDDqpfU58Jg41rvm2Zr302tWS5voY5kH8bxK4/Mf1rGvr+4vnVrmTdt4VQMBR7AVs/D6fWrma8bVTO9mV4afP389AD2xnP4VgXWz7TN5X+r3nb9M8UsTTdN8vNcjG0pUXy810MrqfDEIjsHmP3pW4+g/+vmuWjRpJFROWYgAepru0jFtaxQr0RQv196ihG7uRg4XlzdiCdutbGjR+XYIT1clj/n6YrEfLkKOrHArp41CIqL0UYFdZ6Q6iiigQVL4T/5Kbp3/AGB77/0dZ1FUvhP/AJKbp3/YHvv/AEdZ1dP4kcuO/gS/rqeqUVx/xheeP4WeK3tWkW4XTpijRkhgdhxjHOa8/f4gvN8OPC48N6pND5MllZa3qIs2lksIzEdz7ZEIJLKF3EMBn3Fdh8yd78SvBt54zt9Ntoda/s+ztpxcT2zWonju2UqYxICwyqkE7eQTjI4rF1n4UjWNQvZrvXZxbat9ifWLeO2QC8ktduxlPWIHauQM9OCK46Hx14rl0/w6dd1W40HSbg3vma6mmKz3PlyYgyjIyxb0y3K/Nj5cVW1D4jeJ4viNpFlY6jdSWD6lp9lcW91ZJD50UyRh5kTyi6qSS25pRgkDacUAehJ8MIV8n/iaSfu/FT+KP9SOWbd+569Pn+97dKq+A/hHZ+Dddt7ywvopbO1Mv2eKSwi89Fkz8pn+8QM+gJwASRxXnHhvUdYi/s6y1XUZdWvoPHccEsF9ZhmtYybnEqMR8u7aCCD8oGBgGtTw94+8aXEk7XFxNNef2bqdxqOnvp4jXRpoc/Z1VtoL7umGLZ6igD6CoryD4XeIPFl14u0i08Q6qdQstV8Lxa1tNkkH2acvGpQFRyMOc57jjHSqWt+M/Flv8SpdPguJkKaxa2ltowsQ0d1YuoMtyZtu4EZY5DBV24INAHtlFeRfAbRZoNU8eavqM5utQm166tPPlgVJCkT4B3DkqcjC/dXbx1Neu0AFFFFABXAePLIQanFdIMCdfm/3hx/LFd+OtYfjCy+16NIwGXh/eL9O9cuMp+0otdVqb4efJURxmnydK6K0bgVyli21hXS2T5Ar52Dsz05o1O1QPwamQ5FQzV0VNrmEdxhamk03PNFczlc1SAmm5pTRU3GGagmPBqY1XnPBpDsZN2eDV7wTD5uuGQ9IoifxPH9TWddng10PgCLi9mPcqgP0yT/MV14KPNXiiK7tTZ19FFFfSnkBXj3xbibwX448P/Ee0BWzRl0rXAo4NrI2ElP+42Pr8o7V7DUN3bQXlu9vdwRTwOMPHKgZW+oPBoAlRldVZGDKwyCDkEUtcV8PfGjeJNT8SaPqFimm6vod6beS2Em8NCeYpQcDhhnt/Ou1oAK8E1DUIbH4ia4LhgiSzMu89Ac9/ave68B1rRRqvjnXWmkZIYrk529WJ7VyYu9o27nbgeb2nu7mCmgazp/iG8u/DyQrbSjCSSyKwIOCfU9RV+S51abR9Qt/ENnHGYlBjnUjDtngdev0rftNGsIEItxIMHBKTuOfwNZOtaF9rt3nsbya4KZPlvL5gPsD2NRUqSlCzifR1q1SdNqUU3YwND1iXSpHwgkhk+8hOPxFbUV94YnO+bTreOQ9d9sp/kDVHwdpsF9c3D3SCRIlGFPTJz/hU1n4i0S/1ZLC30uIwsSPPdEUAAdfp+NYUI1XG8XocuEhXcL03oF3qWj2aTHRbOOO5lQxmVY9gCnrWgk0p8IxHSJJI5goUiGESOX6HgkAc85Paotf0GyOnyXun4Qou4hGyrAdag8MaPem2F1FetapJ0VV3bgO5zxTUpqpeWoRqVY1rzV/68zBlg8XaVJDcXF1ciN2G9jIZljyf4l5/QV1PiS0S6l0lJmUXMzBHkQYyOMkD6nj61r/AGK/24GqPn1MCf4Vh6jpl5Z31rqNzeG6iikXeSu0oueuOmK0rVHUjrE3xVV1Y2cfyLNpHp1ze3Om21zfie2A8wiVgB7c8fpWNqmkHT9XtDcSma1lkUF364yMg/hV/wASafPL4l077GJxFdZF0YHaPhejlh3AbjPpirOr6dJqdxbafFM5itl3TTSfM2T0HucDP40q1KPKnEnE0IcicFqZvjHQdW1LWIbm2EVzZxBStu8m0AjqPx9at+HfFF1f6w2mXmmNbzICWKk4THqCOnvVxbK9gkNvZa0GlRQfJlVWIXsfUD8KoalfeINPjLTLCU6edGgb/wDV+Iq3XtG04mssVaFqkNir45RF1SJl4Z4hu/M4P+fSumvPtGn6Qi6LaJcyrtVU3BRj+8T3riNPt7jX9VCzzMWI3PIecKPQV0llcW8OsyaOt7fwzwopQyshWQED7uR79Kwo3cnNI5cNeU5VFG6KMXiu/TVotN1fRiskjBT5bbuD3A5BH41N4z0y3gtorq3iWJt+xggwDkE5x+FdFJFeqp8m6iZv+msWc/kRXFeKL7Uml+yaiIkVSHAjHyt6HJ59auvKLjtYvGVIOHw2Kmj2l/NcJPp8LM8bZD8AA/U8V1U8lzcRBdW0FLgDuu2T8gc4qKKSVfAjtpm77QsR2+WMsGzzj361m6N4l1qAxJrWk3Zt/LAEsVuxct6t2p0aD5eaLKw2Flyc8JEx1mDR4pIdP0g2bOcnzBt59cd6yNCsDq2piORiEwZJGHXH/wCs131rPFqlizy200cTEjZcx7SR64PauE8P6lHpWqu7AtA4KEjkgZ4P6VjVT5lzu5z4iLVSPtZXR0f/AAjukPOYY7l1nXqiyruH4Yqte+E4/Ikks7l3cAkK4B3Y7ZFPutF8NassksbQpPIS/mpLhgx5yQT/ADFacV3p+jaakRntv3a/dhULvPso9a1lTpWujonRw7jdHD6Tp1xqVz5VtgbRlnPRRXYwWGt20YWPUYpcdBKmf161m+A5ARfxqQsrBWH6/wAqoaVYeJL3WVtdcmufsEJZ3ZW2CT0AZcEjOPp7VOHoqUea5GDw0Zw5+axJr99rUGYL1xHG4xmMAKw+v9K53Nd94uFvFoLQswDqV8pWbLZz789M15/muesrS3OLEx5Z2vc2vDFuJtQ8xvuwjd+Pb/PtXSztk1R8P232bTVZhh5fnP07f596syHJrppR5YnfhockF5j7BfN1KFR0XLn8P/r4ro6xfD8WXnnPsgP6n+lbVaGwUUUUAFS+E/8Akpunf9ge+/8AR1nUVS+E/wDkpunf9ge+/wDR1nV0/iRy47+BL+up6pWZ4i17TPDlgt7rV2tratKkCuys2XY4UYAJ5NadcN8YPD2qeJfDen2ehhRdxapaXRdiv7tI5AzPgkA4HOO9dh8yUNX+L/h+zbRZrRzd6ffX01hczlJY5LSSOMuQ0JTeW6DbgH5gea2bP4leELyxS8t9cga2axl1EOyOuYI22u2CoOQwwV+97Vi6T8LUstX03VrnWZrvU4NVn1a5maBUFxJJF5W0KDhFVcY69D61y3in4Mvd2XhLSLSR7q1ttWubm/uywixaTOZJISuSW3Hao69MmgD0iH4geGp9Yh0uC/klvJfKAWO0mZUMqhkDuE2oSCDhiDzUNj8SvCV/LdR2erCZreB7litvLiSJDtZ4jtxKAePk3Vh6t8KLfU/iFF4nl1R4BHMk3k2tssMkgVdvlvKpBeM9wwJxxnFYun/Aq10/TrzT7LXZILeS2ltoJ4rGJLuJXOcNOPmYdiAFyOCaAOl1D4p6MIdOfRVfUHuNatNHuIZUktJLVpzw7JIgbgcgYGfWvQa8h0f4K2+nTGUaugJ1ew1Ypb2CQRhrUEbAitgbs5J65yTkkmvXqACiiigAooooAO9IyhlKsMgjBFKaKAPK7y3Nlqc9uf8Alm5A+nb9K2NPfIFR+NYPJ10SjpNGG/Ecf0FRac/Ir5atD2dVx7M9iEueCZ0UTfLTZelJAcinSdK0esTJblbvQaU9aSuVmwp6Uyn9qaaQIQ9Kqz5xVuqt0cA0DRi3pwTXZeCItmiB8f6yRm/p/SuIvWyTXo3h2LydDsl9Yw358/1r08sjeq32Rz4t2gkaNFFFe6eaFFFFAHBav4Pvo/izo3i/Qnt40e2ksNYikYr50P3o2XAOXVgOvYAZFd7Wf4h0uLW9C1DS7iSWOK8geBniYq6hgRkEdxnNcD8BdbvZ/Dd54Y15s694Yn/s25yeZIgP3Mv0ZOAe+0nvQB6dXgup6tHpvj7XY7klYJrg/NjO0j+nNe9V45L4aHib4j61BJO0MELeY7KMk9AAP8faubEpvl5d7ieMnhJRlTjdt27GLf6ZY36zmy1VrVLnJmSCRSshPUkHoT3xVhptM8OabstliU44RMbpGx1OP511mvJ4E8DRW8WrW6STzcqrqZpGH94joB+XtWvrXgDRNTs2aygWzuGXMckRIXPbK9MfrROjW5LnqVM3xapJ+zWvm/8AI8U8K6pHY6jKbrKxTjDNjgHPH4dan13wPa3kUM2gGCFMnzGeVmUjtjrWr4L8JzeIdVubaaU28Vr/AK5gMtnJAUfkfyru9T8EeEtDso5tWu7iGJpFiEss2Ms3QcDFY4WNVL3Dky/PsVy3p0tPX/gHmt5e2mk+HU0ayl+0ShNjuv3Rk5Y5+pPFbfg+9S80uKBM+fAu1kxzjsa7W9+FukSQOLS4u4ZsfKzMHXPuMf1rzrwr4fuNS8VNpbXDWskBcSyJ1G04IH41Eo1IzvLqZ1M+xEKylOknzab/APAHHw1rV5qrf2pqMs2lhiwiTKM/opAA4H1rU1+S2stDuIX2oDEY44++cYGBXRaLZ+CNZuJrCG/ub+4t4WmleeeRdqqxViegGCPToQelGg+GfBXimzuZdCmuHSKQxNIjuNre24ciuqpQrNar+vuPQrZti5RadFK3n/8Aanl1p4n1C2sxbqI32jarupLAVteEWGpaZfWsk0ouZHLs6MQ+CANwP1FUPFWkPoGuXOnvJ5gjIKPjG5SMg13Xgr4fLd6XbaneX91bTTDzIhbMFKqehJIPJ68Vw0ozc7djyMPn1d1eVU7uPn/wDgtX8H6za3sN/pFzc3lyCA32ggtgYI5PBHHQ+grrNE0/Ura2kGrXbXjyYJBhChOORx1H5V6JFomq22Y7TxPcswGQtzCkxx79D+tc140tfGy6ZMFuoLmz2nzRaJskK98g84+hruqOXL7y/BHr1uIqih71F6eh5poepWWl6vflg/2d2KxsozgBjVrxDc2GsvaPb6ybJ7dt6kWzM2768flW38LfDll4gvb19SVpIbZUxGGKhixPUjn+H9a7XxJfeDvDVncwiDQzqUcRMVpIE3s+PlViclckjk/WscLRqys4HLl+cYmpFSp019//AADzHQrwWN5PLqHiH7bG67VQxsoBz1xWd4u1KDU7uBbPdIsakbtpG4k9BXsGm2PhjXWOl3tppKa3HAs1xBYceWGwQVYAZ+8v51xWnadbeGfihbWl4++1jl/dySY/iT5CfoSOfaliKVRNKdtRY7OcRFqNWmrNpXT/AOAc5pOieIrdRJaK9uG52u3X6rz+tbOfFMCHNrbT49uT+or0zx/aeK51sJfB1/DbyI5WeKZV2upxhskHpzwPX2rG+F8GqG6uW1rUvEZ1CHi5tr6MfZmY5GY2wcrkZG0j6YrojgEocymd0MSo0+dP5X/4B5bq+v6qyyWlzCtqxGGUIVbH4mr1j4SibTY7q8uJIw6CQkABVBGeSa7P44NbibSgAv2rbIWI67OMZ/HOPxrQ8M+LdB1jwxFouvOkJ8gW0qTEqkigYyG7cY7jnpXJGlH2jjUZ5kM5h9YdOstvM8/fwSXGbe7JBGRmPPH1BrI1rw1e6Xb/AGh9skIIBZQRtz65r0DxH4Nka5juvBfiqDTo3hitZoxc7d0SDAbepJZgOOe3Ga1PHes6dZ+BhoseqjUr0pHF5nmCR22sCWcjv8v15ravhKMIc0ZHVi8fh6VL2kLX9TzPTtISx05dX1S5ms4OChiB3c9DkA9a6O+0C+mjIh1O+Xjo/OfrjFejvpWleN/AdpZ3BY2skUeGibDROoxx7g5HNcL8LdD8V2niCXVtf1DUYNEtlkVY9QnbdKuCAShPygcHJ9OK2pYKnKk5c3/BOmhjKUqDla1vPf0PNdStLixvZbe6B85Dyeue+adpNo17qEMAViGOWwP4R1rofGerprPiW9vYf9SzBY/dVAUH8cZ/Gux+F2l+TYz6pKPnm/dxZ/ug8n8T/KvNhRU6nKtjwqOce1r8kYaevT7jInRlGAhAHtVORWCklW/KvS7x8ms2WNp5IoE+9K4QficV6PsPM97+1n/J+P8AwDE0m2ki0+IGNssN549eaueVJ/cb8q9VRQiKi8KowPpS0ew8xf2s/wCT8f8AgHlPlSf3G/KsJvFfh1WKtr2khgcEG8j4/Wvc6KPYeYf2s/5Px/4B4X/wlnhz/oP6R/4Gx/8AxVaXgHVtN1T4m2X9mahaXnl6Pe7/ALPMsm3M1pjO0nGcH8q9irlb35/ipo/bytFvse++e0/l5f6040uV3uZV8x9rTcOW1/M6qvm/xwdZ0fxz8UfFVlcmXUtFsrBdNMtoknlCbIYISDgAbgcdd2T0FfSFFbHmngXxg8XeMPCEkFhZa5O+opYS35uBYxRW9wRIcRKpjlZnCgfKGTjBLc8aSeLte1Hxk9jqXiC48Nq/2FdNtYdLWdL4TIpkYuyE8MxXhgExls4Ne10UAfN3w28cazoHhrwG2t6vf3OnSXl5aaz59k8slq4jYwxMwUuSXwc9ecdBW14E8X+NfFV54Ttn1QWIvrG9u7uR9OVixivDGigHbsJQAfrjPNe70UAfOOl/EPx3LrWorfahZWM6JfrJpl1aSN9lMaO0LqI4d5UbVJYu4YNxzha7r4D+KNb8S2msf2/PeXT2rxIlxJHD5DkqS3lPGibgDjIK5Xjk549UooAKKKKACiiigAoFFFAHIfEGD5LO4HYmM/jyP5GsLT2+YV1vjeLzNBdv+ebq364/rXG6e3zLXz+Yx5a1+56mFd6R1NqcqKlk6VXszlRVlxxWa1iJ6MrNTae3WmGuV7mqDtSUvakqRhVK8PymrhqjenCmgaMK6OXwO9erW6CKCOMcBVC/kK8vs4/P1a1jxkNKoP0zXqlezlUdJS9Djxr+FBRRRXrnCFFFFABXDeNNT8O+AL8eK7/TZRc6nPb6bd38IyI0JO15cnAUeoBPQeldzWP4v8P2firwxqWh6kubW+haJjjJQ/wsPdSAw9wKANgHIyOleVaLrtrpfxT1uG9dYorp/KEjHAVxgjJ7A8j8q6L4Qpr9t4EsLDxbatBqmnFrIyFwwuI4ztSUYJOCoHXkkE9xXG3PhCXxR4913E4traCUGSTbuJJHAA/A1hXv7vLvc4ca5pwdNXd/0Nnx54Cvtd8T2fiHw/e2CXKxrG6XkQljwCcMoKsM8+nbIIrtdZ1uz0HTTNqd1GZY0HyggNK2P4V9z+Vcxb/DDS4Itseo6sjHqUmVR+W2sbXPhRi3kl0nUJZZwMiO4A+c+m4YwfwrSpWrSily7G1fFYqVNLkWnn/VzM+FOvRR+LL4XjrF/aILAk4XzNxYD9WrvfiX4eufE+h2+n2cdt5n2qOUzXBOIAucsFH3jjK4PHzGvL/h94N/4SS8u/t8ktvbWpCOEADl/wC7z0xjnivRv+EI0LTYSZtRvoYkAyZL3YACcDpjvxWOEnUgk0jlyyrXpwUoxvrpqdnNNHbW7y3EipHGu53Y4AA6mvC/BOv28HxDk1C6dYoLySUM7cBd5JGfTnAr0HWPhzpd9ZukFxexT4+R3naRc9sg9RXih0u5XXRpLqFvDcC2wTxuLbevpWeIlNSi7GGPq1Yzg3HZ+up6j48+HsvibxHaajo15aWFpLGYr+WFiskoJz/CMNkYHJ/Otnwdct4asW0nWpMRWoJGozX0bpKM4UBS29TtxxjHB56ZqWXwo0aOJPtVzeTy4+YqyopPsMZH51d/4Vj4c248q5+vnGu1160oKDS+89Z4vFTpqDgtPP8A4B5Z8Q9Xt9Z8VXV1ZNvtwFjR8Y3YHJ/PNd3pOsReKvDNhp9lr8ugataBVymCJAo29DjcCOcZ4Nc58RPAkfh60XUNOnklsy4R0lxujJ6HI6jt0/Oq/wANPB8PiWS5uL95FsoCE2xnBdzzjPYAfzFcFOVSnV0WrPEoVMRQxTslzP7jrJPDni+1v9Y8QWsmjvrM0IhjhSDeZMAKHEjkeWcAHbyvFdzpU95beHoJ/ETW8d5HDuumiPyKR1P+e/SsmLwg1lFt0jXdWtAOFRpRLGP+AsP61yHjTwp4vubV92rHVbZPmMKjymOP9gcH8813Va83HWJ7OIxlXk1p3a7W/wCH/AyvhVr9npviG/W9mS2t7tfkZztUMGyAT0HBNej6i3g+9klmv5dDllljMUkryRbnQjGC2ckcCvCfDejT69rUGnW7LHJITuZ+iADJOP6V7VpXw38PWUSie3e8lHV5nPJ/3Rgfzrkw06ijaJ5mXVsRyWppWXXYgstZ8EeFbJYtMmtEWIMEEGZn5OSN3J5OOpxwK8k8X63/AG/r9zfhDHG+FjQ9QoGBn37/AI17XqHgDw7eW7RiwW3Yj5ZIWKsvv6H8RXjFzon9keNYdJ1Fg0S3Uas+MBo2Yc/kaWJdSVuYnMniJ29pazf4+dzuPCcnj/7BDLbiOazZQY1vSuSvbuGx9a3b/VPHsUBMWi6ezY5aOTcR9AXH9a1PiTqt1ofgnUL3TJDFeRhFhZYhJhi6jG08d6zPAuleLbfVn1DxBrS3mn3VsHW2KbGilbacFcYUAbhwfwrrhhv3fNznqU8A1S5vaNfP8tDyDxHdandatLLrnnC96MsqbCo7ADsK9X8EeAdLTRba61a2FzeToJCHJ2xgjIAA74xnPesX47pEtxo8gA85llVj3Kgrj9Sat+GPijp8WmW1tq8Fwk8KCMyxKGVgBjPXINcUIwhUameRRhSo4iUazv6nWyeE/C8UkccunWSSScIrHBb6DPNeffETwZBZ6zpUehxeWNQcxeUWJVXBHOTyBg/pW3rXjjwZqy251G2nuzbSCaHMPKOOhByKxb3xrD4j8ceHfs0UkFnb3IA83G5mcgZODgdu/rWtX2Mo2W504qWEnBRja7a29f8AI6DRvhxc6an7nxHewM3LC1BjBP581leP/CesW2jS3f8Abt3qFrD80kE7EYH94c4OPpW/8UtA/wCEik8OWht7qWE6gPtDQkhUh2kvux0zgAH/ABo+KF7baF4JGnWqLF54W2hjXoqLjP4ADH4itKtCnCldHRicHQpYfmWmj7/5ni2mWcuo6hBaW4zLM4Ue3qfoOte7wwR2VlDbQDEcKBFHsK4f4UaNthm1ideXzFBn0/ib+n5129y3Ws8LT5Y8z6mGWUPZ0/aPd/kUbhsmrHhyDz9bRiMrAhf8eg/mfyqnMwGSelb/AINiH2Se57yvtH0X/wCuTXUemdDRRRQAUUUUAFcrc/8AJU9O/wCwNc/+j4K6quVuf+Sp6d/2Brn/ANHwUAdVSEhQSSABySaWqmryRxaTeyTW0t3EkDs9vEm95QFOUVe5PQDvmgCSG7tp32QXEMjYzhHBNT18p+BtK1W2tvGGvaF4R1bQvGl7ayx6ZaLpElva2UCkfKrsoV5mAzk9SBjqRXWLJ43mie30mfxdHoc2v6bBb3N7Awvkt2Ui7Zg6EiNW2kMw2jntQB9AUV876kfiJZ6NPYxz+I59NtfEl1bPdeVI149kIkMDgou9495fLID0x04ruYZfGQ+BEz2M11deL0tJVhluLYwTORIwVjG4yH8sDGRknBI5xQB6Re3dtY2slzfXENtbRjLyzOERR7k8Cn288VzbxT20qTQSqHjkjYMrqRkEEcEEd6+b/EOjeJvEmhXtnt8WT+HxrmmGxGowMLwof+PlnVl3eWrFWBYYBB6gV9HWdulpZwW0WfLhjWNc46AYHTjtQBNRRRQAUUUUAFFFFAGX4nTfoF6OuI8/kc157p5+Za9I10btFvh/0xf+VeaaefmWvEzRe/F+R6OD+Bmhqvi3QvDb28eu6nBZPOrNEspPzBcZIwO2RWtBren3clilpcfaVvYmmglgRpInQYyfMUFB1GASM9s1594t0rXG8feF/EGi6UNTh063uo5YvtKQnMigLy3br2NYvh74eeJdDi0ZYfskjw2Gp+ZGZSLeGe4IaKPHDFAepA9azpwg6ad9f+HFNy5tj2R+tZuq6zYaXc6fBfz+VLfz/ZrZdjN5kmC23gHHAPJwK+c9Q8GeI/Dnh/Vbi705rW3u/wCz0a3gmhCvOLhd+1YQAoweCcnB5Y9usg+G2qXclmLvSobTSH1/7c2lJdBltrfySjcggZZuSq56/Ws5YeC1ctClUk9Ej280lfPHiXwrr3hrwpo8GlsbXVTq95pljAJDIv2S63qvQnGwYYZ+6efrua38OtYj8aaTPolnHNYWS2kKzX8scsaxxY3FRgSRuec7CQx5PtHsIfz9/wACvaPsewabfwanYpd2nm+S5YL5sLxNwxU5VwGHIPUc9RxVfUThDXiGp/DrxTP4S8PWn2ET6hZLd7knuIZYFaS4d1Lo/X5Svzqdw6Yr2MRSW+l2kM/lCaOFEcRZ2bgoB255xnpnms6tOMNYyvuXTk3uh3htd/iKzH+0T+Sk16XXnXg5d3iKE/3Uc/pj+tei17OWL9035nHjH769Aooor0TkCiiigAooooA8v+Jmu6r4N8deFdee8lbwndudK1G2OPLgeQ5jn/MYJPQDA+9W/wCDrmM+K/FdrkeatykmPUFcf0/Wtnxh4dsPFnhrUND1dGayvYjG5QgMp6hlyCAwIBHHUV4Jrk174e8aXkGj3l2J4Stskm8tJIAqgbj/ABE4GfU1jWlyWkcWNrew5JtX1/Rn0nVXU9QtdLsZby+mWG3iGWZj+g9T7V53pWl/EW8tVe71uGyVh9ySNGkH1wnH51ieK/APi26i+0XGpLqzRjIi8xgw/wB1TxQ6krXUWKeKqcnNCm/n/VyX4ceMLOLxTrIvZFtbbU5jPEXOFRtxOCegyD19q7XxB4C8P+I0v57pHM98UZruKQF1CgABCQQF+Xpjv9K+dpkkgleKaN45EOGRwQQfQivV/hp8PrW/0yLVddR5Em+aC2yVXb2ZscnPYenrms8NXqRdonJluOrxfs4LXve39anpF/rej6DYqLy/hjSFAoUyBpGAGOAOSa8GuddjvvH8es7PKhN7HMA3UKrL198Dmvcf+EK8N7cf2PaY/wB2vP8A4m/D+2sNOOqaBA6LEc3ECsWAX+8ueeO49PpRXjOSv2NMfTrzjzaWWp7COaK+X7HxTr9skcFpqt8FGFSMSlvoAD/Kvojwj/aX/COWJ1xs6gY8y8YPU4z74xn3rSnWVTRI6MLjY4ltJNWPLvil45tdXtTpGk5kgWQNNORgMR0C+2e/txWr8D9Xs00670uSVI7wzmZFY48xSqjj1I2/rXVXPw/8MXMkjyaWgeQliUldeT6ANgVwfjX4YPYwPfeHXlmSMbntnOXA9UPf6dfrWTjUjL2j1OSdLE0qv1h2l5LsezU12VEZ3YKqjJJOABXzFa+Ldfs08uHV71VHG1pSwH0z0o1Dxdr2oWr215qlzJA4wybsBh6HHWn9aXYr+16dvhdzc0bxDaWfxNbVUxHYS3UgJ6AI+Ru/XNfQHmxiLzd6eXjdvzxj1zXyPur2f4d/D+F9Pt9R8Qq07SKHhtHJ2Ip6Fh3J9Og+vSMPOV2kjDLsRUbcIxvfXtY9Ls7+zvvM+xXcFx5Zw/lSB9p9DjpXjvxR0TV9T8Vz3dhpd5LbpGiCRIydxA5I7+34V6XrXiTRvDaJbzOFkA+S2t0ywH0HCj64rP0r4iaBf3KwPNLZyOcL9pUKrH03AlR+JFbVHCa5JM9+rlOIxdG/K7b3SOV0b4rG0gW11/Tp/tMICNJEcMxH95Wxg/jUuofGC2CY07S5nf1nkCgfgM5/Oux8YeEtP8TWTiaNI70L+6ulHzKe2fUe1fOmrWFzpOoz2V6myeFirDqD7g9xWNSVSnpc8LFVcVhlbmuu9jX1zXL7xbrtvJfPGjOywxqgwkYJ/wDr177o3hbRtJtY4rXT7csgAMrxhnY+pY818wBiDkHmvVvAPxB127uYNMlsDqrdBIjbJFX1Yn5SPc4+tTQmlJ827McBiIKo3V1b67nsSIiLtVVUegGK4z4maHYT+G7vURDHDfWiiaK4QBWyCOCR1/xrs23GM7cKxHG4ZwfevLPinpPiy7smdbiK70xPme3tIyjDHcqSS35++K6qvwvS56+MdqT9242w+L1uunKL7TpmvVXB8thsc+uTyPyNcRfahqXjzxTbpLhTIdiIvKwp1J/mSe/5VyWa9e+FGhmy099UuUxPdDEYI5WP1/E/oBXJFzrNRb0PHo1K2NmqU3otztLa2h0+xgtLZdsMKBFHsP61UuG61cneqExzmvQ2PoUklZGbfvthY13eh2v2PSbWEjDBAW+p5P6muHjg+2atZ22Mq0gLD/ZHJ/QV6NQMKKKKACiiigArhPFetWHh3xvHq+rziCwtNCupZZME4Hn2/QDkknAA967uuB8YaFYeJvGiaNq8RlsbzQbqKVQ2048+3IIPYggEe4oAqQfGXwxNavJ5eqLcrew2BsxaF5/NmR3iwqE5DCN8YPUYOKs2/wAWNAurCwltbbVpr68u5rGPTUtD9qWWEZlDITgbAQSc9xTLH4UaVamwMuq6xdNZahb6jCZWgHzwrIqKdkS5UiVsk/McD5qc/wAKtIF2Ly01LWLPUE1O71WO6t5oxIj3OBNGMoR5ZAHBBIwOaAMXw18ZrCbwbo2p67aXJ1G7sZdSuodNt2lS1tklaMzPk5CZX3PB4rqo/iFpFzr40rTINS1JlMCz3NnamSC384Ax+Y/YEMCSAcA5OK5uT4R+FrLTdK0hdZ1SxYWUukBlu40lv7ZnaVoHymGGWY/IFYAnmr9j4Y8LweLTL4f8Sz6ddPLCtxpVhfxCO4e3UBVeMhnGETDBSuQDuzzQBkeAfjXpmsaDps/ia3udKvLmxuL4zG1kW1kSEkyCJzksVUAnGfQc4Fbi/Fvw4uj6lqN5HqdkthHbzywXFoVmaKdwkUiKCdykntyO4FMt/hD4cj0jw/pk0l/c2WjWl5ZQxyyJ+9juhiTzCqg5A6FduPeo2+EGiTaNqVhe6jrN499Fa273c88bTRw28iyRRoQgULlecqScnJzzQBKPi34f8i632usR6hBfRaf/AGbJZMt1JNIpaMLGezKC2SRwOccZy/DnxgtZ9OgfXNPv1v7y+v7a0s7CyknldbZgDuRdxDYYZ7degFal/wDDrw94i1fVNbtdWvk1C5v7e6+1WNxETa3FtGYQE+RgPlJDK27n0qfw78MNH0LUtIv7e91Se40ye9uI2uJUbzHutvm78IM42jGMdTnNABc/E/RoPFr+GpYb2DVW81YDPEBHK0aFjjDbgCFOCQAexrX+GniG48V+A9F128iihuL63ErxxZ2KckYGST2rnLb4P6Fb+JRrMV/qwdb2e/W2MkRiWWZWVzny95GGOMscdvSuw8IeH7Xwr4Z07Q9PknktLGIRRvOwLkZ/iIAGeewFAGxRRRQAUUUUAVNXGdKvB/0xf+Rry+w+8K9Uv132NyvrGw/SvLLIfMK8bNfiiehgtmdPYH5RWgTxWdY/dFaJ+7XBDY1luQNTTT2HNNNZMsaaSlPSkqBiN0rI1I8GtdulY2pHrQNF7wJHu1a4kxwsWPzI/wAK7quO+H6/Pfv/ALg/nXY19Hl6tQXzPNxTvUYUUUV2nOFFFFABRRRQAV5H4e06O++NGryzLuW0LzLxxu+VR/6ET+FeuV5h4enXT/HnjjUZQfKtYTI/0A3fyU1lVteN+5y4in7SpSilf3v0O01rxNp2kTiC5kd58AmOJc7QehY9B+JqrpXjXR9RvY7RJZIZ5DiMSqAHPoGBIz7Zrzb4b6PH49vb/V/ESG5tIJdqQEkJLOw3OzY6hQVAHTH0q18XPAun6VoD634dg+wTWrL50cBKo6FgM47EEg5HbNZe1qOPtEtD6pYDBwxCwVST53pfom/0I/jxpCQ3lhq8KAeeDBMQOrDlSffGR/wEV2nwx8T2Ws+HrKzWZEv7SFYZICcMQowGA7ggDp0qhaRn4ifCq3MzL9vePhz2njJGT6bsfk1eDTJc6dfPHIJbe6gcqRyrIw/lUufJLnWzPisdGpluMldeT9VufXlIQGBBGQe1fLUPjPxHCoCa1f4H96Yt/Oux+HPxG1CPW4rLXrp7q0umEaySY3ROeAc+hOAfTrWkcRFuxVPNKU5KLTVz0/T/AAPoOn63/atpZhLgElV3EohPdV7H+XauS8Y/EOV/EI8OeGY5bi93+U7QgbmcdUUnhQOcsenPTGa9G1u9Gm6PfXpAP2aB5cHuVUnH6V5b8CtEjF5r2tTfvJ/P+yJI3UYAaQj6ll/Kipe6hDS+59PlmHw9CjUxVSN+W1l0cn39CLU5fG/hq0bVJ4LlreL5pSl8brYvctG/b1K9PUV3nw+8X23jDRvtUKiK6iOyeEHO09iPY9vxHaunZQylWAKkYIPevFvB9ong/wCLN5plvlLK7laFU/hCsnmx4+hBX8aTTpSVnozphOnmNCopRSqQXMmuqW6f6Gd8Y/DI0fWF1KzTbZXrEsB0SXqR9D1/OvO91fSnxR09NR8D6mjLl4UE6eoZTnj8Mj8a+Zt1YV4KM9D89zGgqVW62ep1Pw80X+3/ABXZ2ki7rdD50/psXqPxOB+NfR2s3o0zRr6+KgrawPNt9dqk4/SvKf2f7aMHVLtv9c+2JPZRy3/oS/lXpPjaMzeDddjX7zWM+PrsNbUNKbkj2smw6Shz/aa+655V8MtBi8ZX2panr7Nd20EwXyiSFmnI3Mz46gAqAOn5V1Hjn4Y6RqOkzS6DZRafqkSFovs42JLgfcZRxz69c1Q/Z6Ij8P6xb/xJfb+euGjTH8q9Wp0acZUldbn1WZY6vh8wk6UmlF6Lpb08zzL4FeJZtX8Pz6bfOz3enFVVm6tE2dv5EEfQCsz4x6L56y6hCg822YFyOpjYD+R/mar+A4zo3xZvbMH93cfarcD/AHXEiH67c/nXd+JIBez6hauMpLF5Z/Ff/r1x4ibVCLe6ZzZ1hKdavUjBWjNcy+f/AAT5t3V9BfCbSYdD8GrqFztjlu1NzLI38MYHy8+m3n8TXzwMltoHJOMV9LeOoWs/hrf2sRwVtUtxjjg7U/ka2oaXl2PkMhwyr4lJ90vvZyT+PdZ8SanPb+FIJxFCNw8mFHfaejO0hCrnsvWp/DXxKnt9dGieLIWguGcRpM8XlMrHoHXpg54YHH86t/AKxitfApnVR51zdStI3c7TsA/Jf1NZn7QmiJcaRYavEg+0wS/Z3YDkowJGfoRx/vGqftI0/a31P0KCwlXGPL3TSjdxUvtXXW/XXoXfGfw/sJ/ENlqNuVggnm/0uAcBu+V9Mng/XNdeVWOMKgAUDAA7Csu1vhrXhXQbqQsftVnukwxB3bVDc9euea53w7qd1oWpJ4c1yeSeGViNLv5TkygDPkSH/noo6MfvqD3By6VaPtpU/R/gfMvBRw95RVm3r8tDqJjVObvVufg1RuW2oxrsILvhOHzdYnmIyIo8D6k/4A12Fc/4KixpklxjmaQ4PsOP55roKACiiigAooooAK5WX5/ina46RaLLn33zx4/9Fn866quV/wCap/8AcG/9r0Aee63P44HxJlW1/t7d/bFqtokUROmHTdo84yNjbvzvzk78421gW958QRr3iMeZ4nlQwXbQXotJUW3OcRKLZ08uQ46GFye5z0P0XRQB87eCz43u9X8Ox6paeIFtBqcsc15cCVw0f2Vv3gE0YkhG8j73BPAyBzH8MfDviTw/aeADa2OpJcXF1rEuoLeWpAiYJKIPMbYGRWIUgk8luOCBX0bRQB87Jf8AiuHwcTLD8QbnxLIIk1MPE8cFuxmXc8OxCXAGflhzlCckGs230/xbqFv4Sv8AxCPFkq6V4hvIfOis5BcramP91LsKl8E5G45wCQT3r6booA8BZ/F8VhZC+i8S22jNrmqfbjpVqwvPLyfspVVXcYyc5YDB+XJxVa5g+JOpaaV1S98RWN5a+Dzegaem0T6issuyNiEOZCgj3IpBNfQ9FAGZ4WmvLjwzpE2qK66hJZwvcK6bGEhQFgV7HOeO1adFFABRRRQAUUUUAMmG6GRfVSK8qsx8wr1eT7jfQ15Xar84+tePmv2Pn+h34L7R0Nl0FaJ+7WfZcAVofw159PY3nuRNTDUjdajas2NDT0pKVqSsyhrdKxtT71tHpWTqS5oGjb8Api1u27mQD9P/AK9dVXNeBVxY3P8A11/oK6WvpsF/AieXiP4jCiiiuoxCiiigAooooAK8l1FTj4nOuBuSOLP1Vgf5161XnGoWLDQviDMRzK0jgeyR5/mDWNbZfP8AJl4eN8XRfaSZL8D7VbTwdNGvJ+2zZPrjA/kBW/8AEeHz/Aeup6Wjv/3yM/0rE+DMok8OagqnIj1CQfmqN/7NXT+MI/N8Ja3H/fsZ1/ONqUF+5t5Hp4mTWZOT/nv+Jx/wLAj8LX9sDlYL9lXPoY42/mTWV8ctMtZLVr9IkS7hCbpAMFwW24Pr1H5Ve+BswksNZQdriN/ziUf0qD427jol4UHCtFv9hkf1xXNVlajC3dHNn1NSrYjnV9G/nY8L3VPp8UlzfW0EWfMlkVFx1yTiqW6uu+GlgbvXjckfurNDIf8AePC/1P4VlN8kXI+FwtF160aS6s96+Jcvk+CNTOcbhHGfo0ir/Ws/4OxBPBazKMfaLu5k+uJWX/2WmfF252/Da7mH8TQN/wCREP8ASp/g7z8ONGb+8JW/OVz/AFrtTvW+R+iOLjld+9T/ANtR2deL/EKYWPxc0V92Glnsn/Aysh/QV7RXhnxeQt8WvDLKMhRaA/U3D0YnSK9UXkSUq80/5JHrnio50eSPGRIyoR6jOf6V8ta1aNp2r3lmc/uZWQZ7jPB/LFfUnig4s7cf3p1H6NXz58WrX7N4sMoHFzCkn4jK/wDsorjrz/2jl8j5fN6PNhY1Oz/P/hjtPgnP5OltJnpelW+jIgr2K7gW5tJoH+7KjIfoRivE/hChbwvfv63JA/BF/wAa9stJPOtYZeu9Fb8xV4Kd5TgdeFTWFpTXY8h+BMrw6zrtnJnc8FvLj0Zdyt/T8q9jrxnwRINO+NOq2J4WWO4jVf8AtoJF/wDHSa9mrqw3wW7Ht54r4t1P5kn+B4tey/ZPj1bAEKDdZx7Pa4P6k13cs4nubifPysxIPsOB+leY+NNy/HKORB93ZyPXyCa9BuW8vSLh14Kws3/jprx8ZNt8nmzux8VGNGp/07ieA6Gn2rX7GMDIkuEBHtuFfSvjg/aPA+oSAAgwLL+AIbP6V87/AA8j+0eMdNTHAdn/ACUn+lfSNvb/ANo+EpLRj/rreSD8wy130Ze/Kn3R8bkNqcVXfSS/CzOW+Bkobwhd2+cm21CaL88N/wCzVsfFOAT+CL0EZKSQuPwlTP6ZrjvgPdlrvxDbE8P5F2Pq6sG/9BFdt8S2CeBtVJ7Iv/oa1vF81D5H1OIg6Wbpf30/vaZznw5Jl+Guk55a3nniJ9vNkA/pWhqek2ut2N1YX6FoJUU5Rtro6tlXVhyrKcEEdCBWV8Lm2/DaPuHvptv/AH8J/oa6OA/vm/3P615+2Kptdl+RjjV79Zf3n+Zyug6tdw3r+H/EDhtVgTfDc7dq30IOPMUdnHAdexII4YVpak+y2Y1F4s0WLW7RU817a8gcTWt3GBvglHRh6g8gjoQSD1rM8NanLrV3HpeqQrbaxayol3AudrKTxLGT1jYAkHtgg8g17J5B6ho1v9k0q1gxgpGN316n9c1coooAKKKKACiiue1Pwfo+pX0t3dpfGeUgt5eo3ES8DHCrIFHTsKAOhrlf+ap/9wb/ANr0f8K/8OnHmW15KP7suo3Mi/k0hFaGh+FtG0O6ludLsVguJEEbyb2Ylc5x8xPGaANqiiigAooooAKKKKACiiigAooooAKKKKACiiigAPINeZwRbZsY6GvTK4y6sGhuXOO9eXmcHJRa6XOzCSSbTHWwwBVzPFV4kIAqYCvIjdHU9RDTGqXFRPSkNDTSUp7UlZlBWdqA4rRxUMls87gAVUYuTsgulqzU8GLtsJ/eX+groKoaNai1tNgGCTk1fr6fDQcKUYs8qtLmm2gooorczCiiigAooooAKwpbQXMOvWijieMpj3ZT/jW7WXYP/wATrUE9kNYVvih6/ozWk3G8luv80ea/s8332iz12D/nnNDKR7sm3/2SvUdbTzNGv0/vW8g/8dNeO/Bc/wBm/EnxRpP3RtfC/wDXOXaP0evabxd9pOvqjD9KWHd6STPWztKGYSlHZ2a+aR5D+zpOZofEAJzteD/0Fh/Suq8UWKayurWchws4MYP90gYB/AgGuK/ZsfM3iVeh/wBGP/o2u6tnMsk8h/ikY/rXmYqbVCnbub5vSi8wrxe2n4pHzHcxvbXMsEoxJE5Rh6EHBr1z4V2SxeELm6x+8uZjz/sqMAfnu/OvO/iFD9m8aatGBjM3mf8AfQDf1r1b4aqR8PrE/wB4yn/yIw/pSxUr0k+9j4fJaKhjpRf2b/nY6T4oQiX4Z+S/IP2dT/30tXvhAMfDjRAO0b/+jGqj8SJM/DISnkKbfP4Ooq98H2DfDjRSP7kn/oxq9KnZ1E/7qPr6l/7MS/6eP8jsa8V8fK1z8YtEj7Jc2Q+u12evaq8ZuG/tL4920Y+aO3mZj7BLb/4tquvqorzFk75JVZ9oS/Q9M8U/8e1r/wBdx/6C1eFfGxgNa08d/s5z/wB9GvdvFPFnbn0nX+TV8/8Axsc/8JRaDsLNT/4+9efWX+1/I8HM3bAP1X5nX/Bxf+KRnJ/iunP/AI6g/pXrehPv0i2Pou38jj+leU/B7H/CGpjvPJn9K9K8Lykw3Nuf+WT5X6Nz/PNTg52xMl3OnDx/2Gn6I8z1aMaf8fLC7HAuJlQj/ftyn8xXs9eO/EEeX8WvD7jqZ7I/nJKtexV6VHRyXmepmj5oUJP+RL7jw3W4jffGpwoyvnsuf9yzJP612WoHb4euy3a3c/8AjprmPAq/2t8Ur+6PKp9snBPYGQRKP++c10mrMR4ZvyeotZP/AEA14+LWsZd2/wBDrzJ8tqf8sEvuTPI/hDH53jBWxnyoHf8Akv8A7NX0X4aOdMAP8Mjj/wAeNeCfA6INq2pTd0gVPzbP/ste9+HcfYpAO0rf0rqoP/amvI+VyyFsCn3b/wAjyX4DybvFGuLggLbIv1w7YrtPjVdm28A3aL9+4liiX/vsMf0U1yPwMRT4i1eRO9lAT9WZz/StT4/XYi0XT4CeC0txj3RNo/WSuiLth2fZ14qpnkdNmn9yv+hc8AWrWvwz8PK3WUvOf+Bs7D9GFbcZxKx/2f60sUIs/Dnh+yUFRFbRjb6bYwP61Gp+aU9uBXIo/wC2RXZfoeNiKntIzn3bf3shmbLGsS/0G41TWbS/0aWO213TkaW2mcZSQcboZPVG6HuDhhyK13PzVpeDYma5v7hugKxr+pP9K9g80v8AhTX4fEGmtMsT2t5A5gvLOU/vLWYAbo29eoIYcMCCODWzXJeKtHvbXUl8TeGohJq0KCO6s921dRtwSfLJPAkXJKMe+VPDHG7oGsWWvaTb6jpsvmW0wyMjayEcMjKeVZTkFTyCCDQBoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVby2Eo3Y5q1RUyipKzGnZ3RjtaEdBUTQEdq2ygNRtED2rhng09jeNZmKYj6VE0J9K3DAvpTTbr6VhLAtmirmH5DelOW1cnpW4tuvpUixAdqUcu7g8SZUNiT94VfhtVTHFWgoFLXdSwsKexhOrKQAYGKKKK6jIKKKKACiiigAooooAKxbNtviW6H96P+WK2qwQwTxOP9vK/wDjuf6VyYmXLKm/7xtSV1L0PLIP+JN+0Yyn5Yr3cM+u+Ld/6GMV7iRkEHoa8P8Ai5GNK+JWja1kgRiCY++yXDD/AL5Ir3CroaOUfM9TN/fhQrLrBL5x0PD/ANnaI2+q69Gx+/BA/wCr/wCNdzYDEJ+prifgS2fEuqYHDWMZP/fbf4129kTsf2dv515OL/g0/mduatvH1W/L8jxH4z232fxgJscXFuj59xlf/ZRXovwzIf4eadjt5oP/AH9euZ+PNlm10q/Ufcd4GP1GR/6C1dB8JQT4Atc93lx/32aiq+bDRfmfIYSn7LNKq7q/32Z0fi9TefCXUkT78ahv++ZQ38hT/gZMX+HdnC337eaeJvr5jN/7NVy1tze+CtcscZZ4pkX/AIEnH61ifAubGm63Zngx3gnA9BJGv9VNelhnfkl3jb7j6SXvZfUh/LO/3qx6dXh/wkJ1j4r+JdWPzRRrLsPp5kvy/wDjqkV7B4gvf7O0LUb3ODb20ko+qqT/AEry/wDZxstmjazfkcz3Kw59kXP/ALUreprVhH1ZOCXs8BiKvflivm7s9J8U/wDIMB9JU/nXhXx0sitxpd+PusjQN7YO4fzavc/FTf6BEnd5lH8z/SvOvitpo1DwVeEDMlri4T/gP3v/AB0tXn4qfLiovyPHxVH22BnH5/dqYHwO1NZNNv8ATWP7yKQTr7qwAP5Ff1r13wwCbq+fHy/Io9zzXzx8FJ2TxfKqnh7VwfzU/wBK+j/Cw/4lrP3eVif5f0oo0/8Aa7+V/wBDLLqzngEn0djy/wCIUgm+M3hyBT8yy2ZI/wB2SRj/ADr1/VLtbDTLu8k+5bwvK30UE/0ryC7tm1D9oK3lJBht5Nn4rbbv/QjXa/F/UP7P+H2qsDh51W3Ueu5gD/47uruhLlU5ebPo8XQ9rVwmHXWMfxZyfwFhZ01zU5fmx5VuGPqFLv8Aq61tav8A8irqH/XpL/6AaPg5Zmx+F0U7jEl151y34kqP/HVWpdTTzPDt7Go5a1kUD6qa83GLljTX9dDLMKntcTXku9vu0PNPgQc3Osj/AGIv5tXt2jy+To9/KT/q3kb8lBrw/wCAkbGXWZcfIFiXPqfnNeuzzm38G+JpenlxTsP+/IrSk7YqXp+h4uUw58HTj3f/ALczjfgEga816UDAEFnGPqFkJ/mKrfG0nUfFOl6UvPmrDBj3mmwR+SCr/wCzqhfRtauT/HdLH/3zGP8A4qs7U3XWfj/Z2qcx2kyyMR/0zh3D/wAeOK6lrRjHuz62Xu5piKv8kW/uSR6ZrTh9RCj/AJZRgfQnn+WKoxj9xI395z/h/SpLp/MvrqT1kI/Lj+lRk7bNPfn8zmubCv2mKnP1Pnq3u0UihK2CT2rpvCcezR0fvK7SfrgfoBXJXrYgkPtXeaZCLfTbWEDGyJV/SvXOIs1xOvWlx4U1afxJo0Mk2nXBDaxYRKWLYGPtUSj/AJaAAbwPvqP7yjPbUUAVYtRtJtLXUbedJrF4fPSaL51ePGdy4znj0rl/DXxM8J+Jdbk0jSNSlk1KOE3DwTWU8BWMEAsTIijHIrT07QT4esdXXw+3/HwXuLWymIFvBMVOQmBlUZvmIzgEnGM14xpvwx8b3XhvxVYa3Ho/9teIP3l1rX253eQq6skHliMbYiF2EAnAJ4PAAB79DfWk1uk8N1BJA52rIsgKk+gPSmNqVitl9sa9thaZx55lXZ1x97OOvFeLy/CjVb+GRrqx0WytLzxHYanNotvIXtYLaFAkoHyKGZxkkbQD61n6l8GNYAk/s5NN+wQa/fX9vpXmCOF7aeKJEA3RSIjIUbA2EAMcEUAfQQdSm8MNmM7s8Y9awPEnjDRfD2gnWL28WSzMqwRm2HnNLIzbQihc5bPauXk8B383wPl8F29wthetZNbRv9oadY/mJCGTapZcYUnaOCcCuNuvhDqepW2oSXWmeH7JbzVtOu10m3YyW1vFbjbKwJjUbpFJyAoBAAJPNAHrOu+MdG8P6BY6xrk1xZWl40UcSvbSPL5kgyqGNFZg3UYx14p2heMdA1zSJNT07U4TZRztbSSTBoDHKvVGWQKVYZHBANc98XvBl54t8OaNpejPHai01S2uWKv5RjhjznyyAcMARj6Vwkfww8WW3g9dAaPRtQSLXJtQmuJ5cS6jHIrjzHd4pPLm+bBIU5XgHrkA9yl1CzhgE013bxwld4dpFClfXOenPWntdW6hy08QCYLkuPlz0z6Zrwbw78GNQXTdCtPEdrpN9Fp+jahZGORvNVJ5rhpIWXcv8KkfNwQelTQfB7WjdeEY5bmzGmCxsrbxDDvZvtDWjb4tvHzAnCHOMAUAezWmt2k9ve3Epks4bS4e2ke7XylLKcbgT1Unoe9XhcwHbiaM7lDLhhyCcAj2JrwzW/hNr95azvHLYzFfE9/rAspJQI7iCfhMs0UirIozjKMOTzWj4D+Ez6X4q0bUNbsLGWy0zSFtraJ7g3T29yt5LOjKxjTO1HADADByAMckA9nooooAKKKKACiiigAooooAKKKKACiiigAxRiiigAooooAKKKKACiiigAooooAKKKKACiiigArmNTfytZSXssq5+nFdPXLa4u65n+uf0rzsyfLCLXc6cKrya8jk/j3YCfS9MuducPLbE/76bh+sdeg+GL0aj4a0u93FvPtY5CSeclQTn8a574oQ/b/h5c3CDc8Iiul/4CwJ/wDHd1V/gvem48HvaSNlrC6ltx/uk71/R8fhXRBr2r81c9GqnVyyEv5JNffqcX8BnU+JNQUf9A+PH4Of8a722G1p19JGH615/wDBNTb+OruBhgnTpBj/AHZlH9a9EmTydVvYz18wuPo3P9a8vFL9xF+Z25tb6/PzSOV+Klit94G1IEZeBROh9Cpyf0zR8L4fJ8AaUpHLI7/99Ox/rW/rlo1/ouoWcZUPcW8kKlugLKRz+dN0Ox/svQ7GwyGNtAkRYdyFAJrj5/3XJ5ni+w/2v239234m54VAzep2ypx+def/AAduVt/GOtaeCQWtlJB65hkZP/ZxXe+EmzdagPTy/wD2avK9LL6J+0BJG3yw3NxNGcf9NU8wf+PFa9bDu1KlLzaPTwkFVp4ql15VL7v+HPRvi9ctbfD/AFNY/wDWzhIFA77nAI/LNUfgXbG3+HVm7DBnlllx/wADK/8AstVfjjdmHRbCHsZJLg/RIyB+riuq+H1p9h8D6FbkYZbOJmH+0yhj+pNda1rN9kYzfs8qjD+abf3Kwvid83FlF7s5/DAH8zWTqFst5YXNs/3JomjP0II/rV3W5BJrm3/nnEB+JJP+FRV4eNnevJmFGK9mkzwz4F2bv4mv53GFt7Yxn2ZmGP0Vq+h/Crf6DMndJmH6A/1ry74WaWbGbxPMVx5mpywr7qhOD/48a9K8Mvi6vY/9xx+oP9K66NW+L+VvwPMwVD2WCUXvdv8AE4Pw44m+Lk7AAt9ovCT7KFQfypn7Q19nTtP05Tx8904z/dG1f1ZvyqDwI4m+KkzDqf7Qc/jOP8aofFBDq/xHtrD7wa4tLLHopO9v0eupu9JpdWfZU4KOYwnLanC/3XX6nrGlWa6b4JtbPbtFvYLGQeuRHg5rLjAMKjGQR0rpNaONKusd0I/PiucjGEUe1ceZ6TivI+dw8nLmk+rOS+GWgyaDodxHPEY5prqR8N12g7V/QZ/Gt7xJmP4c+I2B2+buUH6hVrRJwDWZ8S2Wy+GvkE48+SFT9S4dv5Gs8I3Oc6j7M3wVGNKpRow25o/mVPgXHHp/gC5uJTtia7mmZj6KApP/AI5XO/A2F9Z8X+IfEdyCXPyKT/ekYs2PoFA/GrkFz/ZHwIsIFOyXUVaMH/Zld3b/AMc3Vu/AezFt4CW52bftlzLOD6gHYP8A0CvSgryhHsrnpYmfJh8VX61J8q9E239/6Gm5ISY99zfzNOvBsjVfQYoGJNo7Ow/ImjUTzXPlkfjkeFinsjNWMXFzbwEZEkiqR7Z5r0KuG8PR+d4ih7iJGkP5Y/rXc16pxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc1qwzeTj3/pXS1zep/8f031/pXmZp/DXqdWE+NksFt/anhG6sH/AOW0MtufxBA/mK83+Al//wATTV7NzhpreGcL6FSyN/Na9K8MS4a6gJ6MHH48H+QrxfwHM2ifG2axfhJJrm1z/s5Lr+ZUfnTpTvGlP5Hs4Kn7XC4qj2Skvlv+hpfDw/ZPisIjn51vbfnvtl3f+y16Z4jj8nVbeYdJkKn6r/8Arry2KX+z/jpbJnAGoTjH/XaMn+bV6z4vG2Gzkx0m2/mD/hU1Y82HmuzDNb/WqdT+aKf5lGjtQOgpa8Q5Sx4V+XUL9fVUP8680+KQ/sz4lWeogY8tba9Jz/ckKsPyAr0Xw4+zXrhCfvw5H4EVxXx3tgb3SJduRPb3Fu34BSP5mvaoO+FT7P8AU6Mrdsc4P7UWvwv+gz49zMxghXPy2Um33Lug/wDZa9etYVt7WGFPuxoqD6AYrwj4nagL+HwzeSNg3enQSN9TIhP8zXvldtJ3nJ+hhmMXTwmHg/735nJXR8zVbyT/AG9v5DH9KKhgYu0rnq0jN+tTV83VlzTcu7JirJIgtraG2WRbeNUEjtI2O7Mck/nV7w+2NamX1hz+RH+NQU7RDjxAPeJh/KtsI/38X5mdVL2bSPNPhpPv+LdzGP4I7wH8ZgalU/a/jpaK/K/2hO3PrHbnH/oNU/AqfYvjbODwLi4voR/wFmb/ANlq5bZh+NenOejalej84mA/nXqw+GKfc+ixKSr1pR60v8/8j13xK+3SZFHV2Vf1B/pWIvAFavihv3FtH/elz+QP+NZYrhzKV61uyPmsKrUxJP8AVtj0rlfjrdiPwro9vnHmSGb8EiI/m4rqLhxHA7HoBXm3x7m87VdE0svtZbXp6GRgv/slLBu0J/I9XLKfPjab7cz+5f5jvijOuneCfDOn5Aa10xXYf7RRIx/7PXqmg2g0LwHp1l92SK0jiP8AvlRk/mSa8o+KSrqXj610oDMX2iysAvbaTuP/AKHXr/iCXdcQQDooMjD9B/Wu+pU9nGpP5foZ4+/1fD0u95P56/qZkY/fwAfdBJP4Cob9ssaliObl/wDZTH5n/wCtXL6vrsmneIo7PUoUisLwBLS7BO3ze8Un91j1U9+R1xmstjajfuzxsU7zsdd4MhzdXtwfRY1P5k/0rqqxfCUezSd2P9ZIzZ9e39K2q7zmCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5vU/+P6b6/0rpK5vU/8Aj+m+v9K8zNP4a9TqwnxMj0V/L1sDtJGV/r/SvJPHynQvjTb6ntxB59tcP7KcIx/Rq9Vsm2azaH/ax+YIrz79oGzP9p2M6jm4spYvxjYOP/Q6wwzvh79me7lMksY6b2nBr9f0Mj4oA6T8ZrC/zhWmtLk/QEKf/QDXtXi/H9mxE9plP6GvFfi5/wATbSvD+sgjzLrSEk3d9ylWP/ow17Brt0L7wnaXgxiYRSjH+0M/1rpn8FVfMnMbyo4Wb3ScX8nYrIfkH0p1Rw/6pPpUleCcZBaEw+IbOQdGOw/iCKyvjhF/xKNGuMZKX4T8GR/8BWo/y6jYt6TJ/wChCqfxsG7wvZDudQhH6NXrYJ3w80aYJ2x9J/L8zxnxxK8ngfwZPuPy29xED/1zm2j8sCvqAXCtYi5X7pj8wfTGa+ZdctS/ww8MSMu7a9+oP/bUH+jV75ol19p+Hen3OcmTTY2P1MYzXXRlyuT8k/wOzO4KVCi10lNf+TMoWYIt0z1IzU9Rwf6lB7CpK+ePPCn6Ov8AxPo2/wCmbUypNJYLrsOf4o2UfXr/AErfC/xo+pFX4GeZX2NN+MNg75Uf2u6Z/wCuyDH/AKHUviRvsfxc0yToBrEaf9/I0H/s1VfjFI2k+Oob3B2rJa32f91tv/sgp/xguPsPjBbr5QsL2d8rDvhiuf8Ax2vYbtddmfQU4uq6cl9qm1+X+Z6x4lYfa7JSezn+VUqteJx/xMLBvVXH8qq15mP/AI8vl+R85h/4aGMgllgiPSSVVP0zzXlnxHX+0fjJawnlIruytv8Avoq3/sxr1myXdqtjnoHYn/vhq8o1T/SPjMmT/wAxqH/xxR/hW2Fj+69ZfoevlT5atWfam/xaEvpft3x2gi5IXVFb/v3GP/ia9b1Nt+qXDD+Han5D/wCvXlelRCT47W5xydRvCf8AgMT4r0sMXkmkJ+/IzfgTxTxcrUrd5MnM0vaUkulOP9fgEA4mf1bH5CsXX7G11Swnsr+FZraYbXRvzBB6gg4II5BGa2YuLUH1yfzNUJEM08UQ6yOF/M4r1cLHkoxXkfN1XebZN4G1G70WW18LeI5C90YjJp183AvogAWVj/z2TPzD+IfOP4gvdVleJNCtPEGlNY3m9ArLLDNE22S3lU5SRG7Mp5H5HIJFZfhHXLuS7m0DxHsTxBZoHMiLtjvoeALiMdgTwy/wNx0Kk7mZ1NFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzep/wDH9N9f6V0lc3qf/H9N9f6V5mafw16nVhPiZTiB/tKzI/56r/OsD47WwfStGuSPuXhhJ9nRv/ia6GH/AI/7T/rqv86zPjjgeB/NP/LK6icfmR/WsMFrQmepgZOOPo26u336fqeb6g3234VeEXdcsv2u05+rAfogr0fwvc/bvhBo8pO4pBHFn/cfZ/7LXmtnun+CMdwOf7P1gsMdlbr+sldh8L7gTfCaWNWyIbx4wPTLh8f+PVs5e7Lzj+h6WZUv9mTX2ajX3tv9UdXF/ql+lSUyL/Vr9KfXiHkEEi7ryz9pk/8AQhWN8ebsQaBpUe7Ba/WT8FRs/wAxW9GN1/Zj/psp/WvMv2i9TE+s6dpsZ3G2haVwP7zkYH1wo/OvTwsuWhN+aOzKqPtswprort/Jf5kV7ZlPg74RlcfK1xOG/wC2plI/kK9C+FU/9o/CiyjJzJHDLbkehVmA/TFR+LvD0sXwfTToxuudOtIZOB1aMAt+gasX9nrWI7jS9W0onEkFx9pRT/ccAcfRlP8A30K74x5anK+qLxM/rWXSqx+xUb+Tbf6/gdVbHdBGf9kVNUcaGJpIiMeW5X8jUlfPNWdjgvcKj3+TdW9x/wA8nBP06H9Kkpsi7lIPenGTi1JdAaurHGftB2CS2+nXQHLxywE+pGHX+TfnXLfEeUar4R8NaoPmN1pJhc9fniK5/UtXovxItG1f4b3LR83Wmss4+icE/wDfBb8q8m065F/8KJ7ccz6LfiRl/wCmEwK8f8DJr2ZzUryX2lc97Kryw9F/yScX/wBvXt+LR7a1wL/QPDl8rbhLbo+713IpqWuU+Geoi/8Ahhpik7pbC5a2f2AyV/8AHWWuqHSvPxrvV5u6R4UqTozlSfRtfiJ5nkzQS5wEkUk+2cH9K8pvHEPxvjRuM6wh/wC+lGP516pOnmQuvqK8c+Isv9l/Fay1V8+UZLS9+oUKG/VGq8LOyt2aZ6mUQ551YdXCX6G7o5CfHRQPvLeXzc+8TGvQlOyzB9ErzVpTY/tDRCTARrxgP+2sOB/6EK9L2FYxEeqtsb8Dg1WKi5WS7tfkZZnpOnLvTi/zJXG2AL6ACoNITztdtV7KS5/AcfripblxtwKl8Jpv1S4kx9yML+Z/+tXvJWVj5Z6nWVheLfDya7aQtDO1nqtm/n2N6gy0EmPT+JGHDKeGBx6EbtFMDnvCPiF9XjuLLU4FstesCEvbQNkAnpJGTy0T4JVvYg4IIHJ+EPjBpfiLVtLsn0rUtOj1X7ULG6uTEYpzb584fK5ZcAZ+YAGvRTY2p1Bb828RvViMAn2DeIyQxXd1xkA49q878DfB3QfDWi3FtdAahqM8dzA+obGjdYpi25UUswQ4bGR1xzQBuW/xM8G3Fte3EXiCz8izVHmkYsoCO4RXBI+ZSxA3LkZI5otPiDoV3qEot9R06TSY9ObUWv1uhjYszxMduPuhkb5s8kYx3rgYvgRt0G70p9etWSS1hs4bgaZiZY47iKYB283Df6kLgBBzk5xXWeN/hlbeLtc1i9vdRkig1HQ10cwxxfNGVnMwlDZ55IG3HbrzQBrR/EbwlJpEuprrdt9kimW2bKsJPNYZVBGRvJYcgAcgEjgVSg+Knha48S6VosF5JJPqUDT283llY/lkMexs4YNuDDBX+E5IrntU+EVzq1rq02q67aXmsandW1xPcSaZiELbxvHGqRrKGRvnJLrID26cVY0r4U3GnXHh+YeJbm6fT7KfTro3cBla5glcOyq2/MeMbQSXwMelAHT2HxE8J6h9v+xa3bTfYoGuZtgb/VKdpkXj51zxuXIzWbefFDQyNIOjSDUvt2sQ6PKqlontnkR3DMjKGxhOmBnPXiuW0n4JS6Xpl7Y2viTyd9hJYWt5BY+XdwozKRuk8zDAbcEKqZBPNP0X4LNp+pR3kmuwM66xZasY4NPMSZt4ZI9gBlYjd5m7cSSCOhzmgD0fxL4s0PwybYa5qEdtJc7vJj2s7yBcbiFUE4GRk4wMiuWh+L3hhfFepaLqN7BY/Z3tVtZ5JCVuhPCsisBj5ANwGWOOal+Knw7fx01g0WpQafJapIqzG0aSVC+PmjkSSNkIx0JZTxlTisrUfhEbzSvFVm/iCd21z+zM3Fxb+ZJGbNYxuY7xvZ/LyT8uCx60AdlB438Nz+JDoEOr2z6sHaLyBnmRRlkDY2lwOSucjuKwtS+L3g2y0XUtSj1JrtbCBbiSCGJlleNmChkV9oYEkDIOOetZFl8Ho7HxVPqdrq8YtJb6XUEiks99xBJJkt5c2/AALHBKEj1rHsfgPIiaqNQ8TfapL/RpNIaZbErIS0qSCaRmlYu2UwemQeMYoA6W8+Mnhex1+3s7+7jttOuNLTU4b92OH3TNF5ewKTkFCSen869Gt5oriCOeCRJIZFDo6HKspGQQe4Irzm8+Gl3qM2pXGpa9FLd33hl/DrvHY7FG53YTBfMPQOBsz/Dndzgd14e07+x9A0zTPN877FaxW3mbdu/YgXdjJxnGcZNAGhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhVT1A/KlooATauc7R+VJJGki7ZFVl9GGRTqKVguRiCERmMRRhDyV2jB/ClSKNFKpGiqTkgAAZp9FOw7sTav90flRsX+6PypaKVkK4m1c52j8qje3hdtzxRs3qVBNS0UWHdoQjIwRxTI4Iom3RxRo2MZVQKkophcTav8AdH5UbF/uj8qWilZCE2L/AHR+VGxf7o/KloosguN2qQRtGD1GOtMW2gUMFhjAbggKOaloosO7I0hjjBEcaKCckBQKfsX+6PypaKLILsTYv90flUclvDIQZIo2IGAWUGpaKLILtEZgiMgcxIXHRiozT9q/3R+VLRTsF2JsX+6PyoVVXO0AZ9BS0UCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The germinal zone of the physis borders the epiphysis. The epiphyseal cartilage cells grow toward the metaphysis and form columns of cells. These columns degenerate, undergo hypertrophy, and then calcify at the metaphysis to form new bone. The hypertrophic zone (shaded red) is the usual site of physeal fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26918=[""].join("\n");
var outline_f26_18_26918=null;
var title_f26_18_26919="Epidemiology, etiology, and course of chronic kidney disease in children";
var content_f26_18_26919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, etiology, and course of chronic kidney disease in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/18/26919/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/18/26919/contributors\">",
"     Craig S Wong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/18/26919/contributors\">",
"     Bradley A Warady, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/18/26919/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/18/26919/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/18/26919/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/18/26919/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/18/26919/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease (CKD) refers to a state of irreversible kidney damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction of kidney function that can lead to future decreases in kidney function. It is now the accepted term in the pediatric nephrology community replacing the clinical terms of chronic renal failure (CRF) and chronic renal insufficiency (CRI), which describe renal dysfunction of varying degrees from severe to mild in nature. CKD more clearly defines renal dysfunction as a continuum, rather than a discrete change in renal function, and will be used throughout this topic review.",
"   </p>",
"   <p>",
"    CKD in children is the result of a heterogeneous group of disorders. The etiology and epidemiology of CKD in children will be reviewed here. The clinical presentation, evaluation, and management of CKD in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND CLASSIFICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition and classification of chronic kidney disease (CKD) guidelines were introduced by the National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (K/DOQI)",
"    </span>",
"    in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    workgroup defined CKD as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of markers of kidney damage for &ge;3 months, as defined by structural or functional abnormalities of the kidney with or without a decreased glomerular filtration rate (GFR), that is manifested by either pathological abnormalities or other markers of kidney damage, including abnormalities in the blood, urine, or in imaging tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GFR &lt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      for &ge;3 months, with or without kidney damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This definition encompasses all patients who were previously classified as having chronic renal failure (CRF) and chronic renal insufficiency (CRI). The broader implication of this common definition is that patients with CKD can be identified earlier such that progression towards end-stage renal disease (ESRD) can be halted or slowed, and that long-term morbidity from CKD can be reduced.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    workgroup developed a classification system for patients greater than two years of age based upon the level of kidney function, which is independent of the primary renal diagnosis (",
"    <a class=\"graphic graphic_table graphicRef80596 \" href=\"UTD.htm?22/4/22603\">",
"     table 1",
"    </a>",
"    ). This staging system was aimed at promoting early detection and treatment of CKD. The stages and their definitions based upon estimated GFR are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 disease &ndash; Normal GFR (&ge;90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      Stage 2 disease &ndash; GFR between 60 to 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 3 disease &ndash; GFR between 30 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 4 disease &ndash; GFR between 15 and 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 5 disease &ndash; GFR of less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      or ESRD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal levels of GFR vary with age, gender, and body size. GFR increases with maturation from infancy and approaches adult mean value by two years of age (",
"    <a class=\"graphic graphic_table graphicRef55965 \" href=\"UTD.htm?19/61/20443\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Children under two years of age do not fit within the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    classification system because their GFR is normally lower than the GFR of older patients. Thus, the GFR of young children and infants would incorrectly place them in a stage of disease characterized by greater renal impairment than their actual renal function. As an example, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    schema would incorrectly classify a six-month old infant with normal kidney function into stage 2 disease, because the mean GFR for this age is normally below 89",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    (",
"    <a class=\"graphic graphic_table graphicRef55965 \" href=\"UTD.htm?19/61/20443\">",
"     table 2",
"    </a>",
"    ). Despite the lack of a classification schema in children below two years of age, a calculated GFR based upon serum creatinine can be compared to normative age-appropriate values to detect renal impairment in toddlers and infants with CKD.",
"   </p>",
"   <p>",
"    In 2004, the Kidney Disease Improving Global Outcomes (KDIGO) group modified the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    classification system for",
"    <strong>",
"     adults",
"    </strong>",
"    by adding urinary albumin excretion as an additional staging factor to the various levels of GFR. The KDIGO classification system is currently being reviewed for its relevance to pediatric CKD. Although in children, proteinuria is also acknowledged as a risk factor associated with a lower GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/4\">",
"     4",
"    </a>",
"    ], the degree of protein excretion in children in generally based on a ratio of urinary concentration of protein to creatinine rather than the ratio of albumin to creatinine. Currently, the classification of CKD in children remains based on the original",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    system that uses estimated GFR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=see_link\">",
"     \"Definition and staging of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Estimation of GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomerular filtration rate (GFR) is equal to the sum of the filtration rates in all of the functioning nephrons. It thus provides an approximation of the number of functioning nephrons. A reduction in GFR implies a decrease in the number of functioning nephrons due to underlying",
"    <span class=\"nowrap\">",
"     disease/injury,",
"    </span>",
"    which may or may not be reversible.",
"   </p>",
"   <p>",
"    As noted above, normal levels of GFR vary with age, gender, and body size. GFR increases with maturation from infancy, and approaches adult mean values by two years of age (",
"    <a class=\"graphic graphic_table graphicRef55965 \" href=\"UTD.htm?19/61/20443\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    GFR is not measured directly but is estimated from the urinary clearance of a filtration marker. The gold standard of filtration markers is inulin, a physiologically inert substance that is freely filtered at the glomerulus. However, using this exogenous agent requires a continuous intravenous infusion, multiple blood samples, and at times bladder catheterization. Clinically, the GFR can be determined via timed urine collection for creatinine clearance; however, the collection is often inconvenient for families and inaccurate due to missed samples, episodes of incontinence, or voiding problems. Hence, determination of GFR can be time-consuming, costly, and difficult to perform for routine clinical use in children.",
"   </p>",
"   <p>",
"    The above limitations of determining GFR have inspired the utilization of formulas to estimate GFR using endogenous markers such as creatinine or cystatin C [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/5\">",
"     5",
"    </a>",
"    ]. Since the 1980s, the Schwartz equation has been widely used to estimate GFR. The Schwartz equation is based on serum creatinine determined by a Jaffe method [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, the use of the Schwartz equation may provide an overestimate of the GFR if there is an enzymatic determination of serum creatinine. The enzymatic method for determining creatinine results in a lower value compared to the Jaffe method. The following is an updated equation for GFR utilizing an enzymatically determined creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    GFR = 0.413 x height in cm",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    serum creatinine (enzymatic)",
"   </p>",
"   <p>",
"    This equation is valid in a narrow range of GFR between from 15 to 75",
"    <span class=\"nowrap\">",
"     ml/min/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Further work is needed for the validation of this equation in children with higher or normal levels of GFR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Serum creatinine and GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The estimating equations for GFR have their limitations. Hence, there are circumstances where a timed urine collection to determine GFR may be more appropriate, for instance, in patients with an unusual dietary intake (eg, vegetarian diet or creatinine supplements) or in those with decreased muscle mass (eg, amputation, malnutrition, or muscle wasting) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current data on the epidemiology of chronic kidney disease (CKD) in children may underestimate its incidence since CKD is often asymptomatic, especially in the earlier stages of CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\"",
"    </a>",
"    .) As such, current population-based estimates of CKD in children represent those with moderate to severe CKD or ESRD.",
"   </p>",
"   <p>",
"    The most comprehensive report on the epidemiology of CKD in children is from a prospective, population-based registry, ItalKid project, which included all Italian pediatric cases of CKD defined as a creatinine clearance (CrCl) less than 75",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    between 1990 and 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/10\">",
"     10",
"    </a>",
"    ]. The mean yearly incidence and prevalence of CKD were 12.1 and 74.7 cases per million children and adolescents below 20 years of age, respectively. At registration, the mean age was 6.9 years and the mean CrCl was 42",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    .",
"   </p>",
"   <p>",
"    Other reports on the epidemiology of CKD in children have been focused upon patients with stage 4 or 5 disease (ie, CrCl less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ), or those with ESRD requiring renal replacement therapy (RRT).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sweden &ndash; A national survey from 1986 to 1994 reported a yearly incidence and prevalence of CKD (defined as a glomerular filtration rate [GFR] &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ) of 7.7 and 21 per million children between 6 months and 16 years of age, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chile &ndash; A national survey of all pediatric nephrologists in 1996 estimated a yearly incidence and prevalence of CKD of 5.7 and 42.5 per million children under the age of 18 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence and prevalence of CKD are greater in males than females. Two thirds of patients were males in both the previously mentioned Italian registry (ItalKid project) and the chronic renal insufficiency (CRI) registry of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS), which includes patients below 21 years of age with a CrCl less than 75",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. The increased risk of CKD in males is due to the higher incidence of congenital anomalies of the kidney and urinary tract (CAKUT), including obstructive uropathy, renal dysplasia, renal hypoplasia, and prune belly syndrome.",
"   </p>",
"   <p>",
"    In North America, the incidence of CKD is two to three times higher in African-American compared to Caucasian children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/13\">",
"     13",
"    </a>",
"    ]. In the NAPRTCS CRI registry, the ethnic distribution is 61 percent Caucasian, 19 percent African-American, and 14 percent Hispanic children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/13\">",
"     13",
"    </a>",
"    ]. In Australia and New Zealand, the risk of ESRD is greater in children from an indigenous ethnicity (eg, Aborigines and Maoris) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients present throughout childhood. In the NAPRTCS CRI database, which contains over 7000 patients, the age distribution at presentation was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Below 2 years of age &ndash; 20.1 percent",
"     </li>",
"     <li>",
"      2 years of age to below 6 years of age &ndash; 15.9 percent",
"     </li>",
"     <li>",
"      6 years of age to below 13 years of age &ndash; 32.1 percent",
"     </li>",
"     <li>",
"      13 years of age to below 18 years of age &ndash; 28.2 percent",
"     </li>",
"     <li>",
"      18 to 21 years of age &ndash; 3.7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital causes account for almost 60 percent of cases of chronic kidney disease (CKD) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/10,13,15\">",
"     10,13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following distribution of causes is based upon the NAPRTCS CRI database of over 7000 patients who were registered from 1994 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/13\">",
"     13",
"    </a>",
"    ]. The distribution of causes varies by age (",
"    <a class=\"graphic graphic_figure graphicRef68637 \" href=\"UTD.htm?40/1/40990\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital renal anomalies were present in 57 percent of cases. These anomalies included obstructive uropathy (21 percent), renal",
"      <span class=\"nowrap\">",
"       aplasia/hypoplasia/dysplasia",
"      </span>",
"      (18 percent), reflux nephropathy (8 percent), and polycystic kidney disease (4 percent).",
"     </li>",
"     <li>",
"      Glomerular disease was present in 17 percent of patients. It was more common in older children, accounting for approximately 45 percent of cases in patients greater than 12 years of age (",
"      <a class=\"graphic graphic_figure graphicRef68637 \" href=\"UTD.htm?40/1/40990\">",
"       figure 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Focal segmental glomerulosclerosis (FSGS) was the most common glomerular disorder occurring in 9 percent of all CKD cases. African-American children were three times more likely to develop FSGS than Caucasian patients (18 versus 6 percent), and FSGS was the cause of CKD in one-third of African-American adolescent patients.",
"     </li>",
"     <li>",
"      Other causes accounted for approximately 25 percent of cases. In 18 percent of all cases of CKD, the underlying primary diagnosis was not identified (15 percent) or was unknown (3 percent). Other more uncommon causes of CKD in children included hemolytic-uremic syndrome, genetic disorders (eg, cystinosis, oxalosis, and hereditary nephritis [also referred to as Alport's syndrome]), and interstitial nephritis. Unlike adults, diabetic nephropathy and hypertension were rare causes of CKD in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar distribution of primary disorders causing childhood CKD was reported by the Italian registry (ItalKid project) of 1197 patients below 20 years of age with a CrCl less than 75",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The leading cause of CKD was renal",
"      <span class=\"nowrap\">",
"       hypoplasia/dysplasia,",
"      </span>",
"      which occurred with and without urinary tract anomalies in 54 and 14 percent of patients, respectively.",
"     </li>",
"     <li>",
"      Glomerular disease was the cause of CKD in only 7 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND PROGRESSION OF CHRONIC KIDNEY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of renal disease is variable and, at times, unpredictable. The initial injury to the kidney may result in a variety of clinical manifestations. In some cases, individuals may fully recover and suffer little or no sequelae, such as in patients with poststreptococcal glomerulonephritis or in most children with hemolytic-uremic syndrome.",
"   </p>",
"   <p>",
"    However, in children with chronic kidney disease (CKD), there is a generally continued progression of renal disease and functional impairment often leading to ESRD. This was illustrated by data from the CRI registry of NAPRTCS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/13\">",
"     13",
"    </a>",
"    ]. As of 2008, 46 percent of the 7037 cases registered have terminated their CRI status. Of these 3236 cases, termination was due to the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression to ESRD requiring renal replacement therapy (either dialysis or renal transplantation) &ndash; 86 percent.",
"     </li>",
"     <li>",
"      Death &ndash; 4 percent.",
"     </li>",
"     <li>",
"      Renal function regained with a glomerular filtration rate (GFR) greater than 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      &ndash; 3 percent.",
"     </li>",
"     <li>",
"      The remaining patients were lost to follow-up or transferred to a non-participating center.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children with CKD, the persistent decrease of renal function may be a result of repeated and chronic insults to the renal parenchyma leading to permanent damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to the adaptive hyperfiltration response of the kidney, which compensates for the loss of nephrons from the initial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/16\">",
"     16",
"    </a>",
"    ]. In patients with parenchymal injury, the adaptive hyperfiltration process increases the filtration rate in the remaining nephrons by increasing glomerular pressure and flow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. This often results in a normal or near-normal glomerular filtration rate and serum creatinine in patients with mild impairment.",
"   </p>",
"   <p>",
"    Over time, however, the enhanced transglomerular ultrafiltration and glomerular pressure leads to glomerular damage and leakage of protein resulting in interstitial inflammation and fibrosis. This long-term injury is characterized histologically by glomerulosclerosis, vascular sclerosis, and tubulointerstitial fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], and clinically by proteinuria and progressive renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of progression of CKD is usually greatest during the two periods of rapid growth, infancy and puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/20\">",
"     20",
"    </a>",
"    ], when the sudden increase in body mass results in a rise in the filtration demands of the remaining nephrons. As a result, children with CKD should be closely monitored during these two periods for an accelerated progression of CKD. In addition to the increase in body mass, hormonal changes during puberty may also contribute to the rapid decline in renal function seen in adolescence.",
"   </p>",
"   <p>",
"    The rate of progression to ESRD in childhood is inversely proportional to the baseline CrCl at presentation. In addition, genetic, familial, or ethnic predisposition may influence the rate of renal decline. As an example, African-Americans are more susceptible to CKD, and the rate of progression of CKD is faster among African-American males than other ethnic groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link&amp;anchor=H22#H22\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors associated with an increase in the rate of CKD progression include primary disease, hypertension, proteinuria, anemia, hyperphosphatemia, and hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/21\">",
"     21",
"    </a>",
"    ]. Some of these may be modifiable, and therapeutic interventions may result in a reduced rate of deterioration of renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Slowing chronic kidney disease progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     CKiD study",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ongoing prospective study, Chronic Kidney Disease in Children Study (CKiD), is following the course of more than 580 children who were between 1 and 16 years of age at enrollment with CKD. The goals of the study are to identify risk factors for CKD progression and the impact of CKD on growth, cognition, and the risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an initial CKiD study of 419 children with CKD, 76 percent of patients had proteinuria, including 14 percent with nephrotic range proteinuria (defined as a urinary protein to creatinine ratio [U",
"    <span class=\"nowrap\">",
"     prot/Cr]",
"    </span>",
"    of greater than 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/4\">",
"     4",
"    </a>",
"    ]. A decrease in GFR was associated with an increase in U",
"    <span class=\"nowrap\">",
"     prot/Cr.",
"    </span>",
"    At any given level of GFR, a higher U",
"    <span class=\"nowrap\">",
"     prot/Cr",
"    </span>",
"    was seen in patients with a glomerular cause of CKD compared to those with nonglomerular diseases. Patients with glomerular disease who received renin-angiotensin system (RAS) antagonistic therapy had lower U",
"    <span class=\"nowrap\">",
"     prot/Cr",
"    </span>",
"    compared to those with glomerular disease and no RAS antagonistic therapy. Follow-up studies will monitor the impact of proteinuria upon CKD progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, little systemic data exist on infants with CKD, because children under one year of age were not enrolled in the CKiD study. Outcome data of young children with severe CKD (ie, those in need of dialysis or transplant) can, however, be found in the United States Renal Data System (USRDS), NAPRTCS, Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), and the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) databases. Data from the USRDS demonstrate that children zero to four years of age with ESRD have the highest mortality rate compared to other age groups up to 19 years old. In 2007, the mortality rate of children zero to four years of age with ESRD was 45.5 deaths per 1000 patient years compared with 6, 10, 2, and 11 for the age groups of 5 to 9, 10 to 14, and 15 to 19 years of age, respectfully [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a NAPRTCS database analysis, the outcomes of 193 infants initiating dialysis within the first month of life was compared to the outcome of infants who initiated dialysis at 1 to 24 months of age, during the calendar years 1992 to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/24\">",
"     24",
"    </a>",
"    ]. Based upon the mean population during the study period, the estimated incidence rates of dialysis-treated neonatal ESRD were 0.045 cases per million population per year, or .32 cases per 100,000 live births per year. The following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates with dialysis treated for ESRD were more likely to be diagnosed with renal dysplasia or autosomal recessive polycystic kidney disease, whereas older infants were more likely to be diagnosed with congenital nephrotic syndrome",
"     </li>",
"     <li>",
"      Neonates were as likely to terminate dialysis during the study period compared to older infants (81 versus 83 percent)",
"     </li>",
"     <li>",
"      The majority of neonates and older infants terminated dialysis due to kidney transplantation (46.5 versus 57.7 percent)",
"     </li>",
"     <li>",
"      Rates of termination of dialysis due to death were higher for neonates compared to older infants (10.8 versus 7.9 percent)",
"     </li>",
"     <li>",
"      Neonates were more likely to recover native kidney function compared to older infants (14.6 versus 4.1 percent)",
"     </li>",
"     <li>",
"      Neonates had a higher rate of hospitalization compared to older infants (80 versus 73 percent)",
"     </li>",
"     <li>",
"      The mortality rates of neonates and older infants were 24 percent",
"      <span class=\"nowrap\">",
"       (46/193)",
"      </span>",
"      and 20 percent",
"      <span class=\"nowrap\">",
"       (100/505)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the high mortality rates of very young children with ESRD, good long-term outcomes can be achieved. This was illustrated by a retrospective review of 110 infants born from 1986 to 1997, who were either diagnosed with CKD in the first six months of life with a GFR &lt;20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    or required dialysis or renal transplantation in the first two years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/25\">",
"     25",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 101 patients, 28 died and 3 were lost to follow-up. The estimated 5-, 10-, and 20-year patient survival rates were 81, 75, and 72 percent, respectively.",
"     </li>",
"     <li>",
"      Half of the patients had another comorbidity (eg, congenital heart disease, pulmonary disease, or neurologic involvement such as cerebral palsy or developmental delay).",
"     </li>",
"     <li>",
"      Two-thirds of the patients required tube-feeding, one-third gastrostomy feeds, and 13 percent had a Nissen fundoplication.",
"     </li>",
"     <li>",
"      Of the 32 patients who were greater than 18 years of age at follow-up, 17 had normal height. The presence of a comorbidity adversely affected final height.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a smaller case series of 29 infants who required renal replacement therapy in the first year of life, the five-year estimated survival rate was 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26919/abstract/26\">",
"     26",
"    </a>",
"    ]. The main causes of death were severe cardiovascular and cerebral comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic kidney disease (CKD) refers to a state of irreversible kidney damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction of kidney function that generally continues to progress over time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative",
"      <span class=\"nowrap\">",
"       (K/DOQI)",
"      </span>",
"      has defined CKD as a disorder lasting three or more months with either kidney damage defined by structural or functional abnormalities of the kidney, or an estimated glomerular filtration rate (GFR) of less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions and classifications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      workgroup also developed a classification schema based upon the level of kidney function as follows (",
"      <a class=\"graphic graphic_table graphicRef80596 \" href=\"UTD.htm?22/4/22603\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage 1 disease &ndash; Normal GFR (&ge; 90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      Stage 2 disease &ndash; GFR between 60 and 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 3 disease &ndash; GFR between 30 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 4 disease &ndash; GFR between 15 and 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Stage 5 disease &ndash; GFR of less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      or end-stage renal disease (ESRD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal levels of GFR vary with age, gender, and body size. GFR increases with maturation from infancy and approaches an adult mean value by two years of age (",
"      <a class=\"graphic graphic_table graphicRef55965 \" href=\"UTD.htm?19/61/20443\">",
"       table 2",
"      </a>",
"      ). Children under two years of age do not fit within the",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      classification system because they normally have a lower GFR even when corrected for body surface area. In these patients, a calculated GFR based upon serum creatinine can be compared to normative age-appropriate values to detect renal impairment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions and classifications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GFR is equal to the sum of the filtration rates in all of the functioning nephrons. It provides an approximation of the number of functioning nephrons. GFR in children is most commonly estimated by using formulas based on enzymatically determined serum creatinine and height. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Estimation of GFR'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H26#H26\">",
"       \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Serum creatinine and GFR'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Data on the epidemiology of CKD in children are limited, especially in the case of children in the earlier CKD stages who are generally asymptomatic. In children with a GFR less than 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , the reported mean incidence and prevalence in one prospective Italian study were approximately 12.1 and 74.7 cases per million children and adolescents below 20 years of age, respectively. The risk of CKD is greater in boys than girls, and in African-American compared to Caucasian children. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CKD in children is the result of a heterogeneous group of disorders. Congenital disease accounts for almost 60 percent of CKD cases and includes obstructive uropathy, renal hypoplasia, and renal dysplasia. Glomerular disorders are the second largest cause of childhood CKD and are present in 7 to 17 percent of children with CKD. Glomerular disease is more common in children greater than 12 years of age (",
"      <a class=\"graphic graphic_figure graphicRef68637 \" href=\"UTD.htm?40/1/40990\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, CKD continues to progress in a large percentage of patients with persistent deterioration of renal function leading to ESRD. This ongoing loss of renal function may be a result of repeated and chronic insults to the renal parenchyma leading to permanent damage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to the adaptive hyperfiltration response of the kidney. In the latter process (adaptive hyperfiltration), the filtration rate is increased with increasing glomerular pressure and flow, which over time results in glomerular damage and leakage of protein resulting in interstitial inflammation and fibrosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Natural history and progression of chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/2\">",
"      Coulthard MG. Maturation of glomerular filtration in preterm and mature babies. Early Hum Dev 1985; 11:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/3\">",
"      Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/4\">",
"      Wong CS, Pierce CB, Cole SR, et al. Association of proteinuria with race, cause of chronic kidney disease, and glomerular filtration rate in the chronic kidney disease in children study. Clin J Am Soc Nephrol 2009; 4:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/5\">",
"      Schwartz GJ, Mu&ntilde;oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/6\">",
"      Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/7\">",
"      Counahan R, Chantler C, Ghazali S, et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976; 51:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/8\">",
"      Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/9\">",
"      Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/10\">",
"      Ardissino G, Dacc&ograve; V, Testa S, et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 2003; 111:e382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/11\">",
"      Esbj&ouml;rner E, Berg U, Hansson S. Epidemiology of chronic renal failure in children: a report from Sweden 1986-1994. Swedish Pediatric Nephrology Association. Pediatr Nephrol 1997; 11:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/12\">",
"      Lagomarsimo E, Valenzuela A, Cavagnaro F, Solar E. Chronic renal failure in pediatrics 1996. Chilean survey. Pediatr Nephrol 1999; 13:288.",
"     </a>",
"    </li>",
"    <li>",
"     NAPRTCS: 2008 Annual Report, Rockville, MD, EMMES, 2008. Available at https://web.emmes.com/study/ped/announce.htm. (accessed on June 11, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/14\">",
"      Hoy WE. Renal disease in Australian aboriginals. Med J Aust 1996; 165:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/15\">",
"      Mong Hiep TT, Ismaili K, Collart F, et al. Clinical characteristics and outcomes of children with stage 3-5 chronic kidney disease. Pediatr Nephrol 2010; 25:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/16\">",
"      Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/17\">",
"      Fogo AB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007; 22:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/18\">",
"      Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/19\">",
"      Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005; 67:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/20\">",
"      Ardissino G, Testa S, Dacc&ograve; V, et al. Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid Project. Arch Dis Child 2012; 97:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/21\">",
"      Staples AO, Greenbaum LA, Smith JM, et al. Association between clinical risk factors and progression of chronic kidney disease in children. Clin J Am Soc Nephrol 2010; 5:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/22\">",
"      Furth SL, Cole SR, Moxey-Mims M, et al. Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 2006; 1:1006.",
"     </a>",
"    </li>",
"    <li>",
"     www.usrds.org/2009/ref/H_Ref_09.pdf (Accessed on April 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/24\">",
"      Carey WA, Talley LI, Sehring SA, et al. Outcomes of dialysis initiated during the neonatal period for treatment of end-stage renal disease: a North American Pediatric Renal Trials and Collaborative Studies special analysis. Pediatrics 2007; 119:e468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/25\">",
"      Mekahli D, Shaw V, Ledermann SE, Rees L. Long-term outcome of infants with severe chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26919/abstract/26\">",
"      Wedekin M, Ehrich JH, Offner G, Pape L. Renal replacement therapy in infants with chronic renal failure in the first year of life. Clin J Am Soc Nephrol 2010; 5:18.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6115 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-CD1BC1F72F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26919=[""].join("\n");
var outline_f26_18_26919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS AND CLASSIFICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Estimation of GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NATURAL HISTORY AND PROGRESSION OF CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CKiD study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6115|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/1/40990\" title=\"figure 1\">",
"      Causes CKD children age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/4/22603\" title=\"table 1\">",
"      Stages of CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/61/20443\" title=\"table 2\">",
"      Normal GFR children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5594?source=related_link\">",
"      Definition and staging of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_18_26920="Overview of uropathogen virulence factors";
var content_f26_18_26920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 636px\">",
"   <div class=\"ttl\">",
"    Overview of uropathogen virulence factors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 616px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left hand side of this schematic bacterial cell represents uropathogenic Escherichia coli, and the right hand side represents Proteus mirabilis. Proteins that contribute to each mechanism of pathogenesis&mdash;immune evasion, toxin production, iron acquisition, adherence, and motility&mdash;are highlighted for each pathogen. Some strains of uropathogenic",
"    <em>",
"     E. coli",
"    </em>",
"    strains encode the proteins SisA and SisB, which suppress the host inflammatory response during early stages of infection.",
"    <em>",
"     P. mirabilis",
"    </em>",
"    produces urease, which plays a role in the formation of urinary stones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Nature Reviews Urology. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7:430. Copyright &copy; 2010.",
"     <a href=\"file://www.nature.com/nrurol/index.html\" target=\"_blank\">",
"      file://www.nature.com/nrurol/index.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26920=[""].join("\n");
var outline_f26_18_26920=null;
var title_f26_18_26921="Pediculosis capitis nits";
var content_f26_18_26921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65846%7EPC%2F74790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65846%7EPC%2F74790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediculosis capitis nits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pediculosis capitis. Note the whitish nits found along the hair shafts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chung EK, Boom JA, Datto GA, Matz PS (Eds). Visual Diagnosis in Pediatrics. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Courtesy of Hans B Kersten, MD. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Head lice nits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous head lice nits are attached to the hairs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26921=[""].join("\n");
var outline_f26_18_26921=null;
var title_f26_18_26922="Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation";
var content_f26_18_26922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/18/26922/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/18/26922/contributors\">",
"     Kevin R Krull, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/18/26922/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/18/26922/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/18/26922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/18/26922/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/18/26922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention deficit hyperactivity disorder (ADHD) is a disorder that manifests in childhood with symptoms of hyperactivity, impulsivity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inattention. The symptoms affect cognitive, academic, behavioral, emotional, and social functioning (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review focuses on the clinical features and evaluation of ADHD. The epidemiology, pathogenesis, management, and prognosis of ADHD in children and adolescents and ADHD in adults are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link\">",
"       \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link\">",
"       \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=see_link\">",
"       \"Adult attention deficit hyperactivity disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830607547\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Core symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADHD is a syndrome with three categories of symptoms: hyperactivity, impulsivity, and inattention (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ). Each of the core symptoms of ADHD has its own pattern and course of development. The complaint regarding symptoms of ADHD may originate from the parents, teachers, or other caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Hyperactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperactive behavior is identified through excessive fidgetiness or talking, difficulty remaining seated when required to do so, difficulty playing quietly, and frequent restlessness or seeming to be always \"on the go\" (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The hyperactive symptoms typically are observed by the time the child reaches four years of age and increase during the next three to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. They peak in severity when the child is seven to eight years of age, after which they begin to decline steadily. By the adolescent years, the hyperactive symptoms can be barely discernible to observers, but adolescents often report internal restlessness or inability to settle down.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Impulsivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impulsive behavior almost always occurs in conjunction with hyperactivity in young children. Impulsive behavior is manifested by difficulty waiting turns, blurting out answers too quickly, disruptive classroom behavior, intruding or interrupting other's activities, peer rejection, and unintentional injury (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Similar to the hyperactive symptoms, the impulsive symptoms typically are observed by the time the child reaches four years of age and increase during the next three to four years to peak in severity when the child is seven to eight years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In contrast to hyperactive symptoms, impulsive symptoms usually remain a problem throughout the life of the individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H16#H16\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The focus of impulsivity is related to the environment. As an example, adolescents with ADHD who are untreated and in an environment where alcohol and other commonly abused substances are readily available are at greater risk of engaging in drug use or experimentation than are adolescents without ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Inattention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inattention may take many forms, including forgetfulness, being easily distracted, losing or misplacing things, disorganization, academic underachievement, poor follow-through with assignments or tasks, poor concentration, and poor attention to detail (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The symptoms of inattention typically are not apparent until the child is eight to nine years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This delay may relate to reduced sensitivity of assessment of attention problems or increased variability in the normal development of the cognitive skills. Similar to the pattern of impulsivity, symptoms of inattention usually are a lifelong problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H16#H16\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830608835\">",
"    <span class=\"h2\">",
"     Subtypes of ADHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the predominant symptoms, ADHD can be categorized into one of three subtypes: predominantly inattentive; predominantly hyperactive-impulsive; and combined. The subtype of ADHD in a given patient can change from one to another over time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     predominantly inattentive",
"    </strong>",
"    subtype of ADHD is characterized by reduced ability to focus attention and reduced speed of cognitive processing and responding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Children with the inattentive subtype often are described as having a sluggish cognitive tempo and frequently appear to be daydreaming or \"off task\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/11\">",
"     11",
"    </a>",
"    ]. The typical presenting complaints center on cognitive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    academic problems. Symptoms may include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failing to pay close attention to details or making careless mistakes in schoolwork or other activities",
"     </li>",
"     <li>",
"      Difficulty sustaining attention in tasks or play activities",
"     </li>",
"     <li>",
"      Not seeming to listen when spoken to directly",
"     </li>",
"     <li>",
"      Not following through on instructions and failing to finish schoolwork, chores, or duties (not because of oppositional behavior or failure to understand instructions)",
"     </li>",
"     <li>",
"      Difficulty organizing tasks and activities",
"     </li>",
"     <li>",
"      Avoidance or reluctance to engage in tasks that require sustained mental effort (such as schoolwork or homework)",
"     </li>",
"     <li>",
"      Losing things necessary for tasks or activities (eg, toys, school assignments, pencils, books, or tools)",
"     </li>",
"     <li>",
"      Being easily distracted by extraneous stimuli",
"     </li>",
"     <li>",
"      Forgetfulness in daily activities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     predominantly hyperactive-impulsive",
"    </strong>",
"    subtype of ADHD is characterized by the inability to sit still or inhibit behavior. Symptoms may include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fidgeting with hands or feet or squirming in seat",
"     </li>",
"     <li>",
"      Leaving seat in classroom or in other situations where he or she is expected to remain seated",
"     </li>",
"     <li>",
"      Running about or climbing excessively in situations in which it is inappropriate",
"     </li>",
"     <li>",
"      Difficulty playing or engaging in leisure activities quietly",
"     </li>",
"     <li>",
"      Often being \"on the go\" or acting as if \"driven by a motor\"",
"     </li>",
"     <li>",
"      Excessive talking",
"     </li>",
"     <li>",
"      Blurting out answers before questions have been completed",
"     </li>",
"     <li>",
"      Difficulty awaiting his or her turn",
"     </li>",
"     <li>",
"      Interrupting or intruding on others (eg, butting into conversations or games)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with the hyperactive-impulsive subtype of ADHD have relatively good attention skills. Cognitive performance may be unaffected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/12\">",
"     12",
"    </a>",
"    ]. Children with the hyperactive-impulsive subtype of ADHD usually are diagnosed at six to seven years of age, when symptoms of hyperactivity and impulsivity peak.",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     combined subtype",
"    </strong>",
"    of ADHD is characterized by symptoms of hyperactivity, impulsivity, and inattention. The combined subtype is the classic subtype of ADHD and the subtype that is most easily identified. Presenting complaints may include disruptive or aggressive behavior, overactivity, disinhibition, and reduced attention span.",
"   </p>",
"   <p>",
"    Children with the combined subtype of ADHD usually are diagnosed at six to seven years of age, when symptoms of hyperactivity and impulsivity peak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15721103\">",
"    <span class=\"h2\">",
"     Impaired functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to meet criteria for ADHD, core symptoms must impair function in academic, social, or occupational activities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/1\">",
"     1",
"    </a>",
"    ]. Social skills in children with ADHD often are significantly impaired. Problems with inattention may limit opportunities to acquire social skills or to attend to social cues necessary for effective social interaction, making it difficult to form friendships. Hyperactive and impulsive behaviors may result in peer rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/13\">",
"     13",
"    </a>",
"    ]. The negative consequences of impaired social function (eg, poor self-esteem, increased risk for depression and anxiety) may be long-standing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of ADHD overlap with a number of other conditions, including developmental variations, neurologic or developmental conditions, emotional and behavioral disorders, psychosocial or environmental factors, and certain medical problems (",
"    <a class=\"graphic graphic_table graphicRef69771 \" href=\"UTD.htm?43/42/44717\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/1,2,14,15\">",
"     1,2,14,15",
"    </a>",
"    ]. Some of these conditions can coexist with ADHD and may or may not be responsible for some of the symptoms (eg, children who have learning disabilities may develop inattention as a result of inability to understand new information) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/16\">",
"     16",
"    </a>",
"    ]. These conditions usually can be differentiated from ADHD with a thorough history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of a broadband behavior rating scale. If the diagnosis remains uncertain, psychometric testing or a mental health evaluation may be necessary. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Coexisting disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Developmental variations",
"      </strong>",
"      &ndash; Developmental variations include intellectual disability; giftedness; and behaviors that are within the normal range for the child&rsquo;s level of development and do not impair function (eg, a short-attention span or increased motor activity in a preschool child; occasional impulsivity in a school-age child) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/14,15,17\">",
"       14,15,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"       \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5257?source=see_link\">",
"       \"Intellectual disability (mental retardation) in children: Evaluation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Children with developmental variations do not meet the criteria for ADHD (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neurologic or developmental conditions",
"      </strong>",
"      &ndash; Neurodevelopmental conditions that can mimic or co-occur with ADHD include [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/14,18\">",
"       14,18",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Learning disabilities (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link\">",
"       \"Specific learning disabilities in children: Clinical features\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Language or communication disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21399?source=see_link\">",
"       \"Etiology of speech and language disorders in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autism spectrum disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link\">",
"       \"Clinical features of autism spectrum disorders\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neurodevelopmental syndromes (eg, fragile X, fetal alcohol syndrome) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link\">",
"       \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link&amp;anchor=H13#H13\">",
"       \"Infants of mothers with substance abuse\", section on 'Fetal alcohol spectrum disorder'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Seizure disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21912?source=see_link\">",
"       \"Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sequelae of central nervous system infection or trauma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=see_link&amp;anchor=H14#H14\">",
"       \"Neurologic complications of bacterial meningitis in children\", section on 'Neuropsychologic impairment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Metabolic disorders (eg, adrenoleukodystrophy, mucopolysaccharidosis type III) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"       \"Adrenoleukodystrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\", section on 'MPS type III (Sanfilippo syndrome)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Motor coordination disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/28/13770?source=see_link\">",
"       \"Overview of developmental coordination disorder\"",
"      </a>",
"      )",
"      <br/>",
"      <br/>",
"      These disorders usually can be distinguished from ADHD through history and examination. Specialized testing may be necessary in some circumstances (eg, psychometric testing for learning disabilities; genetic testing for fragile X syndrome; electroencephalography for seizure disorder; occupational therapy evaluation for motor coordination disorder, etc). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Emotional and behavioral disorders",
"      </strong>",
"      &ndash; Emotional and behavioral disorders that can mimic or co-occur with ADHD include anxiety disorder, mood disorders, oppositional defiant disorder, conduct disorder, obsessive compulsive disorder, post-traumatic stress disorder, and adjustment disorder. The use of a broadband behavior scale may be helpful in the assessment of these disorders. However, evaluation by a mental health professional generally is necessary for diagnosis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Coexisting disorders'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H189248586\">",
"       'Behavior rating scales'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H25\">",
"       'Indications for referral'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Psychosocial and environmental factors",
"      </strong>",
"      &ndash; Environmental factors that can contribute to inattention, impulsivity, or hyperactivity include a stressful home environment or an inappropriate educational setting. In contrast to ADHD, psychosocial and environmental factors generally affect behavior only in one setting (eg, at home but not at school, or at school, but not at home). Parent-child temperament or &ldquo;personality&rdquo; mismatch and parental mental health conditions (particularly maternal depression) can contribute to parent report of ADHD-type symptoms in the home setting. However, mothers of ADHD children with limited resources or support may also develop stress-related mental health conditions; in such circumstances, multiple respondent (eg, teacher, coach) reports help to confirm the diagnosis of ADHD.",
"     </li>",
"     <li>",
"      <strong>",
"       Medical conditions",
"      </strong>",
"      &ndash; Medical conditions that may have clinical features that mimic ADHD include hearing or visual impairment, lead poisoning, thyroid abnormalities, sleep disorders (eg, obstructive sleep apnea,",
"      <span class=\"nowrap\">",
"       restless-leg/periodic",
"      </span>",
"      limb movement disorder), medication effects (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      ), and substance abuse disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. (See appropriate topic reviews.) These conditions usually can be differentiated from ADHD because their symptoms fluctuate with the disease course or exposure to medication. In contrast, the symptoms in ADHD are persistent and pervasive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation for possible ADHD includes comprehensive medical, developmental, educational, and psychosocial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2,20-24\">",
"     2,20-24",
"    </a>",
"    ]. Comprehensive evaluation is necessary to confirm the presence, persistence, pervasiveness, and functional complications of core symptoms (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ), exclude other explanations for core symptoms (",
"    <a class=\"graphic graphic_table graphicRef69771 \" href=\"UTD.htm?43/42/44717\">",
"     table 2",
"    </a>",
"    ), and identify coexisting emotional, behavioral, and medical disorders. (See",
"    <a class=\"local\" href=\"#H830607650\">",
"     'Diagnostic criteria'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Coexisting disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evaluation should include review of the medical, social, and family histories; clinical interviews with the parent and patient; review of information about functioning in school or day care; and evaluation for coexisting emotional or behavioral disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. The necessary information may be obtained in several ways, including in-person discussions, questionnaires, and Web-based tools, as described below.",
"   </p>",
"   <p>",
"    The complete evaluation may require several office visits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/21\">",
"     21",
"    </a>",
"    ]. It is important to discuss safety and injury prevention at each visit because children with ADHD or symptoms of ADHD are at increased risk of intentional and unintentional injury compared with children without these symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H16#H16\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reevaluation of children with ADHD is warranted whenever symptoms worsen or new symptoms emerge because the differential diagnosis of ADHD is extensive and comorbidity is common. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H22\">",
"     'Coexisting disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the medical history include prenatal exposures (eg, tobacco, drugs, alcohol), perinatal complications or infections, central nervous system infection, head trauma, recurrent otitis media, and medications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/21\">",
"     21",
"    </a>",
"    ]. Family history of similar behaviors is important because ADHD has a strong genetic component. The review of systems should include information about sleep disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/20\">",
"     20",
"    </a>",
"    ]. It is particularly important to obtain a dietary history (eg, appetite, picking eating) and history of sleep patterns before initiation of pharmacotherapy to avoid attributing preexisting problems to medications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/25\">",
"     25",
"    </a>",
"    ]. It is also important to obtain a thorough child and family cardiac history and cardiac review of systems before initiating medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=see_link&amp;anchor=H7#H7\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\", section on 'Genetic factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=see_link&amp;anchor=H10#H10\">",
"     \"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder\", section on 'Recommended approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pediatric care provider can ask the parents the following questions to elicit concerns regarding school performance and behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How is your child doing at school?",
"     </li>",
"     <li>",
"      Have you or the teacher noticed any problems with learning?",
"     </li>",
"     <li>",
"      Is your child happy in school?",
"     </li>",
"     <li>",
"      Does your child have any behavioral problems at school or home, or when playing with friends?",
"     </li>",
"     <li>",
"      Does your child have problems completing school assignments at school or home?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination of most children with ADHD is normal. However, the examination is necessary to evaluate other possibilities in the differential diagnosis. Important aspects of the examination include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/21,26\">",
"     21,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of height, weight, head circumference, and vital signs",
"     </li>",
"     <li>",
"      Assessment of dysmorphic features and neurocutaneous abnormalities",
"     </li>",
"     <li>",
"      A complete neurologic examination, including assessment of vision and hearing",
"     </li>",
"     <li>",
"      Observation of the child's behavior in the office setting; however, this isolated assessment of behavior should be interpreted cautiously; symptoms of ADHD may not be apparent in the structured setting of the clinic visit",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Developmental and behavioral evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the developmental and behavioral history include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specific information about the onset, course, and functional impact of ADHD symptoms",
"     </li>",
"     <li>",
"      Emotional, medical, and developmental events that may provide an alternative explanation for the symptoms (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Developmental milestones, particularly language milestones (",
"      <a class=\"graphic graphic_table graphicRef58598 \" href=\"UTD.htm?16/20/16717\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      School absences",
"     </li>",
"     <li>",
"      Psychosocial stressors",
"     </li>",
"     <li>",
"      Observation of parent-child interactions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The behavioral assessment is focused on determining the age of onset of the core symptoms of ADHD, the duration of symptoms, the settings in which the symptoms occur, and the degree of functional impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2,21,22\">",
"     2,21,22",
"    </a>",
"    ]. This information is necessary to establish the diagnosis of ADHD. (See",
"    <a class=\"local\" href=\"#H830607650\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Information about the core symptoms can be obtained through the use of open-ended questions or from ADHD-specific rating scales. If open-ended questions are used, the examiner must document the presence of the relevant behaviors from the DSM-IV (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189248586\">",
"    <span class=\"h3\">",
"     Behavior rating scales",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various scales have been developed to collect structured observations of behavior (",
"    <a class=\"graphic graphic_table graphicRef81675 \" href=\"UTD.htm?21/27/21949\">",
"     table 4",
"    </a>",
"    ). Completion of these scales by parents and teachers during the diagnostic evaluation helps to establish the presence of core symptoms of ADHD in more than one setting. (See",
"    <a class=\"local\" href=\"#H830607650\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       ADHD-specific scales",
"      </strong>",
"      &ndash; ADHD-specific rating scales (also called narrow-band scales) focus directly on the symptoms of ADHD and can be used to establish the presence of the core symptoms of ADHD. The validity of ADHD rating scales in distinguishing children with ADHD from age-matched control children varies depending upon the age of the child, the scale that is used, and the informant (eg, parent, teacher, adolescent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      ADHD-specific rating scales have a sensitivity and specificity of greater than 90 percent when used in an appropriate population [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. However, most of the studies validating the use of rating scales have taken place in referral rather than primary care settings. The",
"      <a class=\"external\" href=\"file://www.nichq.org/adhd.html\">",
"       National Initiative for Children's Healthcare Quality (NICHQ) ADHD toolkit",
"      </a>",
"      includes the Vanderbilt Assessment Scales, which can be downloaded and printed from the Web site. The Vanderbilt Assessment Scales have been validated in both community and referral settings using longitudinal assessment and follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/29-31\">",
"       29-31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Only the Conners Comprehensive Behavior Rating Scales and the ADHD Rating Scale IV have been validated in preschool-aged children [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2,32\">",
"       2,32",
"      </a>",
"      ]. The Vanderbilt rating scales were not designed for preschool children, but probably can be used in children &ge;4 years [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Broadband scales",
"      </strong>",
"      &ndash; Broadband scales assess a variety of behavioral symptoms, including, but not limited to, the core symptoms of ADHD; they assess internalizing behaviors (eg, feeling depressed, anxious, withdrawn) and externalizing behaviors other than ADHD (eg, aggression). Broadband scales (with the exception of the Conners' Long form) are not recommended to establish the presence of the core symptoms of ADHD because they are less sensitive and specific (&lt;86 percent) than ADHD-specific scales [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/28\">",
"       28",
"      </a>",
"      ]. However, broadband scales can help to identify coexisting conditions and narrow the differential diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link&amp;anchor=H7#H7\">",
"       \"Developmental and behavioral screening tests in primary care\", section on 'Behavioral screening tests'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Educational evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The educational assessment centers on documentation of the core symptoms in the educational setting. Important aspects of the educational evaluation include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Completion of an ADHD-specific rating scale (see",
"      <a class=\"local\" href=\"#H189248586\">",
"       'Behavior rating scales'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      A narrative summary of classroom behavior and interventions, learning patterns, and functional impairment",
"     </li>",
"     <li>",
"      Copies of report cards and samples of schoolwork",
"     </li>",
"     <li>",
"      Review of school-based multidisciplinary evaluations (if such evaluations have been performed)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The teachers who provide the information should have regular contact with the child for a minimum of four to six months if they are to comment reliably on the persistence of symptoms. In the United States, schools are federally mandated to perform appropriate evaluations (eg, language, cognitive) at no cost to the family if a child is suspected of having a disability that impairs functioning (eg, ADHD or learning disability). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32679?source=see_link&amp;anchor=H9#H9\">",
"     \"Support services for the care of chronically ill children\", section on 'Education'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37480?source=see_link&amp;anchor=H4#H4\">",
"     \"Definitions of specific learning disability and laws pertaining to learning disabilities\", section on 'Laws affecting the education of students with disabilities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obtaining information about the core symptoms of ADHD from professionals in after-school programs or other structured settings also may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. This information may be particularly useful in the evaluation of preschool children and adolescents, or if discrepancies exist between the parents&rsquo; and teachers&rsquo; reports of core symptoms. When such discrepancies occur, environmental factors (eg, different expectations, levels of structure, or behavior management strategies) may be contributing to the symptoms. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Coexisting disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation for ADHD should include assessment for coexisting",
"    <span class=\"nowrap\">",
"     behavior/emotional",
"    </span>",
"    disorders including oppositional defiant disorder, conduct disorder, depression, anxiety disorder, and learning disabilities (",
"    <a class=\"graphic graphic_table graphicRef64535 \" href=\"UTD.htm?13/16/13581\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/21,22,36\">",
"     21,22,36",
"    </a>",
"    ]. Evaluation for these disorders may include history, broadband behavior scales (oppositional defiant disorder, conduct disorder, depression, anxiety) or psychometric testing (learning disability) (",
"    <a class=\"graphic graphic_table graphicRef69771 \" href=\"UTD.htm?43/42/44717\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Up to one-half of children with ADHD have one or more coexisting behavioral-emotional conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The coexisting conditions can be primary or secondary (eg, disorders that are exacerbated by the ADHD). In either case, they require treatment in conjunction with treatment for ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H1404650528#H1404650528\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Treatment of coexisting conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anxiety may develop in children with ADHD as a secondary disorder; however, in many cases anxiety appears to be independent of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/37,40\">",
"     37,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with the combined or hyperactive-impulsive subtype of ADHD are at increased risk for developing coexisting behavior problems, including oppositional defiant disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Their excessive activity, impulsive response style, and disinhibited emotional expression frequently put them in conflict with parents and other adults. The increased conflict may lead to increased discipline and less positive reinforcement for the child. Under these circumstances, a potentially self-perpetuating pattern of oppositional defiant behavior can emerge (the oppositional acts bring parental attention, which is reinforcing for the child who rarely receives parental praise) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Learning disabilities and depression are more common in children with the inattentive and combined subtypes of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Children with ADHD and comorbid mood disorder may have family members with a history of major depressive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/47\">",
"     47",
"    </a>",
"    ]. During adolescence, they are at increased risk for attempting suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link&amp;anchor=H18#H18\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Comorbidities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link&amp;anchor=H2#H2\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=see_link&amp;anchor=H7#H7\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\", section on 'Psychiatric disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adolescents with newly diagnosed ADHD should be assessed for substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2\">",
"     2",
"    </a>",
"    ]. Those with signs and symptoms of substance abuse should undergo evaluation and treatment for addiction before treatment for ADHD with medications (if possible) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=see_link&amp;anchor=H2007898672#H2007898672\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications\", section on 'Prerequisites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Psychometric testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychometric testing is not necessary in the routine evaluation for ADHD and does not distinguish children with ADHD from those without ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/22,52\">",
"     22,52",
"    </a>",
"    ]. However, psychometric testing can be valuable in excluding other disorders. The public school system often is the best place to perform psychometric testing (ie, intellectual and academic testing), though more specialized neuropsychological testing requires consultation with a specialist. Testing for learning disabilities can be completed in whole or in part by the school system. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Children with learning, language, visual-motor, or auditory processing problems can be difficult to distinguish from those with ADHD. These problems tend to be pervasive and persistent and can impair academic function through decreased comprehension or excessive frustration. Children with these problems may attempt to avoid tasks through inattention, getting out of their seats, or impulsively guessing at answers. On the other hand, children with ADHD may perform poorly on language and visual-spatial tasks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/53-55\">",
"     53-55",
"    </a>",
"    ], particularly those that require sustained mental effort or are sensitive to impulsive responding (eg, multiple-choice formats).",
"   </p>",
"   <p>",
"    Comprehensive neuropsychologic testing may help to clarify the diagnosis. Children with learning, language, visual-motor, or auditory processing problems usually perform poorly only in their particular problem area, whereas children with ADHD may perform poorly in several areas of evaluation. Assessment of verbal and",
"    <span class=\"nowrap\">",
"     nonverbal/performance",
"    </span>",
"    skills with an intelligence measure such as the Wechsler Intelligence Scale for Children &ndash; Fourth Edition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/56\">",
"     56",
"    </a>",
"    ] or the Differential Abilities Scale [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/57\">",
"     57",
"    </a>",
"    ] will help to identify language",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    visual-spatial processing deficits. Assessment of academic",
"    <span class=\"nowrap\">",
"     skills/achievement",
"    </span>",
"    testing with a tool such as the Wechsler Individual Achievement Test &ndash; Second Edition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/58\">",
"     58",
"    </a>",
"    ], or the Wide Range Achievement Test &ndash; Fourth Edition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/59\">",
"     59",
"    </a>",
"    ] will help to identify potential learning disabilities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link\">",
"     \"Specific learning disabilities in children: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35944?source=see_link\">",
"     \"Specific learning disabilities in children: Evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychometric testing also can help to identify specific problem areas for children with ADHD, including abstract reasoning, mental flexibility, planning, and working memory, a collection of skills broadly categorized as &ldquo;executive functions&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/9,10,53,60\">",
"     9,10,53,60",
"    </a>",
"    ]. Neuropsychological assessment of these skills, as well as direct assessment of attention and behavioral disinhibition, often is desirable to facilitate diagnosis, plan environmental and behavioral interventions, and track progress of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/61-64\">",
"     61-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ancillary evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other evaluations are not routinely indicated to establish the diagnosis of ADHD, but may be warranted to evaluate conditions remaining in the differential diagnosis after the initial assessment. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    above.) These evaluations may include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/20-22,65\">",
"     20-22,65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Speech and language evaluation (language or communication disorder) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26343?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation and treatment of speech and language disorders in children\", section on 'Speech and language evaluation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Occupational therapy evaluation (motor coordination disorder) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/28/13770?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of developmental coordination disorder\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mental health evaluation (mood disorder, anxiety, oppositional defiant disorder, conduct disorder, obsessive compulsive disorder, post-traumatic stress disorder, adjustment disorder) (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Coexisting disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Indications for referral'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Blood lead level (lead poisoning) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/66,67\">",
"       66,67",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thyroid hormone levels (thyroid disorder) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/68,69\">",
"       68,69",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\", section on 'Diagnostic evaluation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Genetic testing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genetics consultation (fragile X syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/70,71\">",
"       70,71",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Overnight polysomnography for children with symptoms suggestive of",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      risk factors for obstructive sleep apnea syndrome or restless legs syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"       \"Evaluation of suspected obstructive sleep apnea in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=see_link\">",
"       \"Restless legs syndrome and periodic limb movement disorder in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neurology consultation or electroencephalography (neurologic or seizure disorder) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"       \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Quantitative EEG (qEEG) is a method of analyzing the electrical activity of the brain to derive quantitative patterns that may correspond to diagnostic information",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cognitive deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/72\">",
"     72",
"    </a>",
"    ]. We do not suggest qEEG for the evaluation of children with ADHD. Although several studies have demonstrated differences in qEEG between children with ADHD and normal children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/73-78\">",
"     73-78",
"    </a>",
"    ], the studies were limited by non-random assignment, lack of blinding, failure to consider comorbidities,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure to control for pharmacologic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/72,76,79\">",
"     72,76,79",
"    </a>",
"    ]. Furthermore, the studies did not demonstrate the specificity of the findings for ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/79\">",
"     79",
"    </a>",
"    ]. Thus, current evidence is insufficient to support the use of qEEG in clinical populations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/76,79\">",
"     76,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830607507\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830607650\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830609458\">",
"    <span class=\"h3\">",
"     ADHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Psychiatric Association has defined consensus criteria for the diagnosis of ADHD, which are published in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM-IV-TR) (",
"    <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/1\">",
"     1",
"    </a>",
"    ]. Several features of the DSM-IV-TR criteria deserve emphasis; the symptoms must:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Be present in more than one setting (eg, school and home)",
"     </li>",
"     <li>",
"      Persist for at least six months",
"     </li>",
"     <li>",
"      Be present before the age of seven years",
"     </li>",
"     <li>",
"      Impair function in academic, social, or occupational activities",
"     </li>",
"     <li>",
"      Be excessive for the developmental level of the child",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, other physical, situational, or mental health conditions that could account for the symptoms must be excluded. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Adherence to the DSM-IV-TR criteria can help to minimize over- and underdiagnosis of ADHD. The diagnostic criteria have high interrater reliability for individual items and for overall diagnosis even though the behavioral characteristics specified in the definition are subject to different interpretation by different observers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/20,80,81\">",
"     20,80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limitations of the DSM-IV-TR criteria include their derivation from studies of children who were evaluated in psychiatric rather than primary care settings and lack of data supporting the number of items required for diagnosis.",
"   </p>",
"   <p>",
"    The response to stimulant medication cannot be used to confirm or refute the diagnosis of ADHD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/80\">",
"     80",
"    </a>",
"    ]. Stimulant medications improve behavior in children with ADHD, children with conditions other than ADHD (eg, learning disabilities, depression), and normal control children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89958659\">",
"    <span class=\"h4\">",
"     ADHD subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the predominant symptoms, ADHD can be categorized into one of three subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predominantly inattentive &ndash; &ge;6 symptoms of inattention (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Predominantly hyperactive-impulsive &ndash; &ge;6 symptoms of hyperactivity-impulsivity (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Combined &ndash; &ge;6 symptoms of inattention and &ge;6 symptoms of hyperactivity-impulsivity (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830609502\">",
"    <span class=\"h3\">",
"     Hyperkinetic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, the diagnosis of hyperkinetic disorder (HKD) is defined by the International Classification of Diseases (10",
"    <sup>",
"     th",
"    </sup>",
"    edition, ICD-10) criteria (",
"    <a class=\"graphic graphic_table graphicRef53723 \" href=\"UTD.htm?0/55/893\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. The ICD-10 criteria for HKD are more restrictive than the DSM-IV criteria for ADHD, requiring that at least six symptoms of inattention, at least three symptoms of hyperactivity, and at least one symptom of impulsivity are present in more than one setting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/24\">",
"     24",
"    </a>",
"    ]. HKD is subdivided into HKD with and without conduct disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830607531\">",
"    <span class=\"h2\">",
"     Diagnosis in preschool children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria for ADHD (without subtyping) can be applied to children as young as four years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2,84\">",
"     2,84",
"    </a>",
"    ]. Longitudinal studies suggest that severe hyperactivity, which is present in only a small subset of preschool children, persists into the school years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/85-87\">",
"     85-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The criterion that impairment is present in at least two settings may be difficult to meet if the child does not attend preschool or a child care program [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2\">",
"     2",
"    </a>",
"    ]. In such circumstances, clinicians who suspect ADHD can recommend that the parents attend a parent-training program or that the child be enrolled in a qualified preschool program (eg, Head Start, public prekindergarten programs, Early Childhood Special Education services) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinician can then obtain information about core symptoms of ADHD and functional impairment from the instructors of the preschool program or the parenting program (if the child is directly observed).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H830607539\">",
"    <span class=\"h2\">",
"     Diagnosis in adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing a new diagnosis of ADHD in adolescents can be challenging. Adolescents may underreport core symptoms or functional impairment and may spend too little time at home for parents to be accurate informants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2,88\">",
"     2,88",
"    </a>",
"    ]. In such cases, it is important for clinicians to obtain information from at least two teachers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other adults with whom the adolescent interacts (eg, guidance counselor, coaches, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation by a pediatric specialist (eg, a psychologist, psychiatrist, neurologist, educational specialist, or developmental-behavioral pediatrician) is indicated for children in whom the following diagnoses are of concern [",
"    <a class=\"abstract\" href=\"UTD.htm?26/18/26922/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intellectual disability (mental retardation)",
"     </li>",
"     <li>",
"      Developmental disorder (eg, speech or motor delay)",
"     </li>",
"     <li>",
"      Learning disability",
"     </li>",
"     <li>",
"      Visual or hearing impairment",
"     </li>",
"     <li>",
"      History of abuse",
"     </li>",
"     <li>",
"      Severe aggression",
"     </li>",
"     <li>",
"      Seizure disorder",
"     </li>",
"     <li>",
"      Coexisting learning",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      emotional problems",
"     </li>",
"     <li>",
"      Chronic illness that requires treatment with a medication that interferes with learning",
"     </li>",
"     <li>",
"      Children who continue to have problems in functioning despite treatment (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=see_link&amp;anchor=H130706622#H130706622\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\", section on 'Response to treatment'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2155755\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Initiative for Children's Healthcare Quality (NICHQ), in conjunction with North Carolina&rsquo;s Center for Child Health Improvement, and the American Academy of Pediatrics (AAP), has developed a toolkit to assist primary care practitioners in the evaluation and management of children with ADHD. The toolkit includes information for parents, copies of ADHD-specific questionnaires for parents and teachers, and an initial primary care evaluation form. It can be downloaded without charge through the",
"    <a class=\"external\" href=\"file://www.nichq.org/adhd.html\">",
"     NICHQ",
"    </a>",
"    but requires registration. A revised edition of the toolkit, which also includes tools and resources for preschool children and adolescents, is available for purchase through the American Academy of Pediatrics.",
"   </p>",
"   <p>",
"    Resources for families of children with ADHD are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef60584 \" href=\"UTD.htm?26/42/27308\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Information for teachers of children with ADHD is available through the",
"    <a class=\"external\" href=\"file://www.help4adhd.org/en/education\">",
"     National Resource Center on ADHD",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/32/11778?source=see_link\">",
"       \"Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/8/33922?source=see_link\">",
"       \"Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/53/35668?source=see_link\">",
"       \"Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attention deficit hyperactivity disorder (ADHD) is a behavioral condition with core symptoms of inattention, hyperactivity, and impulsivity (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      ). The symptoms affect cognitive, academic, behavioral, emotional, and social functioning. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Core symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for ADHD includes developmental variations, neurologic or developmental conditions, emotional and behavioral disorders, psychosocial or environmental factors, and certain medical problems (",
"      <a class=\"graphic graphic_table graphicRef69771 \" href=\"UTD.htm?43/42/44717\">",
"       table 2",
"      </a>",
"      ). Most of these conditions may coexist with ADHD and require simultaneous treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Coexisting disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ADHD requires that the child meet the criteria defined by the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM-IV-TR) (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      ). The response to stimulant medication cannot be used to confirm or refute the diagnosis. (See",
"      <a class=\"local\" href=\"#H830607650\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for ADHD requires comprehensive medical, developmental, educational, and psychosocial evaluation to confirm the presence, persistence, pervasiveness, and functional complications of core symptoms (",
"      <a class=\"graphic graphic_table graphicRef50326 \" href=\"UTD.htm?11/27/11709\">",
"       table 1",
"      </a>",
"      ), exclude other causes of core symptoms (",
"      <a class=\"graphic graphic_table graphicRef69771 \" href=\"UTD.htm?43/42/44717\">",
"       table 2",
"      </a>",
"      ), and identify coexisting learning and psychiatric disorders (",
"      <a class=\"graphic graphic_table graphicRef64535 \" href=\"UTD.htm?13/16/13581\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Coexisting disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation for ADHD requires information about the child's behavior in more than one setting (eg, home and school or after-school program). ADHD-specific behavior scales (",
"      <a class=\"graphic graphic_table graphicRef81675 \" href=\"UTD.htm?21/27/21949\">",
"       table 4",
"      </a>",
"      ) can be used to gather this information from the parents and teacher(s). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Educational evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H189248586\">",
"       'Behavior rating scales'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychometric testing is not necessary in the routine evaluation for ADHD. However, it is valuable in narrowing the differential diagnosis and planning the approach to management. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Psychometric testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation for ADHD does not require blood lead levels, thyroid hormone levels, neuroimaging, or electroencephalography unless these tests are indicated by findings in the clinical evaluation. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Ancillary evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reevaluation of children with ADHD is warranted whenever symptoms worsen or new symptoms emerge because the differential diagnosis of ADHD is extensive and comorbidity is common. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Coexisting disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4th, American Psychiatric Association, Washington, DC 2000. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/2\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/3\">",
"      Applegate B, Lahey BB, Hart EL, et al. Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry 1997; 36:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/4\">",
"      Lahey BB, Applegate B, McBurnett K, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry 1994; 151:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/5\">",
"      Levin FR, Kleber HD. Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harv Rev Psychiatry 1995; 2:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/6\">",
"      Lahey BB, Pelham WE, Loney J, et al. Instability of the DSM-IV Subtypes of ADHD from preschool through elementary school. Arch Gen Psychiatry 2005; 62:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/7\">",
"      Larsson H, Dilshad R, Lichtenstein P, Barker ED. Developmental trajectories of DSM-IV symptoms of attention-deficit/hyperactivity disorder: genetic effects, family risk and associated psychopathology. J Child Psychol Psychiatry 2011; 52:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/8\">",
"      Hinshaw SP, Owens EB, Zalecki C, et al. Prospective follow-up of girls with attention-deficit/hyperactivity disorder into early adulthood: continuing impairment includes elevated risk for suicide attempts and self-injury. J Consult Clin Psychol 2012; 80:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/9\">",
"      Nigg JT, Blaskey LG, Huang-Pollock CL, Rappley MD. Neuropsychological executive functions and DSM-IV ADHD subtypes. J Am Acad Child Adolesc Psychiatry 2002; 41:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/10\">",
"      Weiler MD, Bernstein JH, Bellinger DC, Waber DP. Processing speed in children with attention deficit/hyperactivity disorder, inattentive type. Child Neuropsychol 2000; 6:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/11\">",
"      Carlson CL, Mann M. Sluggish cognitive tempo predicts a different pattern of impairment in the attention deficit hyperactivity disorder, predominantly inattentive type. J Clin Child Adolesc Psychol 2002; 31:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/12\">",
"      Faraone SV, Biederman J, Weber W, Russell RL. Psychiatric, neuropsychological, and psychosocial features of DSM-IV subtypes of attention-deficit/hyperactivity disorder: results from a clinically referred sample. J Am Acad Child Adolesc Psychiatry 1998; 37:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/13\">",
"      Hoza B. Peer functioning in children with ADHD. Ambul Pediatr 2007; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     Leslie LK, Guevara JP. Attention-deficit/hyperactivity disorder. In: American Academy of Pediatrics Textbook of Pediatric Care, McInerny TK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.1201.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/15\">",
"      Morrow RL, Garland EJ, Wright JM, et al. Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. CMAJ 2012; 184:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/16\">",
"      Gilger JW, Pennington BF, DeFries JC. A twin study of the etiology of comorbidity: attention-deficit hyperactivity disorder and dyslexia. J Am Acad Child Adolesc Psychiatry 1992; 31:343.",
"     </a>",
"    </li>",
"    <li>",
"     Hyperactive/impulsive behaviors. In: The Classification of Child and Adolescent Mental Diagnoses in Primary Care. Diagnostic and Statistical Manual for Primary Care (DSM-PC) Child and Adolescent Version, 1st, Wolraich ML.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 1996. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/18\">",
"      Wijburg FA, W��grzyn G, Burton BK, Tylki-Szyma��ska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder. Acta Paediatr 2013; 102:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/19\">",
"      Pearl PL, Weiss RE, Stein MA. Medical mimics. Medical and neurological conditions simulating ADHD. Ann N Y Acad Sci 2001; 931:97.",
"     </a>",
"    </li>",
"    <li>",
"     ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Process of Care Supplemental Appendix. Available at: file://pediatrics.aappublications.org/content/128/5/1007/suppl/DC1 (Accessed on January 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/21\">",
"      Taylor E, D&ouml;pfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder -- first upgrade. Eur Child Adolesc Psychiatry 2004; 13 Suppl 1:I7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/22\">",
"      Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/23\">",
"      National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 2000; 39:182.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. 2008. file://www.nice.org.uk/CG72 (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/25\">",
"      Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 2001; 22:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/26\">",
"      Sleator EK, Ullmann RK. Can the physician diagnose hyperactivity in the office? Pediatrics 1981; 67:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/27\">",
"      Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003; 42:1015.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Healthcare Research and Quality. Diagnosis of Attention-Deficit/Hyperactivity Disorder. Clinical Focus. Rockville, MD, October 1999. file://www.ahrq.gov/clinic/tp/adhddtp.htm (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/29\">",
"      Wolraich ML, Lambert W, Doffing MA, et al. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J Pediatr Psychol 2003; 28:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/30\">",
"      Wolraich ML, Bard DE, Neas B, et al. The psychometric properties of the vanderbilt attention-deficit hyperactivity disorder diagnostic teacher rating scale in a community population. J Dev Behav Pediatr 2013; 34:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/31\">",
"      Bard DE, Wolraich ML, Neas B, et al. The psychometric properties of the vanderbilt attention-deficit hyperactivity disorder diagnostic parent rating scale in a community population. J Dev Behav Pediatr 2013; 34:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/32\">",
"      McGoey KE, DuPaul GJ, Haley E, Shelton TL. Parent and teacher ratings of attention-deficit/hyperactivity disorder in preschool: the ADHD Rating Scale-IV Preschool Version. J Psychopathol Behav Assess 2007; 29:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/33\">",
"      Dreyer BP. The diagnosis and management of attention-deficit/hyperactivity disorder in preschool children: the state of our knowledge and practice. Curr Probl Pediatr Adolesc Health Care 2006; 36:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/34\">",
"      Kaplan A, Adesman A. Clinical diagnosis and management of attention deficit hyperactivity disorder in preschool children. Curr Opin Pediatr 2011; 23:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/35\">",
"      Biederman J, Monuteaux MC, Kendrick E, et al. The CBCL as a screen for psychiatric comorbidity in paediatric patients with ADHD. Arch Dis Child 2005; 90:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/36\">",
"      Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 10 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/37\">",
"      Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001; 40:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/38\">",
"      A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/39\">",
"      Levy F, Hay DA, Bennett KS, McStephen M. Gender differences in ADHD subtype comorbidity. J Am Acad Child Adolesc Psychiatry 2005; 44:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/40\">",
"      Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998; 59 Suppl 7:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/41\">",
"      Neuman RJ, Heath A, Reich W, et al. Latent class analysis of ADHD and comorbid symptoms in a population sample of adolescent female twins. J Child Psychol Psychiatry 2001; 42:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/42\">",
"      Lalonde J, Turgay A, Hudson JI. Attention-deficit hyperactivity disorder subtypes and comorbid disruptive behaviour disorders in a child and adolescent mental health clinic. Can J Psychiatry 1998; 43:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/43\">",
"      Barkley RA, Fischer M, Edelbrock C, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria--III. Mother-child interactions, family conflicts and maternal psychopathology. J Child Psychol Psychiatry 1991; 32:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/44\">",
"      Pliszka SR. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/45\">",
"      Wolraich ML, Hannah JN, Pinnock TY, et al. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry 1996; 35:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/46\">",
"      Wolraich ML, Hannah JN, Baumgaertel A, Feurer ID. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample. J Dev Behav Pediatr 1998; 19:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/47\">",
"      Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991; 148:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/48\">",
"      Lam LT. Attention deficit disorder and hospitalization owing to intra- and interpersonal violence among children and young adolescents. J Adolesc Health 2005; 36:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/49\">",
"      Brent DA, Perper JA, Goldstein CE, et al. Risk factors for adolescent suicide. A comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry 1988; 45:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/50\">",
"      Nasser EH, Overholser JC. Assessing varying degrees of lethality in depressed adolescent suicide attempters. Acta Psychiatr Scand 1999; 99:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/51\">",
"      Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998; 37:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/52\">",
"      Doyle AE, Biederman J, Seidman LJ, et al. Diagnostic efficiency of neuropsychological test scores for discriminating boys with and without attention deficit-hyperactivity disorder. J Consult Clin Psychol 2000; 68:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/53\">",
"      Aman CJ, Roberts RJ Jr, Pennington BF. A neuropsychological examination of the underlying deficit in attention deficit hyperactivity disorder: frontal lobe versus right parietal lobe theories. Dev Psychol 1998; 34:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/54\">",
"      Nigg JT, Swanson JM, Hinshaw SP. Covert visual spatial attention in boys with attention deficit hyperactivity disorder: lateral effects, methylphenidate response and results for parents. Neuropsychologia 1997; 35:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/55\">",
"      Purvis KL, Tannock R. Language abilities in children with attention deficit hyperactivity disorder, reading disabilities, and normal controls. J Abnorm Child Psychol 1997; 25:133.",
"     </a>",
"    </li>",
"    <li>",
"     Wechsler D. Wechsler Intelligence Scale for Children: 4th Edition. Harcourt Assessment, Inc., San Antonio, TX 2003.",
"    </li>",
"    <li>",
"     Elliott C. Differential Ability Scales. The Psychological Corporation, San Antonio, TX 1990.",
"    </li>",
"    <li>",
"     Wechsler Individual Achievement Test-Second Edition. The Psychological Corporation, San Antonio, TX 2001.",
"    </li>",
"    <li>",
"     Glutting JJ, Wilkinson GS. Wide Range Achievement Test &ndash; 3. Wide Range, Inc., Wilmington, DE, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/60\">",
"      Rubia K, Taylor E, Smith AB, et al. Neuropsychological analyses of impulsiveness in childhood hyperactivity. Br J Psychiatry 2001; 179:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/61\">",
"      Hale JB, Hoeppner JA, DeWitt MB, et al. Evaluating medication response in ADHD: cognitive, behavioral, and single-subject methodology. J Learn Disabil 1998; 31:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/62\">",
"      Kempton S, Vance A, Maruff P, et al. Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol Med 1999; 29:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/63\">",
"      Risser MG, Bowers TG. Cognitive and neuropsychological characteristics of attention deficit hyperactivity disorder children receiving stimulant medications. Percept Mot Skills 1993; 77:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/64\">",
"      Tannock R, Ickowicz A, Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1995; 34:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/65\">",
"      Zametkin AJ, Ernst M. Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/66\">",
"      Kahn CA, Kelly PC, Walker WO Jr. Lead screening in children with attention deficit hyperactivity disorder and developmental delay. Clin Pediatr (Phila) 1995; 34:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/67\">",
"      Gittelman R, Eskenazi B. Lead and hyperactivity revisited. An investigation of nondisadvantaged children. Arch Gen Psychiatry 1983; 40:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/68\">",
"      Elia J, Gulotta C, Rose SR, et al. Thyroid function and attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994; 33:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/69\">",
"      Weiss RE, Stein MA, Trommer B, Refetoff S. Attention-deficit hyperactivity disorder and thyroid function. J Pediatr 1993; 123:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/70\">",
"      Stephen E, Kindley AD. Should children with ADHD and normal intelligence be routinely screened for underlying cytogenetic abnormalities? Arch Dis Child 2006; 91:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/71\">",
"      Bastain TM, Lewczyk CM, Sharp WS, et al. Cytogenetic abnormalities in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2002; 41:806.",
"     </a>",
"    </li>",
"    <li>",
"     Krull KR, George MR, Strother D. Quantitative electroencephalography and neurofeedback. In: Pediatric Neuropsychological Intervention: A Critical Review of Science &amp; Practice, Hunter SJ, Donders J (Eds), Cambridge University Press, Cambridge 2007. p.392.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/73\">",
"      Lazzaro I, Gordon E, Li W, et al. Simultaneous EEG and EDA measures in adolescent attention deficit hyperactivity disorder. Int J Psychophysiol 1999; 34:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/74\">",
"      Lazzaro I, Gordon E, Whitmont S, et al. Quantified EEG activity in adolescent attention deficit hyperactivity disorder. Clin Electroencephalogr 1998; 29:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/75\">",
"      Chabot RJ, Merkin H, Wood LM, et al. Sensitivity and specificity of QEEG in children with attention deficit or specific developmental learning disorders. Clin Electroencephalogr 1996; 27:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/76\">",
"      Snyder SM, Hall JR. A meta-analysis of quantitative EEG power associated with attention-deficit hyperactivity disorder. J Clin Neurophysiol 2006; 23:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/77\">",
"      Swartwood JN, Swartwood MO, Lubar JF, Timmermann DL. EEG differences in ADHD-combined type during baseline and cognitive tasks. Pediatr Neurol 2003; 28:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/78\">",
"      Kuperman S, Johnson B, Arndt S, et al. Quantitative EEG differences in a nonclinical sample of children with ADHD and undifferentiated ADD. J Am Acad Child Adolesc Psychiatry 1996; 35:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/79\">",
"      Barry RJ, Clarke AR, Johnstone SJ. A review of electrophysiology in attention-deficit/hyperactivity disorder: I. Qualitative and quantitative electroencephalography. Clin Neurophysiol 2003; 114:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/80\">",
"      Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/81\">",
"      Power TJ, Costigan TE, Leff SS, et al. Assessing ADHD across settings: contributions of behavioral assessment to categorical decision making. J Clin Child Psychol 2001; 30:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/82\">",
"      Rapoport JL, Buchsbaum MS, Zahn TP, et al. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 1978; 199:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/83\">",
"      Peloquin LJ, Klorman R. Effects of methylphenidate on normal children's mood, event-related potentials, and performance in memory scanning and vigilance. J Abnorm Psychol 1986; 95:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/84\">",
"      Lahey BB, Pelham WE, Loney J, et al. Three-year predictive validity of DSM-IV attention deficit hyperactivity disorder in children diagnosed at 4-6 years of age. Am J Psychiatry 2004; 161:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/85\">",
"      Campbell SB, Ewing LJ, Breaux AM, Szumowski EK. Parent-referred problem three-year-olds: follow-up at school entry. J Child Psychol Psychiatry 1986; 27:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/86\">",
"      McGee R, Partridge F, Williams S, Silva PA. A twelve-year follow-up of preschool hyperactive children. J Am Acad Child Adolesc Psychiatry 1991; 30:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/87\">",
"      Riddle MA, Yershova K, Lazzaretto D, et al. The Preschool Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS) 6-Year Follow-Up. J Am Acad Child Adolesc Psychiatry 2013; 52:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/18/26922/abstract/88\">",
"      Adler LA, Newcorn JH. Administering and evaluating the results of the adult ADHD Self-Report Scale (ASRS) in adolescents. J Clin Psychiatry 2011; 72:e20.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 624 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26922=[""].join("\n");
var outline_f26_18_26922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H830607547\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Core symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Hyperactivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Impulsivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Inattention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H830608835\">",
"      Subtypes of ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15721103\">",
"      Impaired functioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Developmental and behavioral evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H189248586\">",
"      - Behavior rating scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Educational evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Coexisting disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Psychometric testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ancillary evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H830607507\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H830607650\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H830609458\">",
"      - ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H89958659\">",
"      ADHD subtype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H830609502\">",
"      - Hyperkinetic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H830607531\">",
"      Diagnosis in preschool children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H830607539\">",
"      Diagnosis in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2155755\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/624|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/27/11709\" title=\"table 1\">",
"      DSM-IV-TR criteria for ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/42/44717\" title=\"table 2\">",
"      DDx ADHD in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/20/16717\" title=\"table 3\">",
"      Major language milestones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/27/21949\" title=\"table 4\">",
"      Behavior rating scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/16/13581\" title=\"table 5\">",
"      Coexisting emotional and behavioral disorders in ADHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/55/893\" title=\"table 6\">",
"      ICD-10 Criteria HKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/42/27308\" title=\"table 7\">",
"      ADHD resources",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32761?source=related_link\">",
"      Adult attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23082?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34423?source=related_link\">",
"      Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=related_link\">",
"      Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37480?source=related_link\">",
"      Definitions of specific learning disability and laws pertaining to learning disabilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21399?source=related_link\">",
"      Etiology of speech and language disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26343?source=related_link\">",
"      Evaluation and treatment of speech and language disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/28/13770?source=related_link\">",
"      Overview of developmental coordination disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21912?source=related_link\">",
"      Overview of the classification, etiology, and clinical features of pediatric seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/32/11778?source=related_link\">",
"      Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/8/33922?source=related_link\">",
"      Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/53/35668?source=related_link\">",
"      Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32282?source=related_link\">",
"      Restless legs syndrome and periodic limb movement disorder in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35944?source=related_link\">",
"      Specific learning disabilities in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32679?source=related_link\">",
"      Support services for the care of chronically ill children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_18_26923="New antidepressants";
var content_f26_18_26923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Generic and brand names of common new generation antidepressants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Generic name",
"      </td>",
"      <td class=\"subtitle1\">",
"       Brand name",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluoxetine",
"      </td>",
"      <td>",
"       Prozac",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Citalopram",
"      </td>",
"      <td>",
"       Celexa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Escitalopram",
"      </td>",
"      <td>",
"       Lexapro",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sertaline",
"      </td>",
"      <td>",
"       Zoloft",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paroxetine",
"      </td>",
"      <td>",
"       Paxil",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fluvoxamine",
"      </td>",
"      <td>",
"       Luvox",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Buproprion",
"      </td>",
"      <td>",
"       Wellbutrin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mirtazapine",
"      </td>",
"      <td>",
"       Remeron",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Venlafaxine",
"      </td>",
"      <td>",
"       Effexor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Duloxetine",
"      </td>",
"      <td>",
"       Cymbalta",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Desvenlafaxine",
"      </td>",
"      <td>",
"       Pristiq",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Agomelatine*",
"      </td>",
"      <td>",
"       Valdoxan*",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Agomelatine/Valdoxan is currently approved for use in Europe but is not FDA-approved for use in the United States.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26923=[""].join("\n");
var outline_f26_18_26923=null;
var title_f26_18_26924="Antiem drugs opioid nausea";
var content_f26_18_26924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anti-emetic drugs used to manage opioid-induced nausea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Neuroleptics",
"       </td>",
"       <td rowspan=\"7\">",
"        Dopamine receptor blockade in lower brainstem (chemoreceptor trigger zone)",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Phenothiazines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Prochlorperazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorpromazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Butyrophenones:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Haloperidol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Atypical:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Olanzepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prokinetic drugs",
"       </td>",
"       <td>",
"        Peripheral effects to increase peristalsis; metaclopramide also has central dopamine antagonist",
"       </td>",
"       <td>",
"        Metoclopramide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-HT3 receptor antagonists",
"       </td>",
"       <td>",
"        Block serotonin receptor (chronic use may cause constipation)",
"       </td>",
"       <td>",
"        <p>",
"         Palonosetron",
"        </p>",
"        <p>",
"         Ondansetron",
"        </p>",
"        <p>",
"         Granisetron",
"        </p>",
"        <p>",
"         Dolasetron",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergic drugs",
"       </td>",
"       <td>",
"        Block acetylcholine release in lower brainstem",
"       </td>",
"       <td>",
"        <p>",
"         Trimethobenzamide",
"        </p>",
"        <p>",
"         Scopolamine",
"        </p>",
"        <p>",
"         Promethazine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines",
"       </td>",
"       <td>",
"        Block histamine receptors in lower brainstem",
"       </td>",
"       <td>",
"        <p>",
"         Meclizine",
"        </p>",
"        <p>",
"         Diphenhydramine",
"        </p>",
"        <p>",
"         Dimenhydrinate",
"        </p>",
"        <p>",
"         Hydroxyzine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticosteroids",
"       </td>",
"       <td>",
"        Multiple effects",
"       </td>",
"       <td>",
"        Dexamethasone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        Reduce anxiety; direct effect on lower brainstem",
"       </td>",
"       <td>",
"        Lorazepam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cannabinoids",
"       </td>",
"       <td>",
"        Binds to cannabinoid receptors to exert direct effect in the lower brainstem",
"       </td>",
"       <td>",
"        <p>",
"         Dronabinol",
"        </p>",
"        <p>",
"         Nabilone",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26924=[""].join("\n");
var outline_f26_18_26924=null;
var title_f26_18_26925="Doses inhaled glucocorticoids";
var content_f26_18_26925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated comparative daily doses for inhaled glucocorticoids in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Low daily dose",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Medium daily dose",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        High daily dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Child 0 to 4",
"       </td>",
"       <td class=\"subtitle2\">",
"        Child 5 to 11",
"       </td>",
"       <td class=\"subtitle2\">",
"        Child 0 to 4",
"       </td>",
"       <td class=\"subtitle2\">",
"        Child 5 to 11",
"       </td>",
"       <td class=\"subtitle2\">",
"        Child 0 to 4",
"       </td>",
"       <td class=\"subtitle2\">",
"        Child 5 to 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Beclomethasone HFA:",
"        </p>",
"        <p>",
"         40 or 80 mcg/puff",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        80 to 160 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        &gt;160 to 320 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        &gt;320 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Budesonide DPI:",
"        </p>",
"        <p>",
"         90, 180, or 200 mcg/inhalation",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        180 to 400 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        &gt;400 to 800 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        &gt;800 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Budesonide inhaled:",
"        </p>",
"        <p>",
"         Inhalation suspension for nebulization (child dose)",
"        </p>",
"       </td>",
"       <td>",
"        0.25 to 0.5 mg",
"       </td>",
"       <td>",
"        0.5 mg",
"       </td>",
"       <td>",
"        &gt;0.5 to 1.0 mg",
"       </td>",
"       <td>",
"        1.0 mg",
"       </td>",
"       <td>",
"        &gt;1.0 mg",
"       </td>",
"       <td>",
"        2.0 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Flunisolide HFA*:",
"        </p>",
"        <p>",
"         80 mcg/puff",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        160 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        320 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        &ge;640 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Fluticasone HFA/MDI:",
"        </p>",
"        <p>",
"         44, 110, or 220 mcg/puff",
"        </p>",
"       </td>",
"       <td>",
"        176 mcg",
"       </td>",
"       <td>",
"        88 to 176 mcg",
"       </td>",
"       <td>",
"        &gt;176 to 352 mcg",
"       </td>",
"       <td>",
"        &gt;176 to 352 mcg",
"       </td>",
"       <td>",
"        &gt;352 mcg",
"       </td>",
"       <td>",
"        &gt;352 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Fluticasone DPI:",
"        </p>",
"        <p>",
"         50, 100, or 250 mcg/inhalation",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        100 to 200 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        &gt;200 to 400 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        &gt;400 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Mometasone furoate DPI:",
"        </p>",
"        <p>",
"         110 mcg/inhalation",
"        </p>",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        110 mcg",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The most important determinant of appropriate dosing is the clinician's judgment of the patient's response to therapy. The clinician must monitor the patient's response on several clinical parameters and adjust the dose accordingly. The stepwise approach to therapy emphasizes that once control of asthma is achieved, the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effect. Some doses may be outside package labeling, especially in the high-dose range. Budesonide nebulizer suspension is the only ICS with FDA approved labeling for children &lt;4 years of age. Metered-dose inhaler (MDI) dosages are expressed as the actuator dose (the amount of the drug leaving the actuator and delivered to the patient), which is the labeling required in the United States. This is different from the dosage expressed as the valve dose (the amount of drug leaving the valve, not all of which is available to the patient), which is used in many European countries and in some scientific literature. Dry powder inhaler (DPI) doses are expressed as the amount of drug in the inhaler following activation. For children &lt;4 years of age: The safety and efficacy of ICSs in children &lt;1 year has not been established. Children &lt;4 years of age generally require delivery of ICS (budesonide and fluticasone HFA) through a face mask that should fit snugly over nose and mouth&nbsp;to avoid getting the medication&nbsp;in the eyes. Wash face after each treatment to prevent local corticosteroid side effects. For budesonide, the dose may be administered one to three times daily. Budesonide suspension is compatible with albuterol, ipratropium, and levalbuterol nebulizer solutions in the same nebulizer. Use only jet nebulizers, as ultrasonic nebulizers are ineffective for suspensions. For fluticasone HFA, the dose should be divided&nbsp;two times daily; the low dose for children &lt;4 years is higher than for children 5 to 11 years of age due to lower dose delivered with face mask and data on efficacy in young children.",
"    <div class=\"footnotes\">",
"     HFA: hydrofluoroalkane; NA: not approved and no data available for this age group.",
"     <br>",
"      *&nbsp;Flunisolide has not been&nbsp;available in the United States or Canada since June 30, 2011. An HFA version is&nbsp;slated for launch in the US market in 2013.",
"      <br/>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26925=[""].join("\n");
var outline_f26_18_26925=null;
var title_f26_18_26926="Cervical esophagostomy";
var content_f26_18_26926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical esophagostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the suturing of the proximal portion of the cervical esophagus to the anterior chest wall. This procedure can be performed as a temporizing procedure for an esophageal perforation when a primary repair cannot be performed due to severe contamination of the mediastinum, large friable defect, or unstable condition of the patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26926=[""].join("\n");
var outline_f26_18_26926=null;
var title_f26_18_26927="Charcot foot";
var content_f26_18_26927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Charcot arthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diabetic patient with Charcot arthropathy characterized by collapse of the arch of the midfoot, which is replaced by a bony prominence (arrow). Several factors contribute to this painless condition, including small muscle wasting, decreased sensation, and maldistribution of weight bearing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_18_26927=[""].join("\n");
var outline_f26_18_26927=null;
